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We used librarian-designed searches of the PubMed Medline and Embase databases to
identify primary research articles on pediatric neoplasms and BDs. English language articles
from PubMed and Embase up to 10/12/2015, and in PubMed up to 5/12/2017 following an
updated search, were eligible for inclusion if they reported primary epidemiological research
results on associations between BDs and pediatric malignancies. Two reviewers coded
each article based on the title and abstract to identify eligible articles that were abstracted
using a structured form. Additional articles were identified through reference lists and other
sources. Results were synthesized for pediatric cancers overall and for nine major pediatric
cancer subtypes.

Results
A total of 14,778 article citations were identified, of which 80 met inclusion criteria. Pediatric
cancer risk was increased in most studies in association with BDs overall with some notable
specific findings, including increased risks for CNS tumors in association with CNS abnormalities and positive associations between rib anomalies and several pediatric cancer types.

Conclusions
Some children born with BDs may be at increased risk for specific pediatric malignancy
types. This work provides a foundation for future investigations that are needed to clarify
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specific BD types predisposing toward malignancy and possible underlying causes of both
BDs and malignancy.

Introduction
Pediatric cancer is diagnosed in >14,000 U.S. children per year from the ages of 0–19 years and
is the leading cause of disease-related death among children aged 1–14 years [1, 2]. Although a
few risk factors have been conclusively identified, including exposure to high dose radiation
and certain genetic syndromes, the etiology underlying most cases remains unknown.
Evidence accumulated over several decades suggests positive associations between birth
defects (BDs) and pediatric malignancy. BDs affect ~1 in 33 U.S. children and are defined as
“structural changes present at birth that can affect almost any part or parts of the body” [3].
BDs are often categorized as major and minor with major anomalies generally considered
those having “an adverse effect on the individual’s health, functioning or social acceptability”
and minor anomalies considered those having “limited social or medical significance”. Major
anomaly examples include spina bifida, cleft lip palate, and Down Syndrome [4]. Minor anomaly examples include low set ears, epicanthal folds, and simian crease [5]. Although certain
genetic syndromes are known to increase pediatric cancer risk (e.g. Down Syndrome and leukemia), other BDs (including major and minor), independent of known cancer predisposition
syndromes, may also be associated with an increased risk.
Recent evidence suggests that 8.5% of children with cancer harbor germline mutations in
well-known cancer genes that predispose them to the development of early-onset malignancy
[6]. However, when considering a more broad predisposition definition including family history, co-morbidities, and types of pediatric cancer, up to about a third of children with cancer
may have a genetic predisposition [7]. Many pediatric cancer predisposition syndromes
involve defects in normal development and many pediatric cancers arise from immature cell
types (e.g. the “blastomas”). Thus, identifying and understanding connections between abnormal fetal or childhood development and the risk of developing cancer will have implications
for surveillance, prognosis, risk stratification and potential personalized therapeutics.
To summarize evidence on associations between pediatric malignancy and BDs, we conducted a systematic literature review to identify articles reporting primary human epidemiological research. This work provides a foundation for future studies and may help to identify
high risk populations for malignancy among individuals with BDs that will enable improved
surveillance, mechanistic research, targeted treatment and outcomes.

Methods
Abbreviations used in this review are provided in Table 1. Our review followed the 2009 Preferred Reporting Method for Systematic Reviews (PRISMA) guidelines [8] (See S1 Checklist).
A summary of the review protocol is provided below.

Search strategy
We identified relevant articles in the Medline PubMed [9] and Embase [10] databases on 9/10/
2015 and 10/12/2015 using librarian designed search strategies. The review was updated on 5/
12/2017 using the PubMed database. (S1 Table). We also examined each article’s reference list
from those included in the review and consulted a well-known review published by the International Agency for Cancer Research in 1999 for any additional studies [11]. Finally, the senior
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Table 1. Abbreviations.
Abbreviation

Full name

Abbreviation

Full name

ALL

Acute Lymphocytic Leukemia

MDS

Myelodysplastic Syndrome

AML

Acute Myeloid Leukemia

MPD

Myeloproliferative Disease

ANLL

Acute Non-Lymphoblastic Leukemia

NB

Neuroblastoma

AST

Astrocytoma

NHL

Non-Hodgkin’s Lymphoma

BC

British Columbia

NOS

Newcastle-Ottawa scale

BDs

Birth Defects

NA

Not applicable

CBT

Childhood brain tumors

ND

Not determined

CI

Confidence Interval

NR

Not Reported

CNS

Central Nervous System

NRCT

National Registry of Childhood Tumours

CPP

Collaborative Perinatal Project

NWTS

National Wilms’ Tumor Study

DS

Down syndrome

OR

Odds Ratio

EPD

Ependymoma

OS

Osteosarcoma

ES

Ewing’s Sarcoma

PNET

Primitive neuro-ectodermal tumor

GCT

Germ cell tumors

PRISMA

Preferred Reporting Method for Systematic reviews

HB

Hepatoblastoma

RB

Retinoblastoma

HD

Hodgkin’s Disease

RB

Retinoblastoma

HGG

High grade glioma

RDD

Random Digit Dialing

HL

Hodgkin’s Lymphoma

RMS

Rhabdomyosarcoma

HM

Hematologic malignancy

RMS

Rhabdomyosarcoma

HR

Hazard Ratio

RR

Risk Ratio

IARC

International Agency For Research On Cancer

SNS

Sympathetic Nervous System

ICD

The International Classification of Diseases

STS

Soft Tissue Sarcomas

IRR

Incidence Rate Ratio

WAGR syndrome

Wilms tumor-aniridia intellectual disability syndrome

LGG

Low Grade Glioma

WT

Wilm’s tumor

LHT

Lymphatic and hematopoietic tissues

UPDB

Utah Population database

MB

Medulloblastoma

https://doi.org/10.1371/journal.pone.0181246.t001

author conducted a few PubMed literature searches based on her expert opinion to identify
additional qualifying articles.

Eligibility criteria and review process
The citation lists obtained from each database search were evaluated for initial eligibility by
at least two coauthors (KA, JL, and KJ). We excluded review articles, editorial commentaries,
meeting abstracts, articles focused solely on syndromes with known genetic etiologies, on
treatment or clinical outcomes, solely on adults ( 18 years), and articles not providing
information on risks specific to children with the exception of the Gelberg et al. study that
reported risks for osteosarcoma from 0–24 years [12]. In addition, lab-based studies and case
reports/series without external comparison groups were excluded. Reviewers classified each
article initially based on title review (and abstract if eligibility was unclear from the title) as:
1) eligible, 2) unclear eligibility, and 3) ineligible. Following reconciliation of articles with
coding disagreement by the senior author and reviewers, articles assigned to category one
were abstracted.

Data collection
Data were abstracted from each article using a pre-designed form that captured: study population, study design and description, sources of information on BDs and cancer, study inclusion
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and exclusion criteria, age groups studied, birth years, cancer diagnosis years, BD case definition, BD types examined, cancer types examined, subject numbers, analysis method, measure
of association reported, and key findings. Any additional information relevant to interpretation of study results was captured in a comment field. To the extent possible, we abstracted the
number of subjects for each comparison group and included this information where the numbers were reported directly or required minimum assumptions to calculate. Any articles that
were identified as ineligible during the abstraction phase were subsequently excluded. During
our update of the review, we also abstracted information where reported on classification of
major and minor anomalies, maximum age at which BDs were ascertained, and cancer risks
by age. We did not attempt to reclassify anomalies from the original reports for summary
purposes.

Quality assessment
We employed a modified Newcastle-Ottawa Scale (NOS), designed for quality assessment of
observational studies [13], that uses a star assignment system to determine overall quality for
case-control, nested case-control, case-cohort, and cohort studies. Case series studies with
external comparison groups were not evaluated. Evaluation criteria are described briefly
below.
Case-control, nested case-control, and case-cohort studies. A) Selection. Up to four
stars were awarded to studies based on: 1) adequate case definition, 2) representativeness of
cases, 3) control selection, and 4) adequate control definition. A case definition was considered
adequate if cases were defined based on either clinical and/or histopathological validation of
their cancer diagnosis or were identified through cancer registry data. Cancer cases were considered representative if they were community/population-based versus hospital-based. For
control selection, a star was given if controls were selected from the same population as cases.
The control definition was considered adequate if the authors provided information to indicate that controls did not have a history of the outcome.
B) Comparability between the groups. Up to two stars were awarded to studies matching
on or adjusting for maternal age and child’s sex, potential confounders of the association
between pediatric malignancy and BDs.
C) Ascertainment of the exposure. Up to three stars were awarded to studies if: 1) BDs
were ascertained through medical records, physical exam, or birth certificate data, 2) they used
the same method of BD ascertainment for cases and controls, and 3) they reported a similar
non-response rate for both cases and controls (<10% difference) or the study used registry
data for BD ascertainment.
Cohort studies. A) Selection. Up to four stars were awarded to studies based on: 1) representativeness of the exposed cohort, 2) selection of the non-exposed cohort, 3) ascertainment
of exposure, and 4) demonstration that the outcome of interest was not present at the start of
the study. Studies were given one star each if the exposed cohort registry/population included
all children from a defined geographic region was representative of the community, if the nonexposed cohort was drawn from the same community as the exposed cohort, if medical records
or BD registry information was used to identify exposed subjects or if the exposure was based
on birth certificate data, and if it was indicated that cancer was not present at the start of the
study.
B) Comparability. Comparability criteria were the same as for case-control studies.
C) Outcome. Up to two stars were awarded based on: 1) assessment of the outcome and 2)
follow-up length. One star was awarded if the outcome was assessed independently or through
medical records or record linkage (i.e. through administrative data through ICD codes). One
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star was given if the follow-up period was long enough for outcomes to occur (we set this
at  6 years with consideration for the age distribution of pediatric cancer).

Statistical methods
Unadjusted odds ratios (ORs) and 95% confidence intervals (CIs) were calculated for casecontrol studies where authors provided data for calculations but did not include these measures of association. To summarize the individual quality of each study, we computed the total
quality points by summing the number of stars received. To compare overall quality of cohort
studies vs. other study designs that differed in their maximum achievable quality points (8 for
cohort vs. 9 for case-control, nested case-control, and case-cohort studies), we calculated a
mean total percent quality for each study design category by dividing the mean total quality
points by the total quality points possible.

Results
A total of 14,407 article citations, 9,672 from Embase and 4,735 from PubMed, were initially
identified. After removing 851 non-unique citations (844 in both PubMed and Embase and 7
contained in Embase twice), 13,556 citations remained. With the addition of 371 articles identified through the reference lists of selected articles, the IARC publication [11], additional
PubMed searches, and the updated systematic search in PubMed, 13,927 records were
screened for eligibility of which 13,789 were excluded. One hundred thirty-eight full-text articles were abstracted and 80 were included (Fig 1).
We organized our review with summaries of the characteristics of included studies followed
by their results for pediatric cancer types using the International Classification of Childhood
Cancer third edition major diagnostic categories [14]. Within each major cancer type, results
are summarized by study design with overall associations generally reported first followed by
findings for specific abnormalities/subgroups.

Characteristics of studies included (Table 2)
Studies from 17 countries (Australia, Brazil Canada, China, Croatia, Denmark, France, Germany, Hungary, Italy, the Netherlands, Norway, Sweden, Switzerland, Turkey, the United
Kingdom, and the United States) were published from 1958–2017. Study designs included 13
cohort, 58 case-control, 3 case-cohort, 3 nested case-control and 3 case series with external
comparison groups. BDs were measured through a variety of methods including interviews,
questionnaires, medical records, physical exams, administrative data linkages and from physician interview/report. Cancers were most commonly ascertained through hospital or population-based tumor registries and death certificates.

Pediatric cancers overall (Table 3)
We identified 24 articles reporting findings for associations between pediatric cancer overall
and BDs.
Case-control studies (n = 12). Three studies reported ~2–4.5 fold increased odds of childhood cancer in association with any/BDs or major BDs [15–17], while one reported no association [18]. For minor anomalies, four studies reported increased odds of varying magnitude
for minor anomalies overall (ORs = 4.25 and 44.6 [19, 20]), and specific minor anomalies (OR
>2-fold [21, 22]). One study reported positive associations ranging from 2.6–14.5 for a number of BD types [17]. Finally, four studies reported generally positive associations between rib
anomalies and childhood cancer with ORs ranging from 1.44 to 5.49 [23–26].
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Fig 1. PRISMA flow diagram. The number of records screened is equal to the sum of the number of records initially identified in PubMed
and Embase after removing overalapping citations and the number of studies with citations identified through other sources shown in the
upper most right text box. After exclusions of non-relevant articles during the screening phase, 138 full-text text articles were abstracted, 58
of which were excluded leaving a total of 80 articles that were included in the review.
https://doi.org/10.1371/journal.pone.0181246.g001

Cohort studies (n = 12). Consistently elevated risks ranging from 1.8–3.05 were reported
for associations between any BDs/major BDs and pediatric cancers [27–35]. Increased cancer
risks were within the same range or lower when children with chromosomal anomalies were
excluded [32, 34–36]. One cohort study reported increased risks in children with different BD
types ranging from 1.69–15.52 with the exception of musculoskeletal abnormalities and limb
reduction defects [31]. Janitz et al. reported increased risks for CNS, eye/ear, cardiovascular,
orofacial, gastrointestinal, genitourinary, and musculoskeletal abnormalities with stronger
risks at younger ages (except orofacial where results were not reported) and when individuals
with chromosomal BDs were excluded [35]. Birthmarks (not including nevus simplex or pigmented nevi or café-au-lait spots <3 cm or fewer than 6) were positively associated with
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Table 2. Characteristics of included studies on the association between birth defects and childhood cancer.
Reference (location)

BD ascertainment

Pediatric cancer case ascertainment:
Comparison group ascertainment
cancer types, age group, diagnosis
dates/years, case identification source

Stewart et al., 1958 [18]
(England and Wales)

Maternal interview

Overall, 0–9 years, 1953–1955 (died of
cancer), Registrar General

Controls were selected from birth
registers matched to cases on age,
sex, and locality.

Ager et al., 1965 [39]
(Minnesota, U.S.)

Maternal interview/medical record
verification. The authors note that
“lesser conditions, such as nevi, were
not recorded”.

Leukemia, 0–4 years, 1953–1957 (died
of leukemia), Minnesota death
certificates

Two control groups were included
with a total of two controls per case. If
available, sex-matched sibling
controls were included with the
birthdate closest to the index child
and who had reached an age at the
time of interview that was the same or
older as the age of the index child
when they died. Neighborhood
controls were matched on sex and
birth date within one year.

Swerdlow et al., 1982 [91]
(United Kingdom)

The Oxford Survey of Childhood
Cancer and antenatal clinical notes

Testicular tumors, 0–15 years, 1953–73
(died of testicular cancer), the Oxford
Survey of Childhood Cancer

The comparison group was "all boys
who died during the same period from
malignant neoplasms other than of
genital site or of teratoma histology".

Wilkins et al., 1984 [77] (Ohio,
U.S.)

Ohio birth certificate files

WT, NR, 1/1/1950-10/31/1981,
Columbus (Ohio) Children’s Hospital
Tumor Registry

Two controls per case were randomly
selected from birth certificate files
with one matched to the case on sex,
race, and birth year and the other
matched on these variables plus
mother’s county of residence.

Johnson et al., 1985 [66]
(Texas, U.S.)

The Texas State Department of
Health birth certificates. Both major
and minor BDs were included.

NB, 0–14 years, 1964–1978 (died of NB), Two controls per case were randomly
Texas death certificates
selected from birth certificates
matched to cases on birth year.

Méhes et al., 1985 [19]
(Switzerland)

Pediatric examination for minor BDs

Overall, leukemia, solid tumors, 1.6–22
years, NR, Swiss University Children’s
Hospitals of Basel and Zurich Oncologic
Departments

Controls with infectious diseases
were matched 1:1 to cases on sex,
age, and ethnic origin. Siblings were
also examined where available.

Bunin et al., 1987 [78]
(Philadelphia, U.S.)

Parental interview

WT, 0–14 years, 1970–1983, three
Philadelphia-area hospitals: Children’s
Hospital of Philadelphia,
St. Christopher’s Hospital for Children,
and Wilmington Medical Center

Controls were selected by RDD
matched to cases at a 1:1 ratio on
telephone area code and exchange,
birth year (within 3 years), and race.

Johnson et al., 1987 [62]
(Texas, U.S.)

The Texas State Department of
Health birth certificates

CNS, 0–14, deaths from 1964–1980,
Texas Department of Health death
certificates

Two controls per case were randomly
selected from Texas live births
frequency matched to cases on race,
sex, and birth year.

Neglia et al., 1988 [67]
(Minnesota, U.S.)

The Minnesota State Department of
Health birth certificates. The authors
note that BDs were coded by HICDA9.

NB, 0–8.9 years, cases born since 1969,
hospital review of NB cases seen in
Minnesota and bordering states

Four controls per case were selected
from live births in Minnesota matched
to cases on birth year.

Shu et al., 1988 [48]
(Shanghai, China)

Interview of parents, grandmothers,
and other relatives

Leukemia, 0–14 years, 7/1/1974-6/30/
1986, Shanghai Cancer Institute Tumor
Registry

Controls were selected from the
Shanghai general population at
random, matched to cases 2:1 on sex
and birth calendar year.

CNS, 0–14 years, 1/1/1968-12/31/1977,
New York State Cancer Registry

Controls were randomly selected
from the New York State birth
certificate files matched to cases at a
2:1 ratio on birth year, sex, and race.

Case-control studies

Baptiste et al., 1989 [55] (New Maternal interview
York State, U.S. (except New
York City, Westchester,
Rockland, Nassau, and Suffolk
counties)

(Continued)
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Table 2. (Continued)
Reference (location)

BD ascertainment

Pediatric cancer case ascertainment:
Comparison group ascertainment
cancer types, age group, diagnosis
dates/years, case identification source

Birch et al., 1990 [56] (United
Kingdom)

Parental interview/medical record
verification (ICD-9 coded 740–759)

CNS, 0–14 years, 1980–1983 from
regional pediatric oncology centers, West
Midlands Regional Cancer Registry,
Manchester Children’s Tumor Registry,
Yorkshire Regional Cancer Registry

Two sets of controls were
ascertained from general practitioner
lists and hospitals matched to cases
on sex and age. The second set
excluded children with "a genetic or
other constitutional disease or
malformation known to be associated
with increased risk of cancer" and any
other major malformation or chronic
disease.

ALL, AML, NHL, NR, 1974–1984,
Pediatric Hospital in Turin

Controls were a random sample of
children hospitalized at the same
hospital as cases.

Magnani et al., 1990 [47] (Italy) Interview of parents/closest relatives

Kajtár et al., 1990 [79]
(Hungary)

Examinations of spine for vertebral
WT, NR, NR, Department of Pediatrics,
anomalies on i.v. pyelograms in cases University Medical School, Hungary
and X-rays in controls

Controls were children with X-ray for
acute abdomen or trauma.

Zack et al., 1991 [40]
(Sweden)

The Swedish Medical Birth Registry
(ICD-8 codes 740–759)

All leukemias, lymphatic leukemias,
myeloid leukemias, other or unspecified
leukemias, 0–11 years, 1973–1984, the
Swedish National Cancer Registry and
Swedish Registry of Causes of Death

Five controls per case were selected
from the Swedish Medical Birth
Registry matched to cases on sex,
birth year and month.

Schumacher et al., 1992 [23]
(Germany)

Chest X-ray examination for rib
anomalies

Overall, yolk sac carcinoma, OS, HD,
histiocytosis X, NHL, ES, WT, STS, ALL,
brain tumor, NB, 9 months-21years, NR,
University Children’s Hospital,
Langenbecksrasse

Chest roentgenograms from patients
without cancer with a similar age
distribution as cases (15 months-14
years) were reviewed for comparison.

Mann et al., 1993 [16] (United
Kingdom)

Parental interview/medical record
verification (ICD-9 coded)

Overall, ALL, other leukemia, HL, other
lymphomas, CNS, STS, bone tumors,
WT, NB, RB, HB, GCT, epithelial tumors,
Other neoplasms, 0–14 years, 1980–
1983, regional pediatric oncology
centers, West Midlands Regional Cancer
Registry, Manchester Children’s Tumor
Registry, Yorkshire Regional Cancer
Registry

Two sets of controls were selected
from general practitioner lists and
hospitals matched to cases on sex
and age. The second set excluded
children with "a genetic or other
constitutional disease or
malformation known to be associated
with increased risk of cancer" and any
other major malformation or chronic
disease.

Savitz et al., 1994 [15] (U.S.)

Maternal interview or alternate
respondent. BDs were recorded
verbatim and blindly classified as
major, minor, or not a defect.

Overall, ALL, brain, lymphoma, STS,
0–14 years, 1/1/1976-12/31/1983,
primary data sources were the Colorado
Central Cancer Registry and the
Colorado Department of Health [106]

Controls were selected through RDD
and frequency matching on location,
sex, and age within 3 years.

Cordier et al., 1994 [61] (Ile de
France, France)

Maternal interview. The authors noted Brain, 0–15 years, 7/1/1985-6/30/1987,
excluding "minor anomalies such as
medical record abstractions from the
nevi or birthmarks".
neurosurgery, neurology, pediatric,
pediatric oncology, or radiology
departments at 13 hospitals

Controls were selected from the
general population through sampling
households on a representative list
provided by the census bureau and
telephone books at random matched
to cases on birth year.

Gold et al., 1994 [64] (U.S.)

Parental interview

Three controls per case were
identified through a variety of
methods including RDD, lists of noninstitutionalized individuals
maintained by the Hawaii Department
of Health and through a random
sample of households (Pierce
County, Washington). Controls were
individually matched to cases on age,
sex, and mother’s racial/ethnic
classification.

Brain, 0–17 years, 1/1/1977-12/31/1981
from eight Surveillance, Epidemiology,
and End Results tumor registries

(Continued)
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Table 2. (Continued)
Reference (location)

BD ascertainment

Pediatric cancer case ascertainment:
Comparison group ascertainment
cancer types, age group, diagnosis
dates/years, case identification source

McCredie et al., 1994 [65]
(Australia)

Maternal interview

Brain, 0–14 years, 1985–1989, New
South Wales Central Cancer Registry

Two controls per case matched on
sex and age were ascertained from
eligible women on the Electoral Roll.

Yang et al., 1995 [86] (U.S.)

Parental interview. BDs were
classified as major and minor.

RMS, 0–20 years, 4/1982-7/1988,
Intergroup RMS study of the Children’s
Cancer Group and the Pediatric
Oncology Group

Controls were ascertained by RDD
matched to cases on telephone area
code and exchange, sex, age, and
race.

Shu et al., 1995 [89] (U.S.,
Canada, Australia)

Self-administered questionnaire

Malignant GCT, 0–14 years, 1982–1989,
Children’s Cancer Group

Controls were ascertained by RDD as
part of the CCG-E04 pool.

Cnattingius et al., 1995 [49]
(Sweden)

Swedish Medical Birth Register (ICD8 to 1986 and ICD-9 after).
Registration was completed upon
mother and child leaving the hospital.

Lymphatic leukemia, 0–14 years who
were born between 1973 and 1989,
diagnoses through 1989, National
Cancer Register

Five controls per case were selected
from the source population who were
alive at the case diagnosis and who
were matched on sex, birth year and
month.

Cnattingius et al., 1995 [41]
(Sweden)

Swedish Medical Birth Register
(ICD-8 to 1986 and ICD-9 after).
Registration completed when mother
and child leave the hospital.

Myeloid leukemia, 0–14 years who were
born between 1973 and 1989, diagnoses
through 1989, National Cancer Register

Same as Cnattingius et al., 1995 [49]

Adami et al., 1996 [54]
(Sweden)

Swedish Medical Birth Register (ICD8 to 1986 and ICD-9 after).

NHL, 0–14 years who were born between Same as Cnattingius et al., 1995 [49]
1973 and 1989, diagnoses through 1989,
the National Cancer Register

Gelberg et al., 1997 [12] (New
York State, U.S., excluding
New York City)

Telephone interview with the subject
and/or parents, birth certificates and
school and medical records

OS, 0–24 years, 1978–1988, the New
York State Cancer Registry

Controls were ascertained from New
York live birth records and matched
to cases at a 1:1 ratio on birth year
and sex.

Altmann et al., 1998 [17]
(Victoria Australia)

The Victorian Perinatal Data
Collection Unit Congenital
Malformations/BDs Register (BDs
coded according to the British
Pediatric Association’s modification of
the ICD-9). The authors noted that
"the register collects information on
both structural defects and
chromosomal anomalies at
birth. . .The register excludes certain
trivial malformations, such as birth
marks, skin tags and hydroceles."
BDs were ascertained up to the age of
15 years.

Overall, leukemia (ALL, AML), CNS
(astrocytoma), SNS (NB), lymphoma,
STS (RMS), renal (WT), RB, germ cell/
gonadal, bone, and hepatic, 0–14 years,
1/1/1984 to 12/31/1993, the Victorian
Cancer Registrar

Four live born controls per who
survived the neonatal period were
selected from Victorian births at
random and matched to cases on
date of birth within 6 months.

Méhes et al., 1998 [52]
(Germany)

Physical exam for mild errors of
morphogenesis

Leukemia, 7 months-14 years, NR, the
Department of Pediatrics, University
Medical School of Pécs and the
University Children’s Hospital, Tübingen,
Germany

There were two control comparison
groups: 1) children with acute
infectious diseases and 2) siblings.

Mertens et al., 1998 [43] (U.S.,
Canada, Western Australia)

Maternal interview (ICD-9 coded 740– ALL, AML, cases from three different
759). Some minor BDs were included. leukemia studies diagnosed at 0–18
months (CCG-E09), 0–17 years
(CCG-E14), 0–14 years, 1983–1994
(CCG-E15), the Children’s Cancer Group

Buck et al., 2001 [68] (New
York State, U.S., excluding
New York City)

Parental telephone interview/
supplemented with data from birth
certificates

Controls were selected from regional
populations by a modified RDD
method and matched on telephone
exchange, age, and race (for E14 and
E15).

NB, 0–5 years, 1976–1987, the New York Controls were randomly selected
State Cancer Registry
from live birth registries and
frequency matched to cases on birth
year.
(Continued)
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Table 2. (Continued)
Reference (location)

BD ascertainment

Pediatric cancer case ascertainment:
Comparison group ascertainment
cancer types, age group, diagnosis
dates/years, case identification source

Infante-Rivard et al., 2001 [42]
(Québec, Canada)

Parental interview for major BDs
(ICD-9 coded 751–754)

ALL, 0–9 years, 1980–1993,
Government-sanctioned tertiary care
centers

Controls were selected from family
allowance files and were individually
matched to cases on age within 3
months, sex, and region of residence
at diagnosis.

Roganovic et al., 2002 [50]
(Rijeka, Croatia)

NR (minor BDs ascertained)

Hematologic, 5 months-16 years, 1983–
1997, the Division of Hematology,
Department of Pediatrics, University of
Rijeka

Controls were healthy children that
were the same age and gender as
cases.

Méhes et al., 2003 [80] (Pécs,
Hungary)

WT, 2 months to 9 years for cases, NR,
Abdominal roentgenograms and
anteroposterior radiographs for cases; Department of Pediatrics, University
Medical School of Pécs, Pécs, Hungary
radiography for trauma or acute
abdomen in controls; physical exam
for both cases and controls. Spinal
dysraphism ascertained.

Controls were children with
radiography for trauma or acute
abdomen ranging in age from 1–10
years.

Menegaux et al., 2005 [71] (U.
S. and Canada)

Maternal interview (ICD-9 coded 740– NB, 0–18 years, 1992–1994, the
759, both major and minor BDs were
Children’s Oncology Group
ascertained).

One control per case was selected by
RDD individually matched to cases
on date of birth within 6 months for
cases aged <3 years and 1 year for
cases aged >3 years.

Merks et al., 2005 [26] (The
Netherlands)

Review of chest radiographs for rib
anomalies

Overall, NB, GCT, RMS, WT, OS, ES,
MB, AST, HD, AML, ALL, NHL, Other
malignancies, 0–18 years, 1/1/1998-12/
31/2002, Late Effects of Childhood
Cancer Clinic and the Emma Children’s
Hospital, Academic Medical Center for
newly diagnosed patients

Controls aged 0–18 years were
selected from patient chest
radiographs ordered by general
practitioners and pediatricians in the
outpatient ward and emergency room
physicians.

Podvin et al., 2006 [44]
(Washington State, U.S.)

Birth records

Leukemia, 0–19 years, 1981–2003,
Washington State Cancer Registry and
the Cancer Surveillance System of
Western Washington

Ten controls without leukemia per
case were randomly selected from
the birth certificate records and were
frequency matched to cases on birth
year.

Urayama et al., 2006 [73]
(California, U.S.)

Birth certificates

NB, 0–4 years, 1988–1997, California’s
statewide cancer registry

Two controls per case were randomly
selected from birth certificates
matched to cases on birth date and
gender. Controls were replaced if
they died younger than their matched
case’s diagnosis age.

Chow et al., 2007 [70]
(Washington, U.S.)

Birth certificates (ICD-9 codes 740–
759, major and minor BDs
ascertained). For individuals who
were born 1987 additional ICD-9
codes for discharges were obtained
through linkage of birth certificates to
the Comprehensive Hospital Abstract
Reporting System.

NB, <20 years, 1993–2004, Washington
State Cancer Registry & Cancer
Surveillance System (CSS) of Western
Washington

Ten controls without NB per case
were randomly ascertained and were
frequency matched on year of
delivery.

Munzer et al., 2007 [69]
(France)

Maternal telephone interview (ICD-10
coded Q00-Q99). BDs were classified
as minor and major according to the
European Surveillance of Congenital
Anomalies.

NB, 0–14 years, 1/1/2003-12/31/2004,
the National Registry of Hematological
Cancer and the National Registry of
Childhood Solid Tumors

Controls were randomly selected
using phone numbers representative
of the French population frequency
matched to cases on age and gender.

Loder et al., 2007 [25]
(Indiana, U.S.)

Chest radiographs were reviewed for
rib number.

Overall, solid, lymphoproliferative, and
neural, 1–12 years, malignancies cared
for from 2001–2005, Riley’s Children’s
Hospital Pediatric Tumor Registry

A similar sized control group
identified from the Radiology
Department logs was selected from
children admitted at the same
hospital for polytrauma.
(Continued)
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Table 2. (Continued)
Reference (location)

BD ascertainment

Pediatric cancer case ascertainment:
Comparison group ascertainment
cancer types, age group, diagnosis
dates/years, case identification source

Mallol-Mesnard et al., 2008
[58] (France)

Maternal interview. BDs were
classified as minor and major
according to the European
Surveillance of Congenital Anomalies.

CNS, 0–14 years, 1/1/2003-12/31/2004,
National Registry of Childhood
Haematological Cancers and the
National Registry of Childhood Solid
Tumors

Controls were selected from the
French population by sampling from
60,000 representative addresses
taken from the French national
telephone directory plus unlisted
phone numbers generated randomly.
Age and gender quotas were applied.

Merks et al., 2008 [21]
(Amsterdam, Netherlands)

Clinical examination by a physician for
major and minor anomalies. BD
classification was based on Merks JH
et al., 2003 [107].

Overall, 0–18 years, 1/2000-3/2003,
Clinic for Late Effects of Childhood
Cancer Clinic in the Emma Children’s
Hospital, Academic Medical Center

Controls were recruited from the city
of Haarlem and the surrounding
semirural and rural area.

Johnson et al., 2009 [88] (U.S.
and Canada)

Maternal interview

GCT, 0–14 years, 1/1/1993-12/31/2001,
the Children’s Oncology Group

The control group was recruited
through RDD and frequency was
matched to cases on sex and birth
year within 1 year at ratios of
approximately 1:2 for males and 1:1
for females.

Johnson et al., 2010 [46] (U.S.
and Canada)

Maternal interview. Both major and
minor BDs were ascertained.

All infant leukemia, ALL, AML, 0–1 year,
1/1/96-10/13/02 (Phase I) 1/1/03-12/31/
06 (Phase II), the Children’s Oncology
Group

Phase one controls (5/1999-10/2002)
were sampled from the population
through RDD. Phase two controls
(10/2003-3/2008) were selected from
state birth registries. Controls were
frequency matched to cases on birth
year and region of residence based
on the phase one case distribution.

Durmaz et al., 2011 [20]
(Turkey)

Two medical geneticists qualified in
pediatric genetic dysmorphology
examined patients for ageindependent minor BDs by using the
London Dysmorphology database.

Overall, hematopoetic, CNS, WT/GCT,
RMS, OS, NR, NR, Cases were
diagnosed at Ege University Faculty of
Medicine, Izmir, Turkey

The control group was randomly
recruited from the Pediatric
Outpatient Service at the Ege
University Medical Faculty.

Partap et al., 2011 [57]
(California, U.S.)

California Office of Vital Records’ birth CNS, LGG, HGG, MB, PNET, GCT,
certificate database
EPD, 0–14 years, 1988–2006, California
Cancer Registry

Four controls that matched to each
case on birth date and sex were
selected from the California birth
certificate database.

Citak et al., 2011 [22] (Turkey)

Two pediatric hematologists/
oncologists examined patients for
minor BDs using the London
Dysmorphology database

ALL, AML, chronic myelocytic leukemia,
chronic myelomonocytic leukemia, MDS,
1.5–18 years, NR, cases diagnosed at a
single institution

The control group consisted of
healthy children of the same age,
gender, and ethnicity.

Zierhut et al., 2011 [24]
(Minnesota, U.S.)

Radiologists’ X-Ray examination for
rib anomalies

Overall, all acute leukemia, ALL, AML,
lymphoma, CNS, NB, renal, bone tumors,
sarcomas, 0–19 years, 2003–2009, the
University of Minnesota Medical CenterFairview

Controls were randomly selected
pediatric patients who received a
chest X-ray at Fairview Ridges
Hospital in Burnsville, MN.

Rudant et al., 2013 [45]
(France)

Maternal interview with structured
questionnaires. BDs were classified
as major and minor according to the
European Surveillance of Congenital
Anomalies.

All acute leukemia, ALL, AML, 0–14
years, 2003–2004, the National Registry
of Childhood Hematopoietic
Malignancies

Controls were recruited at random
from the telephone directory using
gender and age quotas in eight strata
reflecting the expected distribution of
all the cases.

Citak et al., 2013 [22] (Turkey)

Two pediatric hematologists/
oncologists examined patients for
minor BDs using the London
Dysmorphology Database.

Overall, lymphoma, solid tumors, 0.1–18
years, NR, "2 different institutions"

Controls were selected from
individuals seen at the healthy child
clinic of Mersin University Hospital
and Mersin Obstetric, Gynecology
and Children Hospital, Department of
Pediatric Hematology and Oncology
who were within the same age range,
sex, and ethnicity as cases.
(Continued)
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Table 2. (Continued)
Reference (location)

BD ascertainment

Pediatric cancer case ascertainment:
Comparison group ascertainment
cancer types, age group, diagnosis
dates/years, case identification source

Parodi et al., 2014 [72] (Italy)

Parental interview, structured
questionnaire (ICD-9 coded 740–759)

NB, 0–10 years, 1998–2001, Pediatric
Oncology Centers of the Italian
Association of Pediatric Hematology and
Oncology (AIEOP)

Controls were randomly selected
from the National Health Service
database matched on gender, date of
birth and area of residence.

Venkatramani et al., 2014 [84]
(U.S.)

Maternal interview/ the Utah
Population Database (UPDB, ICD-9
codes 740–759)

HB, 0–5 years, 2000–2008, the
Children’s Oncology Group (COG) for the
discovery cohort, the UPDB linked to the
State Cancer Registry from 1978–2010
for the validation cohort

The discovery control group was
identified from the birth registries
from 32 states and matched to cases
on birth weight, gender, birth year,
and region. The validation control
group was selected randomly from
the Utah population and matched
10:1 to cases on gender and birth
year.

Greenop et al., 2014 [60]
(Australia)

Mailed exposure questionnaire

Brain tumors, NR (childhood), 2005–
2010, 10 Australian oncology centers

Controls were recruited through
random digit dialing and matched to
childhood CBT cases on age, sex,
and state of residence at a 3:1 ratio
[108].

Santos et al., 2016 [109]
(Brazil)

Exam for café-au-lait spots by two
trained dysmorphologists

Solid tumors (clear cell renal cell
carcinoma, CNS, EWS, fibrosarcoma,
GCT, HB, OS, RB, RMS, synovial
sarcoma, STS, WT), 0–18, NR, NR

Cases were from Rio De Janeiro and
Sao Paulo. The control group was
comprised of school children from Rio
de Janeiro without a diagnosis of
cancer or a predisposing syndrome.

Rios et al., 2016 [74] (France)

Maternal telephone interview (ICD-10 NB, <6 years, 2003–2004 (ESCALE) and
coded). Minor BDs or unspecified BDs 2010–2011 (ESTELLE), French National
were excluded according to the
Registry of Childhood Cancer
European Surveillance of Congenital
Anomalies.

The analysis was based on pooled
data from two French case-control
studies (ESTELLE and ESCALE).
Controls were frequency matched to
cases on sex and age so that there
would be at least one control per
case.

Hall et al.c, 2017 [90]
(California, U.S.)

California birth certificates

GCT, yolk sac tumors, teratomas, 5
years, 1988–2013, California Cancer
Registry

Controls were randomly selected
from California birth records
frequency matched to cases on birth
year.

Bailey et al., 2017 [59]
(France)

Maternal telephone interview

Brain tumors, 0–14 years, 2003–2004
(ESCALE) and 2010–2011 (ESTELLE),
French National Registry of Childhood
Cancer

Same as Rios et al., 2016 [74].

Windham et al., 1985 [27]
(Norway)

Medical Birth Registry (ICD-8 codes
740–759)

Overall, leukemia, nervous system
tumors, renal cancer, eye cancer, NB,
0–13 years, 1967–1980, the Norwegian
Cancer Registry

Individuals without BDs from the
Norwegian Medical Birth Registry
comprised the unexposed group.

Mili et al., 1993 [28] (Georgia,
U.S.)

The Metropolitan Atlanta Congenital
Defects Program (major BDs, six-digit
code for reportable BDs, a
modification of the British Pediatric
Association Code, which uses a
modification of ICD-9 codes). BDs
were captured in the first year of life.

Overall, leukemia, brain tumors, NB, WT,
RB, 0–14, 1/1/1975-12/31/1988, the
Georgia Center for Cancer Statistics at
Emory University

The expected number of cancer
cases was calculated based on
Atlanta Surveillance Epidemiology
and End Results rates.

Mili et al., 1993 [29] (Iowa, U.
S.)

The Iowa Birth Defects Registry (only
major BDs, six-digit code for
reportable BDs, a modification of the
British Pediatric Association Code,
which uses a modification of ICD-9
codes). BDs were captured in the first
year of life.

Overall, leukemia, brain tumors, NB,
sarcoma, 0–7 years, 1/1/1983-12/31/
1989, the State Health Registry of Iowa’s
Cancer Registry (a SEER registry)

The expected number of cancer
cases was calculated based on Iowa
Surveillance Epidemiology and End
Results rates.

Cohort studies

(Continued)
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Table 2. (Continued)
Reference (location)

BD ascertainment

Pediatric cancer case ascertainment:
Comparison group ascertainment
cancer types, age group, diagnosis
dates/years, case identification source

Agha et al., 2005 [33] (Ontario, Canadian Congenital Anomalies
Canada)
Surveillance System (ICD-9 codes
740.0–759.9). BDs were captured in
the first year of life.

Overall, leukemia, lymphoma, CNS,
sympathetic nervous system, RB, renal
tumors, bone tumors, STS, GCT,
trophoblastic and other gonadal
carcinoma, and malignant epithelial,
0–19 years, 1979–1996, the Ontario
Cancer Registry

Children without BDs were selected
from the Birth Certificate File of
Ontario. For every child with a BD,
one child without BDs was selected
matched on birth year, maternal age,
birth order, mother’s marital status,
and parent’s place of birth (Ontario
vs. other).

Johnson et al., 2007 [37] (U.S.) Both maternal interview using
standardized tools and medical
examinations of the children for
birthmarks

Overall, 0–8 years, 1959–1966, the
Collaborative Perinatal Project (CPP)
subject population

Children without birthmarks in the
CPP cohort were used as the
comparison group.

Bjørge et al., 2008 [75]
(Norway)

The Medical Birth Registry of Norway

NB, 0–14 years, 1967–2004, the Cancer
Registry of Norway

The comparison group included all
live born children in Norway during
1967–2004 without reported
congenital malformations.

Rankin et al., 2008 [30]
(Northern Region, United
Kingdom)

Northern Congenital Abnormality
Survey (ICD-10 coded BDs). The
authors note including only "major
congenital anomaly subtypes" BDs
were captured in the first year of life.

Overall, ALL, AML, other leukemia, HL
and NHL, brain, NB, WT, RB, RMS, and
others, NR, 1985–2001, the Northern
Region Young Persons Malignant
Disease Registry

Children without BDs born in the
Northern Region were used as the
comparison group.

Carozza et al., 2012 [31]
(Texas, U.S.)

Texas Birth Defects Registry (1979
British Pediatric Association
Classification of Diseases and the
1979 ICD-9-CM, as modified by the U.
S. CDC and the Texas Department of
State Health Services). Major
structural and chromosomal BDs were
included. More minor defects were
included if the individual also had a
major BD. BDs were captured in the
first year of life.

Overall, leukemia, lymphoma, CNS, NB,
RB, renal tumors, hepatic tumors,
malignant bone tumors, STS, GCT, other
epithelial, 0–14 years, 1996–2005, the
Texas Cancer Registry

All children live born in Texas and not
registered in the Texas Birth Defects
Registry who were identified through
birth certificates were included as the
controls.

Fisher et al., 2012 [36]
(California, U.S.)

The California Birth Defects
Monitoring Program and birth
certificates (major BDs were classified
based on the British Pediatric
Association Classification of Diseases
codes, as modified by the CDC). BDs
were captured in the first year of life.

Overall, leukemia, lymphoma, CNS, NB,
WT, Non-CNS germ cell, RMS, 0–14
years, 1988–2006, the California Cancer
Registry

Children without major BDs born from
1988–2004 were used as the
comparison group.

Botto et al., 2013 [32] (Utah,
Arizona, Iowa, U.S.)

State Birth Defect Surveillance
Program (selected major BDs as
defined by the National Birth Defect
Prevention Network); BD’s were
captured up to 15 years of age.

Overall, leukemia, MDS/MPD,
lymphoma, brain tumor, NB spectrum,
RB, kidney tumor, liver tumor, sarcoma,
germ cell, trophoblastic and gonadal
tumor, 0–14 years, 1968–2005 for AZ,
1983–2005 for IA, 1994–2008 for Utah,
Arizona and Utah state cancer registries

The comparison group included
individuals without BDs selected
randomly from state birth certificates
who were frequency matched 3:1 to
the cases by birth year.

Sun et al., 2014 [38]
(Denmark)

Danish National Hospital Register
(Danish version of ICD-8 codes from
1977–1993: 740–743, 746–747, 759,
ICD-10 codes from 1994 onwards
Q00-07, Q20-28, Q90-99)

Overall, CNS, mesothelial and soft
tissue, skin, lymphatic and
haematopoietic, other systems, 0–19
years, 1/1/1977-12/31/2007, Danish
Cancer Registry

The comparison group consisted of
all children without BDs live born in
Denmark between 1977–2007 after
excluding missing data, adopted
children, twins, and chromosomal
anomalies.

Dawson et al., 2015 [34]
(Western Australia)

Western Australian Register of
Development Anomalies (British
Pediatric Association Classification of
Diseases, a five-digit extension of
ICD-9). BDs were captured in the first
year of life.

Overall, leukemia, lymphoma, CNS, NB,
RB, renal tumors, hepatic, bone, STS,
gonadal and germ cell, other epithelia/
melanoma, >90 days-14 years, 1982–
2007, Western Australia Cancer Registry

The comparison group included all
live born children with > 90 days of
follow-up born in Western Australia
from 1982–2007 BDs.

(Continued)
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Table 2. (Continued)
Reference (location)

BD ascertainment

Pediatric cancer case ascertainment:
Comparison group ascertainment
cancer types, age group, diagnosis
dates/years, case identification source

Janitz et al., 2016 [35]
(Oklahoma, U.S.)

Oklahoma Birth Defects Registry (as
defined by the CDC British Pediatric
Association codes for congenital
anomaly categories and classified
according to the National Birth
Defects Prevention Network (2004)).
BDs were reported up to age 6 years
but signs/symptoms must have been
present by age 2 years.

Overall, leukemia, lymphoma, CNS,
hepatic tumors, STS, GCT, 0–12 years,
1/1/1997-3/31/2009, Oklahoma Central
Cancer Registry

The comparison group comprised all
singleton births in Oklahoma from 1/
1/1997 to 3/31/2009 who were not
linked to the Oklahoma Birth Defects
Registry.

Johnson et al., 2008 [76]
(Minnesota, U.S.)

Minnesota Birth Registry records

NB, 28 days-14 years, 1988–2004,
Minnesota Cancer Surveillance System

The sub-cohort was comprised of
four individuals per childhood cancer
case randomly matched to cases on
birth year who were born from 1976–
2004.

Puumala et al., 2008 [82]
(Minnesota, U.S.)

Minnesota Birth Registry records

WT, 28 days-14 years, 1988–2004,
Minnesota Cancer Surveillance System

Same as Johnson et al., 2008 [76]

Spector et al., 2008 [85]
(Minnesota, U.S.)

Minnesota Birth Registry records

HB, 28 days-14 years, 1988–2004,
Minnesota Cancer Surveillance System

Same as Johnson et al., 2008 [76]

Case-cohort studies

Nested case-control studies
Wanderas et al., 1998 [92]
(Norway)

Medical Birth Registry (ICD-8 codes
Testicular GCTs, 0–28 years, 1967 to
and classifications by the Medical
June 1996, Norwegian Cancer Registry
Birth Registry and Statistics Norway).
The authors indicate BDs of "all types"
were included (Table 2). Recorded
“presentation anomalies” (present at
birth).

Approximately 100 controls per case
were obtained from the Norwegian
Birth Registry for the birth period of
1967–1995.

Lindblad et al., 1992 [81]
(Sweden)

Swedish Medical Birth Registry. BDs
captured up to one month of age.

WT, 0–11 years, 1973–1984, Swedish
National Cancer Registry

Five sex and birth month and year
matched controls without cancers
were selected for each case from the
Medical Birth Register.

Linet et al., 1996 [63]
(Sweden)

The National Medical Birth Register
(ICD-8 codes 740–759)

Brain tumors, 0–17 years, 1973–1989,
the National Cancer and Death Registers

Same as Lindblad et al., 1992 [81]

Case series studies with external comparison groups
Breslow et al., 1982 [83] (The
National Wilms’ Tumor Study
(NWTS))[110]

The NWTS registration form (ICD-9
codes 741–759)

WT, 0–15 years, 10/1969–3/1981, the
NWTS Statistical Center; histologic
confirmation was available for 75% of the
patients

Survey findings were compared to
the CPP and results from the CDC
Surveillance system on BDs.

Ruymann et al., 1988 [87]
(Ohio, U.S.)

Autopsy reports (major and minor
ascertained)

RMS, NR, NR, Autopsy results from
children in the Intergroup
Rhabdomyosarcoma Studies I and II

Rates were compared with those
from the NWTS and the CPP.

Narod et al., 1997 [53] (United
Kingdom)

A postal questionnaire to family
physicians of children diagnosed with
cancer and who were alive at the end
of 1988 (ICD-9 codes 7400–7599)

Leukemia, lymphoma, brain and spinal
cord, NB, RB, WT, liver, OS, ES, STS,
gonadal and germ cell, 0–14 years,
1971–1986, National Registry of
Childhood Tumors

The expected number of cancer
cases was calculated based on two
groups: 1) the frequency of BDs
among children in the study group,
and 2) the frequency of BDs recorded
in the British Columbia Health
Surveillance Registry (BC Registry).

https://doi.org/10.1371/journal.pone.0181246.t002

childhood cancers (HRs 2.81 and 2.03 for those diagnosed at 0–8 and 1–8 years respectively)
[37]. Botto et al. examined a number of specific BD types in children without chromosomal
anomalies observing that a majority increased risk [32]. Finally, Sun et al. reported BDs of
both the circulatory and nervous system were positively associated with pediatric cancer with
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Table 3. Studies on the association between birth defects and childhood cancer.
Reference

Comparison
group 1¥

Comparison
group 2¥

Cancer type

Birth defect

Risk estimate (95%
CI)

Comments

BDs excluding DS and naevi.

Overall case-control studies
Stewart et al.,
1958 [18]

1,416 (25)

1,416 (25)

Overall

Any BD

1.0 (0.57–1.75)a,b

Méhes et al.,
1985 [19]

104 (72)

104 (36)

Overall

Minor

4.25 (2.38–7.59)a,b

Schumacher et
al., 1992 [23]

1,000 (242)

200 (11)

Overall

Rib

5.49 (2.94–10.25)a,b

1,000 (22)

200 (1)

Overall

Cervical rib left

4.48 (0.60–33.40)a,b

1,000 (21)

200 (1)

Overall

Cervical rib right

4.27 (0.57–31.92)a,b

1,000 (161)

200 (7)

Overall

Cervical rib bilateral

5.29 (2.44–11.46)a,b

1,000 (5)

200 (0)

Overall

Synostoses

ND

1,000 (12)

200 (1)

Overall

Aplasia/hypo-

2.42 (0.31–18.69)a,b

1,000 (21)

200 (1)

Overall

Bifurcation

4.27 (0.57–31.92)a,b

Mann et al.,
1993 [16]

555 (60)

555 (27)

Overall

Any BD

2.37 (1.48–3.79)a,b

Data not shown for 555 hospital
controls.

Savitz et al.,
1994 [15]

242 (21)

212 (11)

Overall

Major BD

2.1 (0.9–5.0)b

Estimate adjusted for diagnosis year.

Altmann et al.,
1998 [17]

570 (55)

2,280 (58)

Overall

Any BD

4.5 (3.1–6.7)b

570 (18)

2,280 (5)

Overall

Chromosomal (758)

16.7 (6.1–45.3)b

570 (6)

2,280 (3)

Overall

Chromosomal excluding
DS (758)

9.2 (2.3–37.3)b

Adjusted for 6-month calendar period,
gender, birth weight, gestational age,
and maternal age.

570 (5)

2,280 (3)

Overall

Nervous system (740–
742, 340–2, 344, 350–9)

6.5 (1.5–27.8)b

570 (8)

2,280 (4)

Overall

Cardiac septal/bulbous
cords (745)

8.6 (2.6–29.0)b

570 (3)

2,280 (4)

Overall

Ventricular septal defect
(745.40–49)

4.4 (0.9–22.3)b

570 (4)

2,280 (4)

Overall

Ventricular septal defect
4.1 (1.0–16.8)b
excluding DS (745.40–49)

570 (9)

2,280 (7)

Overall

Other heart/circulatory
system (746–747)

5.5 (2.0–15.0)b

570 (6)

2,280 (7)

Overall

Other heart circulatory
excluding DS (746–747)

3.6 (1.2–10.8)b

570 (3)

2,280 (1)

Overall

Respiratory system (748)

14.5 (1.5–142)b

570 (5)

2,280 (3)

Overall

Eye/face/neck (743, 744)

7.3 (1.7–30.9)b

570 (7)

2,280 (11)

Overall

Gastrointestinal system
(750,751)

3.3 (1.2–9.0)b

570 (13)

2,280 (22)

Overall

Musculoskeletal system
(754–756)

2.7 (1.3–5.4)b

570 (4)

2,280 (5)

Overall

Congenital dislocation of
hip (754.30)

3.2 (0.9–12.5)b

570 (6)

2,280 (9)

Overall

Genitourinary system
(752–753)

2.9 (1.0–8.1)b

570 (3)

2,280 (5)

Overall

Hypospadias (752.60)

2.6 (0.6–10.9)b

570 (2)

2,280 (1)

Overall

Endocrine/metabolic
(240–279)

8.4 (0.8–93.2)b

570 (2)

2,280 (2)

Overall

Cleft lip and/or palate
(749)

9.0 (0.8–100)b

906 (78)

881 (54)

Overall

Cervical rib

1.44 (1.01–2.07)a,b

906 (48)

881 (58)

Overall

Aplasia 12th ribs

0.79 (0.54–1.18)a,b

906 (8)

881 (8)

Overall

Lumbar ribs

0.97 (0.36–2.60)a,b

906 (5)

881 (6)

Overall

Bifurcation

0.81 (0.25–2.66)a,b

906 (2)

881 (3)

Overall

Synostosis-Bridging

0.65 (0.11–3.88)a,b

906 (1)

881 (0)

Overall

Segmentation

ND

218 (39)

200 (16)

Overall

Abnormal rib number
(normal = 24 ribs)

2.5 (1.4–4.6)b

Merks et al.,
2005 [26]

Loder et al.,
2007 [25]

Children with a known BD or DS were
excluded.

(Continued)
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Table 3. (Continued)
Reference

Comparison
group 1¥

Comparison
group 2¥

Cancer type

Birth defect

Risk estimate (95%
CI)

Comments

Merks et al.,
2008 [21]

903 (65)

923 (6)

Overall

Blepharophimosis

11.1 (4.8–25.4)b

903 (58)

923 (2)

Overall

Asymmetric lower limbs

29.6 (7.3–121.0)b

903 (30)

923 (3)

Overall

Sydney crease

10.2 (3.1–33.4)b

903 (26)

923 (3)

Overall

Broad foot

8.9 (2.7–29.2)b

903 (14)

923 (0)

Overall

Isolated short metatarsals

1 (1.8-1)b

903 (13)

923 (0)

Overall

Short distal phalanx of
thumb

1 (1.6-1)b

Cases and controls were examined by
two different observers. Although the
authors report that "11% of controls and
7% of patients were scored
independently by 2 observers, resulting
in high scores", they do not report the
data associated with this comment.

903 (18)

923 (2)

Overall

Port-wine stain (Major
anomaly)

9.2 (2.1–39.5)b

903 (12)

923 (0)

Overall

Hyperconvex nails

1 (1.5-1)b

903 (43)

923 (16)

Overall

Retrognathia

2.8 (1.6–4.8)b

903 (25)

923 (6)

Overall

Hypoplastic alae nasi

4.3 (1.8–10.3)b

903 (52)

923 (24)

Overall

Prominent ears

2.2 (1.4–3.6)b

903 (15)

923 (2)

Overall

Broad hand

7.7 (1.8–33.4)b

903 (32)

923 (12)

Overall

Scoliosis

2.7 (1.4–5.3)b

903 (51)

923 (26)

Overall

Hypertelorism

2.0 (1.3–3.2)b

903 (15)

923 (3)

Overall

Tall stature

5.1 (1.5–17.6)b

903 (18)

923 (3)

Overall

Microcephaly

6.1 (1.8–20.8)b

Overall

Macrocephaly

4.4 (1.3–15.5)b

903 (13)

923 (3)
a

Durmaz et al.,
2011 [20]

200 (192 )

200 (70 )

Overall

Any minor

44.6 (20.7–95.7)a,b

Zierhut et al.,
2011 [24]

455 (31)

1,133 (51)

Overall

Any rib

1.60 (1.00–2.65)b

455 (29)

1,133 (47)

Overall

Rib number (<24 or >24)

1.66 (1.00–2.74)b

455 (6)

1,133 (9)

Overall

Cervical ribs

1.63 (0.55–4.80)b

116 (6)

Overall

Eye

4.78 (1.88–12.20)b

116 (7)

Overall

Ear

10.23 (4.37–23.94)b

116 (75)

116 (21)

Overall

Mouth

8.28 (4.51–15.18)b

116 (35)

116 (5)

Overall

Hand

9.59 (3.60–25.56)b

116 (41)

116 (8)

Overall

Feet

7.38 (3.27–16.64)b

42 (22,856)

NA

Overall

Any BD

1.9 (1.4–2.5)c*

NR (NR)

NA

Overall

Any BD (Male)

1.7c*

NR (NR)

NA

Overall

Any BD (Female)

2.1c*

NR (NR)

NA

Overall (0–4 years)

Any BD (Male)

1.5c

NR (NR)

NA

Overall (0–4 years)

Any BD (Female)

2.4c*

NR (NR)

NA

Overall (5–9 years)

Any BD (Male)

2.7c*

NR (NR)

NA

Overall (5–9 years)

Any BD (Female)

1.5c

Mili et al., 1993
[28]

31 (19,373)

400 (524,931)

Overall

Any BD

2.2 (1.5–3.2)d

Did not exclude any known genetic
syndromes. Estimates adjusted for age.
The authors also note adjusting for sex
and race in some analyses.

Mili et al., 1993
[29]

16 (10,891)

290 (241,473)

Overall

Any BD

2.0 (1.2–3.3)d

Did not exclude any known genetic
syndromes. Estimates adjusted for age
and sex. The authors note that "by age
5 years, the risk of cancer for children
with BDs was 2.0 times the risk for the
general population; by age 8 years, the
risk of cancer for children with BDs was
1.5 times the risk for the general
population."

Agha et al.,
2005 [33]

139 (45,200)

73 (45,200)

Overall

Any BD

2.0 (1.8–2.4)c

33 (NR)

6 (NR)

Overall (<1 year)

Any BD

5.8 (3.7–9.1)c

Did not exclude any known genetic
syndromes.

Citak et al., 2013 116 (24)
[22]
116 (46)

a

Estimates adjusted for sex and age.

Minor anomalies for major sites are
presented; includes only patients with
lymphoma and solid tumors.

Overall cohort studies
Windham et al.,
1985 [27]

Did not exclude any known genetic
syndromes. Estimates are age
standardized.

(Continued)
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Table 3. (Continued)
Reference

Comparison
group 1¥

Comparison
group 2¥

Cancer type

Birth defect

Risk estimate (95%
CI)

Comments

Johnson et al.,
2007 [37]

5 (NR)

40 (NR)

Overall (0–8 years)

Birthmarks

2.81 (1.11–7.13)e

3

33 (NR)

Overall (1–8 years)

Birthmarks

2.03 (0.62–6.62)e

Individuals with suspected birthmarks
were excluded. The authors note that
none of the individuals were recorded
as having a genetic syndrome.

Rankin et al.,
2008 [30]

39 (NR)

812a (NR)

Overall

Any BD

2.86 (2.11–3.89)f;
1.8 (1.2–2.7)f DS
excluded

Four cases of DS were observed in the
cohort.

Carozza et al.,
2012 [31]

239 (115,686)

2,112
(3,071,255a)

Overall

Any BD

3.05 (2.65–3.50)f

Genetic syndromes were not excluded.
The authors note that excluding
subjects with chromosomal anomalies
resulted in a lower IRR for leukemia and
total cancers but not for other cancers.

17 (115,686)

NR (3,071,255a)

Overall

CNS

3.61 (2.10–5.79)f

4 (115,686)

NR (3,071,255a)

Overall

Neural tube

3.03 (0.83–7.78)f

6 (115,686)

NR (3,071,255a)

Overall

Eye and ear

3.47 (1.27–7.56)f

5 (115,686)

NR (3,071,255a)

Overall

Anophthalmia/
microphthalmia

6.91 (2.24–16.14)f

91 (115,686)

NR (3,071,255a)

7 (115,686)
60 (115,686)

Cardiac and circulatory

3.50 (2.81–4.31)f

Overall

Conotruncal

3.14 (1.26–6.47)f

a

Overall

Septal

3.05 (2.32–3.94)f

a

NR (3,071,255 )
NR (3,071,255 )

54 (115,686)

NR (3,071,255 )

Overall

Left ventricular outflow
tract

4.22 (3.16–5.53)f

5 (115,686)

NR (3,071,255a)

Overall

Respiratory

3.58 (1.16–8.36)f

11 (115,686)

NR (3,071,255a)

Overall

Oral clefts

2.69 (1.34–4.82)f

13 (115,686)

NR (3,071,255a)

Overall

Gastrointestinal

1.69 (0.90–2.89)f

5 (115,686)

NR (3,071,255a)

Overall

Gastrointestinal atresia/
stenosis

2.56 (0.83–5.97)f

34 (115,686)

NR (3,071,255a)

5 (115,686)
1 (115,686)

Fisher et al.,
2012 [36]

Overall

a

Overall

Genitourinary

2.37 (1.64–3.32)f

a

Overall

Musculoskeletal

0.88 (0.29–2.06)f

a

Overall

Limb reduction

0.80 (0.02–4.49)f

a

NR (3,071,255 )
NR (3,071,255 )

3 (115,686)

NR (3,071,255 )

Overall

Abdominal wall

2.26 (0.47–6.62)f

55 (115,686)

NR (3,071,255a)

Overall

Chromosomal (includes
trisomies 21, 13, and 18)

15.52 (11.66–20.27)f

132 (59,258)

NR (NR)

Overall

Non-chromosomal

1.58 (1.33–1.87)e

90 (6,327)

NR (NR)

Overall

Chromosomal

12.44 (10.10–15.32)e

0 (488)

NR (NR)

Overall

Amniotic bands (658)

-

0 (423)

NR (NR)

Overall

Anencephalus (740)

-

3 (1,124)

NR (NR)

Overall

Spina bifida (741)

3.19 (1.03–9.89)e

35 (7,678)

NR (NR)

Overall

Other BD of nervous
system (742)

5.83 (4.18–8.14)e

24 (6,392)

NR (NR)

Overall

BD of eye (743)

4.90 (3.28–7.32)e

26 (11, 025)

NR (NR)

Overall

BD of ear, face, neck
(744)

2.94 (2.00–4.33)e

25 (10,151)

NR (NR)

Overall

Bulbus cordis anomaly/
cardiac septal closure
(745)

3.36 (2.27–4.98)e

23 (7,990)

NR (NR)

Overall

Other BD of heart (746)

3.99 (2.65–6.01)e

21 (6,840)

NR (NR)

Overall

Other BD of circulatory
system (747)

4.28 (2.79–6.57)e

24 (7,958)

NR (NR)

Overall

BD of respiratory system
(748)

4.25 (2.85–6.35)e

5 (4,662)

NR (NR)

Overall

Cleft lip and palate (749)

1.25 (0.52–3.02)e

23 (10,608)

NR (NR)

Overall

Other BD of upper
alimentary (750)

2.45 (1.62–3.69)e

11 (5,419)

NR (NR)

Overall

Other BD of digestive
system (751)

2.44 (1.35–4.40)e

22 (9,522)

NR (NR)

Overall

BD of genital organs (752) 2.62 (1.72–3.98)e

15 (5,989)

NR (NR)

Overall

BD or urinary system
(753)

Children with leukemia were excluded
from the non-chromosomal analysis.
Results for specific BDs exclude
children with chromosomal anomalies.

3.15 (1.90–5.23)e

(Continued)
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Table 3. (Continued)
Reference

Botto et al.,
2013 [32]

Comparison
group 1¥

Comparison
group 2¥

Cancer type

Birth defect

Risk estimate (95%
CI)

23 (10,263)

NR (NR)

Overall

Certain congenital
musculoskeletal
deformities (754)

2.56 (1.70–3.86)e

23 (11,329)

NR (NR)

Overall

Other BD of limbs (755)

2.37 (1.57–3.57)e

30 (11,168)

NR (NR)

Overall

Certain congenital
musculoskeletal anomaly
(756, excluding 754)

3.37 (2.35–4.83)e

31 (11,444)

NR (NR)

Overall

BD of integument (757)

3.09 (2.17–4.40)e

15 (3,161)

NR (NR)

Overall

Other and unspecified BD
(759)

7.80 (4.70–12.94)e

123 (44,151)

161 (147,940)

Overall

Any BD

2.9 (2.3–3.7)f

77 (39,726)

161 (147,940)

Overall

Non-chromosomal

2.0 (1.5–2.6)f

9 (4,311)

161 (147,940)

Overall

Brain

2.2 (1.1–4.3)f

<5 (1,334)

161 (147,940)

Overall

Neural tube defects, all

2.3 (0.7–7.3)f

<5 (1,108)

161 (147,940)

Overall

Spina bifida w/out
anencephalus

2.7 (0.9–8.4)f

0 (226)

161 (147,940)

Overall

Encepahalocele

0.0f

5 (1,801)

161 (147,940)

Overall

Microcephaly

2.9 (1.2–7.1)f

<5 (63)

161 (147,940)

Overall

Holoprosencephaly

24.5 (3.4–175.3)f

<5 (1,271)

161 (147,940)

Overall

Hydrocephalus (no spina
bifida)

0.9 (0.1–6.3)f

8 (928)

161 (147,940)

Overall

Eye

9.4 (4.6–19.1)f

<5 (432)

161 (147,940)

Overall

Anophtalmia/
microphthalmia

8.4 (2.7–26.3)f

6 (530)

161 (147,940)

Overall

Congenital cataract

11.6 (5.1–26.1)f

<5 (31)

161 (147,940)

Overall

Aniridia

30.8 (4.3–219.9)f

<5 (626)

161 (147,940)

Overall

Ear (anotia/microtia)

1.7 (0.2–11.9)f

<5 (422)

161 (147,940)

Overall

Craniosynotosis

3.4 (0.5–24.4)f

28 (11,211)

161 (147,940)

Overall

Heart

2.9 (1.9–4.3)f

<5 (465)

161 (147,940)

Overall

Complex heart defects

3.6 (0.5–25.6)f

<5 (172)

161 (147,940)

Overall

Common truncus

13.1 (1.8–93.3)f

<5 (687)

161 (147,940)

Overall

Transposition of great
arteries

3.7 (0.9–14.9)f

<5 (759)

161 (147,940)

Overall

Tetralogy of Fallot

1.6 (0.2–11.4)f

<5 (350)

161 (147,940)

Overall

Atrioventricular septal
defect (AV canal)

9.1 (2.2–36.6)f

<5 (64)

161 (147,940)

Overall

Total anomalous
pulmonary venous return

20.5 (2.9–146.4)f

0 (182)

161 (147,940)

Overall

Pulmonary valve atresia

0.0f

0 (153)

161 (147,940)

Overall

Tricuspid valve atresia
and stenosis

0.0f

0 (141)

161 (147,940)

Overall

Ebstein anomaly

0.0f

0 (509)

161 (147,940)

Overall

Hypoplastic left heart
syndrome

0.0f

<5 (1,024)

161 (147,940)

Overall

Coarctation of the aorta

1.1 (0.1–7.6)f

<5 (540)

161 (147,940)

Overall

Aortic valve stenosis

4.5 (1.1–18.1)f

0 (203)

161 (147,940)

Overall

Other major congenital
heart defects

0.0f

<5 (1,037)

161 (147,940)

Overall

Pulmonary valve stenosis

2.2 (0.5–8.9)f

5 (2,330)

161 (147,940)

Overall

Ventricular septal defect,
membranous

2.5 (1.0–6.0)f

<5 (1,276)

161 (147,940)

Overall

Ventricular septal defect,
NOS

2.2 (0.8–6.1)f

6 (1,404)

161 (147,940)

Overall

Atrial septal defect

5.1 (2.2–11.4)f

Comments

Children with chromosomal anomalies
were excluded. The relative hazard of
cancer for children with nonchromosomal anomalies was highest in
the first 3 years of life (figure 3).

(Continued)
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Table 3. (Continued)
Reference

Sun et al., 2014
[38]

Comparison
group 1¥

Comparison
group 2¥

Cancer type

Birth defect

Risk estimate (95%
CI)

6 (4,756)

161 (147,940)

Overall

Orofacial

1.3 (0.6–2.8)f

5 (1,656)

161 (147,940)

Overall

Cleft palate/without cleft
lip

3.2 (1.3–7.9)f

<5 (3,100)

161 (147,940)

Overall

Cleft lip with or without
cleft palate

0.3 (0–2.2)f

0 (387)

161 (147,940)

Overall

Choanal atresia

0.0f

13 (7,207)

161 (147,940)

Overall

Gastrointestinal (GI)

1.7 (1.0–3.0)f

<5 (1,367)

161 (147,940)

Overall

GI atresias, all

2.4 (0.8–7.6)f

<5 (562)

161 (147,940)

Overall

Esophageal atresia/TE
Fistula

2.0 (0.3–14)f

0 (67)

161 (147,940)

Overall

Duodenal atresia

0.0f

0 (79)

161 (147,940)

Overall

Jejunal/Ileal atresia

0.0f

0 (9)

161 (147,940)

Overall

Small intestinal atresia

0.0f

<5 (1,025)

161 (147,940)

Overall

Rectal/intestinal atresia/
stenosis

3.2 (1.0–10)f

6 (5,071)

161 (147,940)

Overall

Pyloric stenosis

1.1 (0.5–2.4)f

<5 (377)

161 (147,940)

Overall

Hirschsprung disease

5.2 (1.3–20.8)f

<5 (163)

161 (147,940)

Overall

Bilary atresia

15.2 (3.8–61.3)f

<5 (1,479)

161 (147,940)

Overall

Abdominal wall defects
and variants

2.3 (0.7–7.2)f

<5 (368)

161 (147,940)

Overall

Omphalocele

3.2 (0.4–22.8)f

<5 (972)

161 (147,940)

Overall

Gastroschisis

2.3 (0.6–9.3)f

0 (17)

161 (147,940)

Overall

Cloacal exstrophy

0.0f

0 (66)

161 (147,940)

Overall

Bladder exstrophy

0.0f

0 (131)

161 (147,940)

Overall

Epispadias

0.0f

<5 (605)

161 (147,940)

Overall

Diaphragmatic hernia

5.3 (1.3–21.5)f

20 (10,877)

161 (147,940)

Overall

Genitourinary (GU)

1.8 (1.2–2.9)f

12 (4,349)

161 (147,940)

Overall

Renal, all

3.3 (1.8–5.9)f

5 (977)

161 (147,940)

Overall

Renal agenesis/
hypoplasia

8.3 (3.4–20.2)f

8 (3,561)

161 (147,940)

Overall

Obstructive GU defect

2.5 (1.2–5.1)f

8 (6,691)

161 (147,940)

Overall

Hypospadias (includes 1st
degree)

1.1 (0.5–2.2)f

<5 (1,019)

161 (147,940)

Overall

Limb deficiencies

1.9 (0.5–7.7)f

<5 (663)

161 (147,940)

Overall

Transverse

3.0 (0.7–12.2)f

<5 (299)

161 (147,940)

Overall

Preaxial

4.0 (0.6–28.2)f

0 (332)

161 (147,940)

Overall

Postaxial

0.0f

0 (439)

161 (147,940)

Overall

Limb deficiency, Not
elsewhere classfied/Not
otherwise specified

0.0f

218 (0)

161 (147,940)

Overall

Amniotic bands

0.0f

46 (4,425)

161 (147,940)

Overall

Chromosomal

13.2 (9.5–18.3)f

14 (4,484)

207 (1,547,126)

Overall (<1 year)

Nervous system (cohort
entry on day of birth)

23.41 (13.62–40.22)e

NR (NR)

NR (NR)

Overall (<1 year)

Nervous system (cohort
entry at BD diagnosis)

23.86 (11.23–50.70)e

36 (4,484)

1,824 (1,547,126)

Overall (1–15 years)

Nervous system (cohort
entry on day of birth)

6.58 (4.73–9.16)e

NR (NR)

NR (NR)

Overall (1–15 years)

Nervous system (cohort
entry at BD diagnosis)

5.55 (3.7–8.23)e

12 (24,643)

<207 (1,547,126)

Overall (<1 year)

Circulatory system
(cohort entry on day of
birth)

3.64 (2.03–6.51)e

Comments

Children with chromosomal anomalies
were excluded. Estimates adjusted for
calendar year and sex.

(Continued)
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Table 3. (Continued)
Reference

Dawson et al.,
2015 [34]

Comparison
group 1¥

Comparison
group 2¥

Cancer type

Birth defect

Risk estimate (95%
CI)

NR (NR)

NR (NR)

Overall (<1 year)

Circulatory system
(cohort entry at BD
diagnosis)

1.12 (0.28–4.51)e

93 (4,484)

1,824 (1,547,126)

Overall (1–15 years)

Circulatory system
(cohort entry on day of
birth)

3.31 (2.68–4.07)e

NR (NR)

NR (NR)

Overall (1–15 years)

Circulatory system
(cohort entry at BD
diagnosis)

1.36 (0.95–1.94)e

94 (32,310)

894a (608,726a)

Overall

Any BD

1.96 (1.57–2.43)e

3 (1,062)

894a (608,726a)

Overall

Chromosomal

2.03 (0.66–6.31)e

54 (31,211)

894a (608,726a)

Overall

Non-chromosomal

1.16 (0.88–1.53)e

0 (1,409)

894a (608,726a)

Overall

Nervous

0, -e

0 (645)
3 (1,479)
14 (5,617)

a

Overall

Eye

0, -e

a

a

Overall

Ear, face, neck

1.41 (0.46–4.38)e

a

a

Overall

Cardiovascular

1.76 (1.04–2.99)e

a

a

894 (608,726 )
894 (608,726 )
894 (608,726 )

1 (228)

894 (608,726 )

Overall

Respiratory

3.64 (0.52–25.63)e

3 (3,318)

894a (608,726a)

Overall

Gastrointestinal

0.61 (0.20–1.88)e

14 (9,577)

894a (608,726a)

Overall

Urogenital

0.97 (0.57–1.65)e

14 (8,222)
7 (2,348)
5 (3,307)

Janitz et al.,
2016 [35]

a

a

a

Overall

Musculoskeletal

1.14 (0.67–1.93)e

a

a

Overall

Skin

1.98 (0.94–4.17)e

a

a

Overall

Other

1.04 (0.43–2.51)e

a

a

894 (608,726 )
894 (608,726 )
894 (608,726 )

57 (32,273)

894 (608,726 )

Overall (all ages > 90
days of follow-up)

N BDs

1.19 (0.91–1.56)e

44 (32,273)

468a (608,726a)

Overall (3 months– 4
years)

N BDs

1.74 (1.28–2.37)e

7 (32,273)

83a (608,726 a)

Overall (3–12 months)

N BDs

1.59 (0.73–3.43)e

37 (31,368)

385a (586,277a)

Overall (1–4 years)

N BDs

1.77 (1.26–2.48)e

12 (26,598)

232a (485,396a)

Overall (5–9 years)

N BDs

0.95 (0.53–1.70)e

a

a

1 (19,590)

194 (367,319 )

Overall (10–14 years)

N BDs

0.10 (0.01–0.72)e

56 (23,368)

475 (567,867)

Overall

Any BD (w/chromosomal)

3.0 (2.2–3.9)e†

NA

NA

Overall (<1 year)

Any BD (w/chromosomal)

14.1 (8.3–23.7)e

NA

NA

Overall (3 years)

Any BD (w/chromosomal)

2.3 (1.6–3.2)e

NA

NA

Overall (6 years)

Any BD (w/chromosomal)

1.1 (0.7–1.9)e

NA

NA

Overall (9 years)

Any BD (w/chromosomal)

0.8 (0.4–1.4)e

NA

NA

Overall (12 years)

Any BD (w/chromosomal)

0.6 (0.3–1.1)e

12a (1,259)

NR (NR)

Overall

Chromosomal

11.9 (6.7–12.2)e†

NA

NA

Overall (<1 year)

Chromosomal

84.7 (33.8–211.9)e

NA

NA

Overall (3 years)

Chromosomal

7.3 (3.2–16.6)e

NA

NA

Overall (6 years)

Chromosomal

2.9 (0.8–9.6)e

NA

NA

Overall (9 years)

Chromosomal

1.6 (0.4–7.1)e

NA

NA

Overall (12 years)

Chromosomal

1.1 (0.2–5.9)e

NR (2,143)

NR (NR)

Overall

CNS (w/chromosomal)

3.0 (1.2–7.2)e†

NA

NA

Overall (<1 year)

CNS (w/chromosomal)

18.8 (4.6–77.8)e

NA

NA

Overall (3 years)

CNS (w/chromosomal)

2.0 (0.6–6.5)e

NA

NA

Overall (6 years)

CNS (w/chromosomal)

0.8 (0.1–4.9)e

NA

NA

Overall (9 years)

CNS (w/chromosomal)

0.5 (0.1–4.3)e

NA

NA

Overall (12 years)

CNS (w/chromosomal)

0.3 (0.0–4.0)e

NR (1,179)

NR (NR)

Overall

Eye/Ear (w/chromosomal) 3.6 (1.4–9.7)e†

NA

NA

Overall (<1 year)

Eye/Ear (w/chromosomal) 27.9 (6.1–127.0)e

NA

NA

Overall (3 years)

Eye/Ear (w/chromosomal) 2.2 (0.5–9.1)e

NA

NA

Overall (6 years)

Eye/Ear (w/chromosomal) 0.8 (0.1–6.8)e

Comments

Any BD included all BDs. Other risk
estimates excluded syndromes known
to be associated with cancer (e.g. DS)
(N category).

HRs were estimated at each age.
Specific type BD analyses exclude
children with chromosomal anomalies
unless specifically noted that they are
included (w/chromosomal). The authors
note that the proportional hazards
assumption was not met for the overall
association and that a continuous time
interaction model was used for those
noted with an ‘†’. The HRs for
genitourinary and musculoskeletal(nonchromosomal) were adjusted for
maternal education and prenatal care,
respectively.

(Continued)
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Table 3. (Continued)
Reference

Comparison
group 1¥

Comparison
group 2¥

Cancer type

Birth defect

Risk estimate (95%
CI)

NA

NA

Overall (9 years)

Eye/Ear (w/chromosomal) 0.4 (0.0–5.9)e

NA

NA

Overall (12 years)

Eye/Ear (w/chromosomal) 0.3 (0.0–5.4)e

NR (7,059)

NR (NR)

Overall

Cardiovascular (w/
chromosomal)

4.4 (2.9–6.6)e†

NA

NA

Overall (<1 year)

Cardiovascular (w/
chromosomal)

22.5 (11.0–46.1)e

NA

NA

Overall (3 years)

Cardiovascular (w/
chromosomal)

3.2 (1.9–5.4)e

NA

NA

Overall (6 years)

Cardiovascular (w/
chromosomal)

1.5 (0.7–3.2)e

NA

NA

Overall (9 years)

Cardiovascular (w/
chromosomal)

0.9 (0.4–2.5)e

NA

NA

Overall (12 years)

Cardiovascular (w/
chromosomal)

0.7 (0.2–2.1)e

NR (1997)

NR (NR)

Overall

Orofacial (w/
chromosomal)

2.5 (0.9–6.6)e

NR (3,736)

NR (NR)

Overall

Gastrointestinal (w/
chromosomal)

2.4 (1.4–5.1)e†

NA

NA

Overall (<1 year)

Gastrointestinal (w/
chromosomal)

21.1 (7.0–63.2)e

NA

NA

Overall (3 years)

Gastrointestinal (w/
chromosomal)

1.1 (0.3–3.8)e

NA

NA

Overall (6 years)

Gastrointestinal (w/
chromosomal)

0.3 (0.1–2.2)e

NA

NA

Overall (9 years)

Gastrointestinal (w/
chromosomal)

0.2 (0.0–1.6)e

NA

NA

Overall (12 years)

Gastrointestinal (w/
chromosomal)

0.1 (0.0–1.3)e

NR (4,124)

NR (NR)

Overall

Genitourinary (w/
chromosomal)

2.5 (1.3–5.1)e†

NA

NA

Overall (<1 year)

Genitourinary (w/
chromosomal)

15.6 (5.0–48.6)e

NA

NA

Overall (3 years)

Genitourinary (w/
chromosomal)

1.6 (0.6–4.3)e

NA

NA

Overall (6 years)

Genitourinary (w/
chromosomal)

0.7 (0.2–2.9)e

NA

NA

Overall (9 years)

Genitourinary (w/
chromosomal)

0.4 (0.1–2.4)e

NA

NA

Overall (12 years)

Genitourinary (w/
chromosomal)

0.3 (0.0–2.1)e

NR (6,825)

NR (NR)

Overall

Musculoskeletal (w/
chromosomal)

1.2 (0.6–2.6)e†

NA

NA

Overall (<1 year)

Musculoskeletal (w/
chromosomal)

5.3 (1.4–20.5)e

NA

NA

Overall (3 years)

Musculoskeletal (w/
chromosomal)

1.0 (0.4–2.5)e

NA

NA

Overall (6 years)

Musculoskeletal (w/
chromosomal)

0.6 (0.2–2.0)e

NA

NA

Overall (9 years)

Musculoskeletal (w/
chromosomal)

0.4 (0.1–1.9)e

NA

NA

Overall (12 years)

Musculoskeletal (w/
chromosomal)

0.3 (0.0–1.8)e

44 (22,109a)

475 (567,867)

Overall

Non-chromosomal

2.5 (1.8–3.3)e†

NA

NA

Overall (<1 year)

Non-chromosomal

10.7 (6.0–19.1)e

NA

NA

Overall (3 years)

Non-chromosomal

2.0 (1.4–2.9)e

NA

NA

Overall (6 years)

Non-chromosomal

1.0 (0.6–1.8)e

NA

NA

Overall (9 years)

Non-chromosomal

0.7 (0.4–1.4)e

NA

NA

Overall (12 years)

Non-chromosomal

0.5 (0.3–1.2)e

Comments

(Continued)
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Table 3. (Continued)
Reference

Comparison
group 1¥

Comparison
group 2¥

Cancer type

Birth defect

Risk estimate (95%
CI)

NR (1,998)

NR (NR)

Overall

CNS

1.9 (0.6–5.9)e†

NR (1,179)

NR (NR)

Overall

Eye/Ear

2.0 (0.5–8.1)e

NR (3,369)

NR (NR)

Overall

Cardiovascular

2.8 (1.7–4.8)e†

NA

NA

Overall (<1 year)

Cardiovascular

11.1 (4.2–29.4)e

NA

NA

Overall (3 years)

Cardiovascular

2.4 (1.3–4.4)e

NA

NA

Overall (6 years)

Cardiovascular

1.3 (0.5–3.2)e

NA

NA

Overall (9 years)

Cardiovascular

0.9 (0.3–2.8)e

NA

NA

Overall (12 years)

Cardiovascular

0.7 (0.2–2.6)e

NR (1,887)

NR (NR)

Overall

Orofacial

2.6 (1.0–6.9)e

NR (3,552)

NR (NR)

Overall

Gastrointestinal

2.2 (1.0–4.9)e†

NA

NA

Overall (<1 year)

Gastrointestinal

18.5 (5.7–60.2)e

NA

NA

Overall (3 years)

Gastrointestinal

1.0 (0.3–3.8)e

NA

NA

Overall (6 years)

Gastrointestinal

0.3 (0.0–2.4)e

NA

NA

Overall (9 years)

Gastrointestinal

0.2 (0.0–1.8)e

NA

NA

Overall (12 years)

Gastrointestinal

0.1 (0.0–1.5)e

NR (3,932)

NR (NR)

Overall

Genitourinary

1.7 (0.7–4.0)e†

NA

NA

Overall (<1 year)

Genitourinary

3.6 (0.5–26.4)e

NA

NA

Overall (3 years)

Genitourinary

1.2 (0.4–3.6)e

NA

NA

Overall (6 years)

Genitourinary

0.8 (0.2–3.8)e

NA

NA

Overall (9 years)

Genitourinary

0.7 (0.1–4.5)e

NA

NA

Overall (12 years)

Genitourinary

0.6 (0.1–5.1)e

NR (6,575)

NR (NR)

Overall

Musculoskeletal

1.3 (0.6–2.8)e

Comments

Leukemias, myeloproliferative diseases, myelodysplastic diseases, and lymphoma case-control studies
Ager et al., 1965
[39]

112 (5)

Siblings: 105 (3);
Neighborhood:
112 (1)

Leukemia

Any BD

Siblings: 1.59 (0.37–
6.82)a,b;
Neighborhood: 5.19
(0.60–45.13)a,b

DS cases were excluded.

Méhes et al.,
1985 [19]

49 (37)

37 (25) sibling,
49 (19) controls

Leukemia

Minor BD

Siblings: 1.48 (0.57–
3.82)a,b;
Controls: 4.87 (2.04–
11.60)a,b

Major anomalies were also reported;
however there was insufficient detail to
evaluate associations. The authors note
two ALL cases with DS and fetal
hydantoin syndrome were excluded.

Shu et al., 1988
[48]

309 (0)

618 (0)

Leukemia

Any BD

ND

The only BD noted was one DS case.
DS cases were excluded.

Magnani et al.,
1990 [47]

Zack et al., 1991
[40]

Schumacher et
al., 1992 [23]

Mann et al.,
1993 [16]

142 (4)

307 (6)

ALL

Any BD

1.45 (0.40–5.24)a,b

22 (0)

307 (6)

AML

Any BD

-

19 (0)

307 (6)

NHL

Any BD

-

411 (31)

2,055 (99)

All leukemias

Any BD

1.6 (1.1–2.4)b

411 (3)

2,055 (3)

All leukemias

Cleft lip or cleft palate

5.0 (1.0–24.8)b

411 (19)

2,055 (80)

Lymphatic leukemias

Any BD

1.2 (0.7–2.0)b

411 (3)

2,055 (3)

Lymphatic leukemias

Cleft lip or cleft palate

5.0 (1.0–24.8)b

411 (10)

2,055 (11)

Myeloid leukemias

Any BD

5.2 (2.1–12.9)b

411 (0)

2,055 (0)

Myeloid leukemias

Cleft lip or cleft palate

ND

411 (2)

2,055 (8)

Any BD

1.3 (0.3–6.5)b

411 (0)

2,055 (8)

Other or unspecified
leukemias

Cleft lip or cleft palate

ND

227 (61a)

200 (11)

ALL

Rib

6.31 (3.21–12.40)a,b

63 (7 )

200 (11)

NHL

Rib

2.15 (0.80–5.80)a,b

54 (4a)

200 (11)

HD

Rib

1.37 (0.42–4.50)a,b

148 (11)

148 (8)

ALL

Any BD

1.41 (0.55–3.60)a,b

23 (3)

23 (0)

Other leukemias

Any BD

ND

32 (4)

32 (1)

HL

Any BD

4.43 (0.47–42.02)a,b

31 (3)

31 (4)

Other lymphomas

Any BD

0.72 (0.15–3.54)a,b

a

The authors note that only children with
DS or cleft lip or palate had an
increased risk of leukemia.

DS occurred in three leukemia cases. A
variety of BDs were reported in single
cases and controls but no formal
analysis was done. Estimates adjusted
for diagnosis age, sex, and diagnosis
year. Pedigree was shown for one case
with a ALL.
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Table 3. (Continued)
Reference

Comparison
group 1¥

Comparison
group 2¥

Cancer type

Birth defect

Risk estimate (95%
CI)

Comments

Savitz et al.,
1994 [15]

71 (6)

212 (11)

ALL

Major

2.1 (0.8–7.8)b

26 (2)

212 (11)

Lymphoma

Major

1.6 (0.3–7.5)b

DS exclusion not noted. Estimates
adjusted for diagnosis age, sex, and
diagnosis year.

Cnattingius et
al., 1995 [49]

613 (NR)

3,065 (NR)

Lymphatic leukemia

Cleft lip or palate (ICD-8
code 749)

2.0 (0.4–10.3)b

Authors’ note: "Among infants with
congenital malformations, only those
with Down’s syndrome . . . had an
increased risk of lymphatic leukemia."
The authors did not report risk
estimates for BDs overall.

Cnattingius et
al., 1995 [41]

84 (5)

490 (18)

Myeloid leukemia

Any BD

1.4 (0.5–3.8)b

DS cases were excluded.

84 (3)

490 (3)

Myeloid leukemia

Heart

5.0 (1.01–24.8)b

Adami et al.,
1996 [54]

168 (5)

840 (37)

NHL

Any BD (ICD-9 codes
740–759)

0.7 (0.3–1.7)b

DS exclusion not noted.

Altmann et al.,
1998 [17]

224 (19)

NR (NR)

Leukemia

Any BD

3.7 (2.2–6.5)b

185 (9)

NR (NR)

ALL

Any BD

2.0 (0.96–4.1)b

32 (7)

NR (NR)

AML

Any BD

11.6 (4.6–29.4)b

32 (1)

NR (3)

AML

Non-DS chromosomal

20.3 (1.8–224)b

DS cases were not excluded except
where noted. Any BD estimates
adjusted for 6-month calendar period,
gender, birth weight, gestational age,
and maternal age.

NR (NR)

Lymphoma

Any BD

2.1 (0.5–9.2)b

45 (2)
a

Méhes et al.,
1998 [52]

100 (82 )

Controls: 200
(83a); Siblings: 80
(69a)

Leukemia

Mild errors of
morphogenesis (55
MEMs based on Pinsky et
al.[111])

NR

DS exclusion not noted. Case and
control mean MEM numbers were 1.59
and 0.69 (p<0.01); Cases and sibling
mean MEM numbers were 1.59 and
1.51 (not significant).

Mertens et al.,
1998 [43]

2,117 (526)

2,368 (443)

ALL

Overall (at least 1 BD)

1.43 (1.25–1.66)a,b

2,117 (664)

2,368 (552)

ALL

Total no. of abnormalities

1.50 (1.32–1.72)b

2,117 (4)

2,368 (10)

ALL

Cleft lip or palate

0.45 (0.14–1.38)b

2,117 (5)

2,368 (7)

ALL

Club foot

0.80 (0.25–2.51)b

2,117 (161)

2,368 (136)

ALL

Large or multiple
birthmarks

1.35 (1.07–1.71)b

2,117 (8)

2,368 (8)

ALL

Deafness or impaired
hearing

1.12 (0.42–2.99)b

Estimates adjusted for maternal race,
maternal education, and family income.
After exclusion of DS cases, the
significant associations between
pancreatic or digestive tract
abnormalities and ALL and between
multiple birthmarks and both ALL and
AML remained.

2,117 (20)

2,368 (18)

ALL

Blindness or difficulty
seeing

1.25 (0.66–2.36)b

2,117 (10)

2,368 (4)

ALL

Eyes different colors or
missing iris

2.81 (0.92–8.53)b

2,117 (5)

2,368 (3)

ALL

Water on the brain or
hydrocephalus

1.87 (0.46–7.64)b

2,117 (4)

2,368 (3)

ALL

Spina bifida or other
spinal

1.49 (0.34–6.61)b

2,117 (2)

2,368 (7)

ALL

Cerebral palsy

0.32 (0.07–1.42)b

2,117 (3)

2,368 (2)

ALL

Unusually small head or
microcephaly

1.68 (0.29–9.86)b

2,117 (3)

2,368 (2)

ALL

Unequal sized limbs or
hemihypertrophy

1.68 (0.29–9.86)b

2,117 (73)

2,368 (72)

ALL

Any skeletal deformity

1.14 (0.82–1.59)b

2,117 (98)

2,368 (75)

ALL

Hole in heart or other
heart

1.48 (1.09–2.01)b

2,117 (29)

2,368 (13)

ALL

Pancreas or digestive
tract

2.52 (1.33–4.75)b

2,117 (47)

2,368 (49)

ALL

Any other BDs

1.08 (0.72–1.61)

2,117 (39)

2,368 (31)

ALL

Genitourinary

1.42 (0.88–2.27)b

605 (149)

769 (115)

AML

Overall (at least 1 BD)

1.86 (1.42–2.44)a,b

605 (231)

769 (135)

AML

Total no. of abnormalities

2.90 (2.27–3.70)b

(Continued)
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Table 3. (Continued)
Reference

Comparison
group 1¥

Comparison
group 2¥

Cancer type

Birth defect

Risk estimate (95%
CI)

Comments

605 (5)

769 (1)

AML

Cleft lip or palate

6.40 (0.98–41.64)b

605 (1)

769 (2)

AML

Club foot

0.64 (0.06–6.88)b

605 (39)

769 (27)

AML

Large or multiple
birthmarks

1.89 (1.15–3.11)b

605 (5)

769 (1)

AML

Deafness or impaired
hearing

6.40 (0.98–41.64)b

605 (3)

769 (7)

AML

Blindness or difficulty
seeing

0.54 (0.14–2.07)b

605 (0)

769 (0)

AML

Eyes different colors or
missing iris

-

605 (3)

769 (2)

AML

Water on the brain or
hydrocephalus

1.91 (0.33–11.14)b

605 (3)

769 (1)

AML

Spina bifida or other
spinal defect

3.83 (0.47–31.45)b

605 (3)

769 (0)

AML

Unusually small head or
microcephaly

ND

605 (2)

769 (0)

AML

Unequal sized limbs or
hemihypertrophy

ND

605 (16)

769 (12)

AML

Any skeletal deformity

1.71 (0.81–3.62)b

605 (27)

769 (17)

AML

Hole in heart or other
heart

2.07 (1.13–3.78)b

605 (6)

769 (4)

AML

Pancreas or digestive
tract

1.92 (0.55–6.68)b

605 (7)

769 (11)

AML

Genitourinary

0.81 (0.31–2.09)b

605 (10)

769 (17)

AML

Other BDs

0.74 (0.34–1.63)b

Infante-Rivard et 491 (49)
al., 2001 [42]

491 (46)

ALL

Any BD

1.07 (0.70–1.65)b

DS exclusion not noted. Estimates
adjusted for maternal education,
paternal and maternal age.

Roganovic et al., 64 (55)
2002 [50]

64 (43)

Hematologic
malignancies (HM)

Any minor

2.98 (1.24–7.17)a,b

DS exclusion not noted. The authors
also reported data for ALL, AML, NHL
and HD but did not report the overall
number of cases who had at least one
minor anomaly for each of these
subtypes. The authors also noted “a
statistically significant excess of
multiple birthmarks”.

Merks et al.,
2005 [26]

26 (0)

881 (54)

AML

Cervical rib

-

132 (16)

881 (54)

ALL

Cervical rib

2.11 (1.17–3.81)a,b

92 (5)

881 (54)

HD

Cervical rib

0.88 (0.34–2.26)a,b

106 (8)

881 (54)

NHL

Cervical rib

1.25 (0.58–2.70)a,b

Podvin et al.,
2006 [44]

595 (11)

5,950 (93)

Leukemia

Other malformations (not
DS)

1.2 (0.6–2.2)b

Estimates adjusted for maternal age.

Loder et al.,
2007 [25]

109a (16)

200 (16)

ALL, AML, lymphoma

Abnormal rib number
(normal = 24 ribs)

2.0 (1.0–4.1)b

Children with a known BD or DS were
excluded.

Johnson et al.,
2010 [46]

443 (77)

324 (40)

All infant leukemia

Any BD

1.2 (0.8–1.9)b

443 (41)

324 (18)

All infant leukemia

Large or multiple
birthmarks

1.3 (0.7–2.4)b

DS cases excluded. Estimates adjusted
for birth year and follow-up time.

443 (9)

324 (9)

All infant leukemia

Urogenital system

0.7 (0.2–2.0)b

443 (29)

324 (15)

All infant leukemia

Other

1.4 (0.7–2.8)b

264 (47)

324 (40)

Infant ALL

Any BD

1.4 (0.8–2.3)b

264 (26)

324 (18)

Infant ALL

Large or multiple
birthmarks

1.5 (0.8–3.0)b

264 (5)

324 (9)

Infant ALL

Urogenital system

0.8 (0.2–2.6)b

264 (17)

324 (15)

Infant ALL

Other

1.5 (0.7–3.3)b

172 (30)

324 (40)

Infant AML

Any BD

1.4 (0.8–2.4)b

172 (15)

324 (18)

Infant AML

Large or multiple
birthmarks

1.4 (0.6–2.9)b

172 (4)

324 (9)

Infant AML

Urogenital system

0.7 (0.2–3.2)b

172 (12)

324 (15)

Infant AML

Other

1.6 (0.7–3.8)b

(Continued)
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Table 3. (Continued)
Reference

Comparison
group 1¥

Comparison
group 2¥

Cancer type

Birth defect

Risk estimate (95%
CI)

Comments

109 (29)

HM

Minor

4.95 (2.78–8.82)a,b

Cases with major malformations and
syndromes were excluded. Among
minor anomalies, pigmented nevi and
café-au-lait spots were significantly
more frequent in the cases.

112 (109a)

200 (70a)

HM

Any minor

67.48 (20.7–220.3)a,b

112 (22)

200 (13)

HM

Hand

3.5 (1.69–7.29)b

112 (34)

200 (7)

HM

Feet

12.02 (5.11–28.25)b

Patients with known genetic syndromes
were excluded. Data on 19 specific
minor anomalies was also reported (not
shown).

112 (53)

200 (37)

HM

Eye

3.9 (2.36–6.62)b

112 (9)

200 (7)

HM

Nose

2.4 (0.87–6.65)b

112 (64)

200 (27)

HM

Mouth

8.5 (4.92–14.83)b

112 (49)

200 (8)

HM

Ear

18.7 (8.4–41.53)b

221 (15)

1,133 (51)

Leukemias, MPD, MDS

Abnormal ribs (normal =
24 ribs)

1.55 (0.84–2.88)b

Citak et al., 2011 109 (70)
[51]

Durmaz et al.,
2011 [20]

Zierhut et al.,
2011 [24]

Rudant et al.,
2013 [45]

105 (6)

1,133 (51)

Lymphoid leukemias

Abnormal ribs

1.27 (0.51–3.11)b

78 (8)

1,133 (51)

AML

Abnormal ribs

2.29 (1.02–5.13)b

20 (0)

1,133 (51)

Chronic
myeloproliferative
diseases

Abnormal ribs

-

18 (1)

1,133 (51)

Other specified or
unspecified leukemias

Abnormal ribs

1.16 (0.15–8.98)b

50 (1)

1,133 (51)

Lymphomas and
reticuloendothelial
neoplasms

Abnormal ribs

0.37 (0.05–2.89)b

29 (0)

1,133 (51)

HL

Abnormal ribs

-

12 (1)

1,133 (51)

NHL (except Burkitt’s
lymphoma)

Abnormal ribs

1.67 (0.21–13.41)b

9 (0)

1,133 (51)

Other specified or
unspecified lymphomas

Abnormal ribs

-

764 (35)

1,681 (51)

Acute leukemia

Any BD

1.5 (1.0–2.4)b

764 (26)

1,681 (32)

Acute leukemia

Minor

1.8 (1.0–3.1)b

764 (9)

1,681 (19)

Acute leukemia

Major

1.1 (0.5–2.4)b

764 (3)

1,681 (6)

Acute leukemia

Face/tongue/mouth

0.9 (0.2–3.7)b

764 (3)

1,681 (9)

Acute leukemia

Heart

0.7 (0.2–2.8)b

764 (4)

1,681 (1)

Acute leukemia

Digestive tract

0.01<p<0.05

764 (7)

1,681 (10)

Acute leukemia

Urinary system

1.7 (0.6–4.7)b

764 (3)

1,681 (6)

Acute leukemia

Genital organs

1.0 (0.2–4.2)b

764 (9)

1,681 (23)

Acute leukemia

Skeleton

0.8 (0.4–1.9)b

764 (5)

1,681 (0)

Acute leukemia

Skin

0.001<p<0.01

764 (2)

1,681 (0)

Acute leukemia

Nervous System

NR

648 (28)

1,681 (51)

ALL

Any BD

1.4 (0.9–2.2)b

648 (20)

1,681 (32)

ALL

Minor

1.6 (0.9–2.8)b

648 (8)

1,681 (19)

ALL

Major

1.1 (0.5–2.5)b

648 (2)

1,681 (6)

ALL

Face/tongue/mouth

0.7 (0.1–3.5)b

648 (2)

1,681 (9)

ALL

Heart

0.5 (0.1–2.6)b

648 (4)

1,681 (1)

ALL

Digestive tract

0.01< p<0.05

648 (6)

1,681 (10)

ALL

Urinary system

1.6 (0.6–4.9)b

648 (2)

1,681 (6)

ALL

Genital organs

0.8 (0.1–3.9)b

648 (8)

1,681 (23)

ALL

Skeleton

0.9 (0.4–2.0)b

Estimates adjusted for sex and age.

DS cases excluded. Estimates adjusted
for age x gender, maternal age at child’s
birth, parental professional category. Pvalues were calculated by Fisher’s
exact test.

(Continued)
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Table 3. (Continued)
Reference

Comparison
group 1¥

Comparison
group 2¥

Cancer type

Birth defect

Risk estimate (95%
CI)

648 (5)

1,681 (0)

ALL

Skin

NR

648 (0)

1,681 (0)

ALL

Nervous System

NR

101 (6)

1,681 (51)

AML

Any BD

2.3 (1.0–5.7)b

101 (5)

1,681 (32)

AML

Minor

3.0 (1.1–8.2)b

101 (1)

1,681 (19)

AML

Major

NR

18 (0)

NR (NR)

Pro-B

Any BD

-

508a (22)

NR (NR)

Pre-B/Common B

Any BD

1.3 (0.8–2.2)b

32 (0)

NR (NR)

B mature

Any BD

-

67 (5)

NR (NR)

T-cell

Any BD

2.4 (0.9–6.3)

Comments

Leukemias, myeloproliferative diseases, myelodysplastic diseases, and lymphoma cohort studies
20 (22,856)

NR (NR)

Leukemia

Any BD

2.4 (1.6–3.7)c

NR (NR)

NR (NR)

Leukemia

Any BD (Male)

2.6c*

NR (NR)

NR (NR)

Leukemia

Any BD (Female)

2.2c*

NR (NR)

NR (NR)

Leukemia (0–4 years)

Any BD (Male)

2.4c*

NR (NR)

NR (NR)

Leukemia (0–4 years)

Any BD (Female)

2.4c*

NR (NR)

NR (NR)

Leukemia (5–9 years)

Any BD (Male)

3.9c*

NR (NR)

NR (NR)

Leukemia (5–9 years)

Any BD (Female)

1.7c*

Mili et al., 1993
[28]

8 (19,373)

116 (544,304)

Leukemia

Any BD

2.0 (0.8–3.9)d; 1.2
(0.40–2.9)d DS
excluded

Did not exclude any known genetic
syndromes. Estimates adjusted for age.
The authors also note adjusting for sex
and race in some analyses.

Mili et al., 1993
[29]

3 (10,891)

102 (241,473)

Leukemia

Any BD

1.1 (0.2–3.2)d; 0.36
(0.009–2.0)d DS
excluded

Leukemia was only associated with DS.
Estimates adjusted for age and sex.

Agha et al.,
2005 [33]

48 (45,200)

19 (45,200)

Leukemia

Any BD

2.7 (2.1–3.6)c

NA

NA

Leukemia

Chromosomal

8.8 (5.2–14.8)g

8 (45,200)

9 (45,200)

Lymphoma

Any BD

1.0 (0.6–1.6)c

Did not exclude any known genetic
syndromes. O/E ratios are age
standardized.

NA

NA

Lymphoma

Certain musculoskeletal
deformities

3.5 (1.5–8.4)g

10 (NR)

218a (NR)

ALL

Any BD

2.73 (1.49–5.02)f

7 (NR)

19a (NR)

AML

Any BD

21.97 (12.07–39.96)f

1 (NR)

8a (NR)

Other leukemia

Any BD

7.45 (1.27–43.60)f

5 (NR)

56a (NR)

HL and NHL

Any BD

5.32 (2.35–12.04)f

a

Leukemia

Any BD

1.39 (1.09–1.75)f

a

Windham et al.,
1985 [27]

Rankin et al.,
2008 [30]

Carozza et al.,
2012 [31]

84 (115,686)
8 (115,686)

137 (3,071,255 )

Lymphoma

Any BD

1.80 (0.76–3.64)f

Fisher et al.,
2012 [36]

29 (59,258)

NR

Leukemia

Non-chromosomal

0.96 (0.66–1.38)e

77 (6,327)

NR

Leukemia

Chromosomal

28.99 (23.07–36.42)e

33 (6,327)

NR

ALL

Chromosomal

14.95 (10.59–21.11)e

35 (6,327)

NR

AML

Chromosomal

101.22 (70.87–
144.57)e

17 (59,258)

NR

Lymphoma

Non-chromosomal

2.24 (1.38–3.63)e

13 (44,151)

45 (147,940)

Leukemia

Structural

1.19 (0.6–2.2)f

12 (44,151)

36 (147,940)

ALL

Structural

1.38 (0.7–2.6)f

<5 (44,151)

5 (147,940)

AML

Structural

0.83 (0.1–7.1)f

0 (44,151)

<5 (147,940)

Other and unspecified

Structural

-

<5 (44,151)

<5 (147,940)

MDS/MPD

Structural

12.41 (1.3–119.3)f

<5 (44,151)

10 (147,940)

Lymphoma

Structural

1.65 (0.5–5.3)f

<5 (44,151)

6 (147,940)

NHL

Structural

0.69 (0.1–5.7)f

<5 (44,151)

<5 (147,940)

HL

Structural

1.03 (0.1–9.2)f

<5 (44,151)

0 (147,940)

Other, unspecified

Structural

-

Botto et al.,
2013 [32]

742 (3,071,255 )

The authors note that most of the
excess was due to DS cases.
Estimates are age standardized.

The authors report that the association
between leukemia and BDs was still
present after excluding DS cases.

Genetic syndromes were not excluded.
The authors note that excluding
subjects with chromosomal anomalies
resulted in a lower IRR for leukemia and
total cancers but not for other cancers.

Children with chromosomal anomalies
were excluded.

(Continued)
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Table 3. (Continued)
Reference

Comparison
group 1¥

Comparison
group 2¥

Cancer type

Birth defect

Risk estimate (95%
CI)

Comments

Sun et al., 2014
[38]

1 (4,484)

47 (1,547,126)

LHT (<1 year)

Nervous system (cohort
entry on day of birth)

7.35 (1.01–53.3)e

NR (NR)

NR (NR)

LHT (<1 year)

Nervous system (cohort
entry at BD diagnosis)

-

Children with chromosomal anomalies
were excluded. Estimates adjusted for
calendar year and sex.

5 (4,484)

787 (1,547,126)

LHT (1–15 years)

Nervous system (cohort
entry on day of birth)

2.12 (0.88–5.11)e

NR (NR)

NR (NR)

LHT (1–15 years)

Nervous system (cohort
entry at BD diagnosis)

1.56 (0.50–4.85)e

4 (24,643)

47 (1,547,126)

LHT (<1 year)

Circulatory system
(cohort entry on day of
birth)

5.34 (1.92–14.83)e

NR (NR)

NR (NR)

LHT (<1 year)

Circulatory system
(cohort entry at BD
diagnosis)

2.36 (0.33–17.08)e

40 (4,484)

787 (1,547,126)

LHT (1–15 years)

Circulatory system
(cohort entry on day of
birth)

3.27 (2.38–4.49)e

NR (NR)

NR (NR)

LHT (1–15 years)

Circulatory system
(cohort entry at BD
diagnosis)

1.43 (0.84–2.43)e

13 (32,273)

291a (608,726)

Leukemia MPD and
MPS

N BDs

0.83 (0.48–1.44)e

9 (32,273)

242a (608,726)

ALL

N BDs

0.69 (0.36–1.34)e

1 (32,273)

36a (608,726)

AML

N BDs

0.52 (0.07–3.76)e

Other leukemias

N BDs

4.30 (1.23–15.09)e

Dawson et al.,
2015 [34]

a

7 (32,273)

9 (608,726)
a

3 (32,273)
Janitz et al.,
2016 [35]

Lymphoma

N BDs

1.63 (0.75–3.53)e

a

Leukemia

Any BD (w/chromosomal)

2.3 (1.4–3.8)e

a

85 (608,726)
a

18 (23,368 )
a

194 (567,867)

10 (22,109 )

194 (567,867)

Leukemia

Non-chromosomal

1.4 (0.7–2.6)e

5 (22,109a)

39a (567,867)

Lymphoma

Any BD (w/chromosomal)

2.8 (1.0–7.9)e

5 (22,109a)

39a (567,867)

Lymphoma

Non-chromosomal

3.0 (1.1–8.4)e

Excluded syndromes known to be
associated with cancer (e.g. DS) (N
category).

For lymphoma, the exact number of
cases was suppressed.

Leukemias, myeloproliferative diseases, myelodysplastic diseases, and lymphoma case series with an external comparison group studies
Narod et al.,
1997 [53]

6,588 (6)

NA

Leukemia

Spina bifida

0.76 (NRCT); 1.8
(BC)

6,588 (8)

NA

Leukemia

Cardiac septal

0.54; 0.28

6,588 (36)

NA

Leukemia

Genitourinary

0.64; 0.56

6,588 (6)

NA

Leukemia

Spine and rib

0.4; 3.1*

2,191 (3)

NA

Lymphoma

Cardiac septal

0.61; 0.31

2,191 (20)

NA

Lymphoma

Genitourinary

1.1; 0.94

2,191 (7)

NA

Lymphoma

Spine and rib

1.3; 10.9**

Two hundred seventy-five cases with an
established genetic cause were
removed; authors report RRs but do not
define the RR abbreviation.

Central nervous system and miscellaneous intracranial and intraspinal neoplasms case-control studies
Johnson et al.,
1987 [62]

499 (NR)

998 (NR)

CNS

Any BD

NR

Genetic syndromes were not noted as
excluded; The authors concluded that
there was no association.

Baptiste et al.,
1989 [55]

338 (14)

676 (28)

CNS

Any BD

1.00 (0.49–2.00)h

Does not include Neurofibromatosis
Type 1 cases.

78 (7)

CNS

Any BD

2.6 (0.9–7.6)h

78 (4)

CNS

Medically confirmed BDs

2.7 (0.7–10.9)h

Hospital controls and children with
single small birthmarks were excluded.

Birch et al., 1990 78 (16)
[56]
78 (10)
Schumacher et
al., 1992 [23]

234 (64a)

200 (11)

Brain

Rib

6.47 (3.30–12.67)a,b

Mann et al.,
1993 [16]

78 (10)

78 (3)

CNS

Any BD

3.68 (0.97–13.92)a,b

No CNS tumor cases were noted with
genetic syndromes; Four cases were
reported by Birch et al. [56] but one
case with a hairy mole/naevus was
excluded.

Cordier et al.,
1994 [61]

75 (NR)

113 (NR)

Brain

BDs (excluding minor)

NR

The authors note that the percentage of
children reported with BDs (excluding
minor anomalies) was higher among
controls (11%) than cases (7%).

(Continued)
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Table 3. (Continued)
Reference

Comparison
group 1¥

Comparison
group 2¥

Cancer type

Birth defect

Risk estimate (95%
CI)

Comments

361 (1)

1,086 (6)

Brain

Ear/Congenital deafness

0.50 (0.06–4.17)a,b

361 (3)

1,086 (3)

Brain

Vertebral/back/curvature
of the spine

3.03 (0.61–15.06)a,b

361 (3)

1,086 (6)

Brain

Eye

1.50 (0.38–6.06)a,b

361 (0)

1,086 (1)

Brain

Cleft lip or palate

-

361 (1)

1,086 (0)

Brain

Hydrocephalus

-

361 (0)

1,086 (9)

Brain

Congenital heart disease

-

361 (0)

1,086 (7)

Brain

Polydactyly/other digit

-

361 (4)

1,086 (0)

Brain

Neurofibromatosis

-

361 (0)

1,086 (4)

Brain

Absent/extra/deformed
kidney

-

361 (0)

1,086 (1)

Brain

Spina bifida

-

361 (5)

1,086 (3)

Brain

Club foot

5.07 (1.21–21.32)a,b

361 (1)

1,086 (10)

Brain

Digestive System

0.30 (0.04–2.34)a,b

361 (2)

1,086 (2)

Brain

Other urogenital system

3.02 (0.42–21.51)a,b

361 (14)

1,086 (27)

Brain

Other/multiple

1.58 (0.82–3.05)a,b

McCredie et al.,
1994 [65]

82 (17)

164 (32)

Brain

Birthmarks/deformities

1.1 (0.5–2.1)b

Estimate adjusted for years of schooling
of father.

Savitz et al.,
1994 [15]

47 (3)

212 (11)

CNS

Major

1.2 (0.3–4.7)b

Genetic syndromes were not noted as
excluded. All cases were noted to have
had a CT scan but not controls.

Altmann et al.,
1998 [17]

92 (9)

NR (NR)

CNS

Any BD

4.7 (2.2–10.0)b

92 (4)

NR (3)

CNS

Nervous system

27.8 (6.1–127)b

92 (2)

NR (11)

CNS

Eye/face/neck

16.8 (2.7–103)b

DS cases were not excluded. Any BD
estimates adjusted for 6-month
calendar period, gender, birth weight,
gestational age, and maternal age.

39 (3)

NR (NR)

AST

Any BD

3.5 (0.98–12.5)b

Merks et al.,
2005 [26]

21 (2)

881 (54)

MB

Cervical

1.61 (0.37–7.10)a,b

22 (4)

881 (54)

AST

Cervical

3.40 (1.11–10.41)a,b

Loder et al.,
2007 [25]

37 (13)

200 (16)

Neural (CNS)

Abnormal rib number
(normal = 24 ribs)

6.23 (2.7–14.5)b

Children with a known BD or DS were
excluded.
Estimates adjusted for age and sex.

Gold et al., 1994
[64]

Mallol-Mesnard
et al., 2008 [58]

Durmaz et al.,
2011 [20]

Partap et al.,
2011 [57]

209 (8)

1,681 (57)

All CNS

Any BD

1.1 (0.5–2.3)b

209 (6)

1,681 (38)

All CNS

Major

1.2 (0.5–2.9)b

33 (1)

1,681 (57)

EPD

Any BD

1.0 (0.1–7.2)b

100 (3)

1,681 (57)

Embryonal

Any BD

0.8 (0.2–2.6)b

100 (2)

1,681 (38)

Embryonal

Major

0.8 (0.2–3.5)b

26 (1)

1,681 (57)

AST

Any BD

1.2 (0.2–9.2)b

26 (1)

1,681 (38)

AST

Major

1.9 (0.2–14)b

45 (3)

1,681 (57)

Other gliomas

Any BD

2.0 (0.6–6.6)b

45 (3)

1,681 (38)

Other gliomas

Major

2.9 (0.9–10)b

28 (9)

200 (13)

CNS

Hand

6.8 (2.57–18.01)b

28 (9)

200 (7)

CNS

Feet

13.06 (4.37–39.01)b

28 (16)

200 (37)

CNS

Eye

5.9 (2.56–13.46)b

28 (4)

200 (7)

CNS

Nose

4.6 (1.25–16.85)b

28 (24)

200 (27)

CNS

Mouth

38.4 (12.37–119.43)b

28 (11)

200 (8)

CNS

Ear

15.5 (5.50–43.80)b

3,733 (45)

14,932 (90)

CNS

Any BDs

1.82 (1.25–2.65)b

NR (NR)

NR (NR)

CNS (<2 years)

Any BD

1.70 (1.12–2.57)b

NR (NR)

NR (NR)

CNS (<1 year)

Any BD

2.91 (1.68–5.05)b

1,380 (NR)

14,932 (90)

LGG

Any BDs

0.71 (0.29–1.72)b

757 (NR)

14,932 (90)

HGG

Any BDs

0.64 (0.19–2.24)b

516 (NR)

14,932 (90)

MB

Any BDs

3.19 (1.29–7.87)b

402 (NR)

14,932 (90)

PNET

Any BDs

2.97 (1.21–7.28)b

187 (NR)

14,932 (90)

GCT

Any BDs

7.20 (2.10–24.63)b

292 (NR)

14,932 (90)

EPD

Any BDs

1.17 (0.13–10.61)b

Patients with known genetic syndromes
were excluded. Data on 19 specific
minor anomalies was also reported.

Estimates adjusted for birth weight, birth
order, race, Hispanic ethnicity, and
maternal age.

(Continued)
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Table 3. (Continued)
Reference

Comparison
group 1¥

Comparison
group 2¥

Cancer type

Birth defect

Risk estimate (95%
CI)

Comments

Zierhut et al.,
2011 [24]

34 (3)

1,133 (51)

CNS and miscellaneous
intracranial and
intraspinal neoplasms

Abnormal ribs

2.00 (0.59–6.77)b

Estimates adjusted for sex and age.

Greenop et al.,
2014 [60]

282 (14)

898 (38)

CBT

BD

1.17 (0.63–2.2)a,b

Bailey et al.,
2017 [59]

510 (19a)

3,102 (109a)

Any CBT

BD

1.0 (0.6–1.6)b

64 (3a)

3,102 (109a)

EPD

BD

1.4 (0.4–4.5)b

120 (5a)

3,102 (109a)

a

206 (7 )
a

109 (4 )

AST

BD

1.2 (0.5–2.9)b

a

Embryonal

BD

0.9 (0.4–1.9)b

a

Other gliomas

BD

1.0 (0.4–2.8)b

3,102 (109 )
3,102 (109 )

Estimates adjusted for sex and age.

Central nervous system and miscellaneous intracranial and intraspinal neoplasms cohort studies
Windham et al.,
1985 [27]

9 (22,856)

NR (NR)

Nervous system

Any BD

1.7 (0.9–3.2)c

6 (NR)

NR (NR)

CNS tumor (malignant
and benign)

CNS defect

34.7c* (NR)

Did not exclude any known genetic
syndromes. Estimates are age
standardized. The authors note that the
RR = 34.7 was significant and that risk
was limited to first two years of life.

NR (NR)

NR (NR)

Nervous system

Male

2.0c

NR (NR)

NR (NR)

Nervous system

Female

1.3c

NR (NR)

NR (NR)

Nervous system (0–4
years)

Male

2.6c*

NR (NR)

NR (NR)

Nervous system (0–4
years)

Female

1.3c

NR (NR)

NR (NR)

Nervous system (5–9
years)

Male

1.2c

NR (NR)

NR (NR)

Nervous system (5–9
years)

Female

1.4c

Mili et al., 1993
[28]

10 (19,373)

77 (544,304)

Brain

Any BD

2.2 (1.04–4.0)d

Did not exclude any known genetic
syndromes. Estimates adjusted for age.
The authors also note adjusting for sex
and race in some analyses.

Mili et al., 1993
[29]

3 (10,891)

52 (241,473)

Brain

Any BD

2.1 (0.4–6.2)d

Did not exclude any known genetic
syndromes. Estimates adjusted for age
and sex.

Agha et al.,
2005 [33]

35 (45,200)

15 (45,200)

CNS

Any BD

2.5 (1.8–3.4)c

NA

NA

CNS

Other nervous system

5.7 (2.7–11.9)g

Did not exclude any known genetic
syndromes. O/E ratio is age
standardized.

Rankin et al.,
2008 [30]

4 (NR)

198a (NR)

Brain

Any BD

1.20 (0.45–3.24)f

Did not exclude any known genetic
syndromes.

Carozza et al.,
2012 [31]

35 (115,686)

394 (3,071,255a)

CNS

Any BD

1.11 (0.76–1.57)f

Genetic syndromes were not excluded.
The authors note that excluding
subjects with chromosomal anomalies
resulted in a lower IRR for leukemia and
total cancers but not for other cancers.

Fisher et al.,
2012 [36]
Botto et al.,
2013 [32]

Sun et al., 2014
[38]

34 (59,258)

NR

CNS

Non-chromosomal

1.80 (1.28–2.53)e

3 (6,327)

NR

CNS

Chromosomal

1.87 (0.60–5.79)e

16 (44,151)

38 (147,940)

Brain

Structural

1.74 (1.0–3.1)f

5 (44,151)

17 (147,940)

AST

Structural

1.22 (0.4–3.33)f

<5 (44,151)

13 (147,940)

MB

Structural

1.27 (0.4–3.9)f

7 (44,151)

8 (147,940)

Other brain

Structural

3.62 (1.3–10)f

9 (4,484)

28 (1,547,126)

CNS (<1 year)

Nervous system (cohort
entry on day of birth)

111.2 (52.46–
235.61)e

NR (NR)

NR (NR)

CNS (<1 year)

Nervous system (cohort
entry at BD diagnosis)

87.98 (31.06–
249.20)e

17 (4,484)

330 (1,547,126)

CNS (1–15 years)

Nervous system (cohort
entry on day of birth)

17.11 (10.51–27.86)e

NR (NR)

NR (NR)

CNS (1–15 years)

Nervous system (cohort
entry at BD diagnosis)

13.21 (7.24–24.08)e

1 (4,484)

28 (1,547,126)

CNS (<1 year)

Circulatory system
(cohort entry on day of
birth)

2.24 (0.31–16.48)e

Children with chromosomal anomalies
were excluded.

Children with chromosomal anomalies
were excluded. Estimates adjusted for
calendar year and sex.
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PLOS ONE | https://doi.org/10.1371/journal.pone.0181246 July 27, 2017

29 / 56

Pediatric cancer risk in association with birth defects: A systematic review

Table 3. (Continued)
Reference

Comparison
group 1¥

Comparison
group 2¥

Cancer type

Birth defect

Risk estimate (95%
CI)

NR (NR)

NR (NR)

CNS (<1 year)

Circulatory system
(cohort entry at BD
diagnosis)

2.36 (0.33–17.08)e

13 (4,484)

330 (1,547,126)

CNS (1–15 years)

Circulatory system
(cohort entry on day of
birth)

2.56 (1.47–4.45)e

NR (NR)

NR (NR)

CNS (1–15 years)

Circulatory system
(cohort entry at BD
diagnosis)

1.43 (0.84–2.43)e

Dawson et al.,
2015 [34]

14 (32,273)

207a (608,276)

CNS cancer and
intracranial/spinal

N BDs

1.26 (0.74–2.17)e

16 (32,273)

215a (608,276)

CBT

N BDs

1.39 (0.84–2.31)e

Janitz et al.,
2016 [35]

11 (23,368)

91a (567,867)

CNS

Any BD (w/chromosomal)

3.1 (1.6–5.7)e†

NA

NA

CNS (<1 year)

Any BD (w/chromosomal)

17.9 (3.5–91.5)e

NA

NA

CNS (3 years)

Any BD (w/chromosomal)

3.6 (1.9–6.8)e

NA

NA

CNS (6 years)

Any BD (w/chromosomal)

1.9 (0.8–4.5)e

NA

NA

CNS (9 years)

Any BD (w/chromosomal)

1.3 (0.4–4.0)e

NA

NA

CNS (12 years)

Any BD (w/chromosomal)

1.0 (0.3–3.8)e

10 (22,109a)

91a (567,867)

CNS

Non-chromosomal

2.9 (1.5–5.6)e†

NA

NA

CNS (<1 year)

Non-chromosomal

25 (4.8–130.0)e

NA

NA

CNS (3 years)

Non-chromosomal

3.4 (1.7–6.7)e

NA

NA

CNS (6 years)

Non-chromosomal

1.6 (0.6–4.1)e

NA

NA

CNS (9 years)

Non-chromosomal

1.0 (0.3–3.4)e

NA

NA

CNS (12 years)

Non-chromosomal

0.7 (0.2–3.1)e

Comments

Excluded syndromes known to be
associated with cancer (e.g. DS) (N
category).
HRs were estimated at each age.
The authors note that the proportional
hazards assumption was not met for the
overall association and that a
continuous time interaction model was
used for those noted with an ‘†’.

Central nervous system and miscellaneous intracranial and intraspinal neoplasms nested case-control studies
Linet et al., 1996
[63]

570 (25)

2,850a (129)

Brain

Any BD

1.0 (0.6–1.5)b

205 (8)

1,025a (46)

Low grade AST

Any BD

0.9 (0.4–1.8)b

58 (3)

290a (16)

High grade AST

Any BD

0.9 (0.3–3.3)b

93 (4)

a

465 (23)

MB

Any BD

0.9 (0.3–2.6)b

54 (2)

a

EPD

Any BD

0.7(0.1–2.9)b

a

Other

Any BD

1.4 (0.6–3.1)b

160 (8)

270 (15)
800 (29)

Estimates adjusted for matching
variables.

Central nervous system and miscellaneous intracranial and intraspinal neoplasms case series with an external comparison group
Narod et al.,
1997 [53]

4,698 (167)

NA

Brain/Spinal

Total

0.86; 0.56

4,698 (8)

NA

Brain/Spinal

Spina bifida (741)

1.4 (NRCT); 3.3**
(BC)

4,698 (10)

NA

Brain/Spinal

Hydrocephalus (7423)

2.5*; 4.0***

4,698 (7)

NA

Brain/Spinal

Pyloric stenosis (7505)

1.4; 0.9

4,698 (6)

NA

Brain/Spinal

Skull (7560)

1.4; 1.4

4,698 (9)

NA

Brain/Spinal

Spine (7561)

0.98; 9.6***

4,698 (6)

NA

Brain/Spinal

Cardiac septal

0.57; 0.29

4,698 (26)

NA

Brain/Spinal

Genitourinary

0.65; 0.57

4,698 (12)

NA

Brain/Spinal

Spine and rib

1.0; 8.6***

4,698 (127)

NA

Brain/Spinal

Other

0.76; 0.46

Two hundred seventy-five cases with an
established genetic cause were
removed; authors report RRs but do not
define the RR abbreviation. The authors
note that 10 cases of hydrocephalus
occurred in CNS tumor cases, which
may be an effect rather than a cause of
the tumor.

Neuroblastoma and other peripheral nervous cell tumors case-control studies
Johnson et al.,
1985 [66]

157 (3)

314 (2)

NB

Any BD

3.04 (0.50–18.38)a,b

The authors note that the cases and
controls had diverse BDs.

Neglia et al.,
1987 [67]

97(6)

388a(3)

NB

Physical anomalies

8.61 (2.00–43.86)b

After removal of 4 of the 6 anomalies
identified in cases that were secondary
to the tumor, the association was no
longer significant.

Schumacher et
al., 1992 [23]

88 (29a)

200 (11)

NB

Rib

8.44 (3.98–17.93)a,b

Mann et al.,
1993 [16]

31 (4)

31 (4)

NB

Any BD

1.0 (0.23–4.42)a,b

Matched pairs analysis

(Continued)
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Table 3. (Continued)
Reference

Comparison
group 1¥

Comparison
group 2¥

Cancer type

Birth defect

Risk estimate (95%
CI)

Comments

Altmann et al.,
1998 [17]

56 (7)

NR (NR)

SNS

Any BD

7.2 (3.0–17.1)b

52 (7)

NR (NR)

NB

Any BD

7.9 (3.3–18.8)b

52 (2)

NR (NR)

NB

Eye/face/neck

26.6 (4.3–166)b

DS cases were not excluded. Any BD
estimates adjusted for 6-month
calendar period, gender, birth weight,
gestational age, and maternal age.

52 (2)

NR (NR)

NB

Gastrointestinal system

9.3 (1.9–46.1)b

52 (1)

NR (NR)

NB

Nervous system

18.3 (1.8–184)b

Buck et al., 2001
[68]

130 (2)

301 (4)

NB

Any BD

1.2 (0.2–6.3)b

Merks et al.,
2005 [26]

61 (6)

881 (54)

NB

Cervical

1.67 (0.69–4.05)a,b

Menegaux et al.,
2005 [71]

538 (73)

504 (24)

NB

Any BD (ICD-10 740–
759)

2.58 (1.57–4.25)b

Chow et al.,
2007 [70]

Urayama et al.,
2007 [73]

Munzer et al.,
2008 [69]

Zierhut et al.,
2011 [24]

538 (23)

504 (3)

NB

Major

7.53 (2.23–25.5)b

538 (8)

504 (4)

NB

Minor

1.86 (1.06–3.25)b

538 (3)

504 (0)

NB

CNS (ICD-10 740–742)

ND

538 (11)

504 (1)

NB

Eye (743)

10.9 (1.38–85.8)b

538 (15)

504 (3)

NB

Cardiac (745–747)

4.27 (1.22–15.0)b

538 (6)

504 (2)

NB

Face (749–7502)

3.40 (0.68–17.1)b

538 (7)

504 (1)

NB

Digestive system (7505–
751)

5.98 (0.7–50.8)b

538 (16)

504 (3)

NB

Genital and urinary (752–
753)

5.84 (1.67–20.4)b

538 (9)

504 (1)

NB

Genital (752)

10.2 (1.27–82.6)b

538 (8)

504 (2)

NB

Urinary (753)

4.49 (0.93–21.7)b

538 (10)

504 (6)

NB

Musculoskeletal (754–
756)

1.55 (0.55–4.35)b

538 (19)

538 (14)

NB

Other (757–759)

1.21 (0.59–2.49)b

240 (23)

2,400 (116)

NB

Any BD

2.11 (1.32–3.40)b

240 (9)

2,400 (14)

NB

Major only

6.86 (2.92–16.08)b

240 (5)

2,400 (9)

NB

Cardiac only

5.84 (1.93–17.66)b

240 (2)

2,400 (25)

NB

Urogenital only

0.85 (0.20–3.62)b

508 (33)

1,015 (39)

NB

Any BD

1.77 (1.09–2.88)b

NR

NR

NB

Any BD

1.53 (0.87–2.68)b

228 (NR)

NR

NB (<1 year)

Any BD

1.57 (0.76–3.27)b

102 (NR)

NR

NB (1–4 years)

Any BD

1.04 (0.41–2.68)b

191 (12)

1,681 (57)

NB

Any BD

2.2 (1.1–4.5)b

191 (2)

1,681 (19)

NB

Minor BD

1.7 (0.4–7.7)b

191 (10)

1,681 (38)

NB

Major BD

2.4 (1.1–5.4)b

191 (0)

1,681 (5)

NB

Heart

-

191 (1)

1,681 (2)

NB

Digestive

4.6 (0.3–69)b

191 (4)

1,681 (10)

NB

Urinary

4.4 (1.1–17)b

191 (1)

1,681 (6)

NB

Genital organs

1.7 (0.2–15.0)b

191 (5)

1,681 (22)

NB

Skeleton

3.3 (1.1–9.6)b

191 (14)

1,681 (2)

NB

Others

0.7 (0.1–5.7)b

74 (7)

187 (2)

NB (<1 year)

Any BD

16.8 (3.1–90)b

74 (7)

187 (1)

NB (<1 year)

Major BD

31.3 (3.6–272)b

74 (0)

187 (1)

NB (<1 year)

Minor BD

-

117 (5)

1,494 (55)

NB ( 1 year)

Any BD

1.0 (0.3–2.9)b

117 (3)

1,494 (37)

NB ( 1 year)

Major BD

1.9 (0.4–8.6)bb

117 (2)

1,494 (18)

NB ( 1 year)

Minor BD

0.7 (0.2–3.0)b

31 (2)

1,133 (51)

NB and other peripheral
nervous cell tumors

Abnormal ribs

1.48 (0.34–6.40)b

The authors note that 9/11 eye
anomalies reported among cases were
most likely secondary to the tumor but
the overall BD association remained
unchanged when eye anomalies were
excluded. Estimates adjusted for
mother’s educational level, mother’s
race and household income at birth.

Major anomalies are based on Cordier
et al. [61], excluding 2 individuals with
chromosomal anomalies. Estimates
adjusted for birth year.
The OR = 1.77 is unadjusted. Other
estimates adjusted for race/ethnicity,
gestational age/ birth weight index,
percentage of the adult population with
a college degree, initiation of prenatal
care, type of delivery and maternal
pregnancy history.
Estimates adjusted for age and gender.

Estimates adjusted for sex and age.
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Table 3. (Continued)
Reference

Comparison
group 1¥

Comparison
group 2¥

Cancer type

Birth defect

Risk estimate (95%
CI)

Comments

Parodi et al.,
2014 [72]

153 (7)

1,044 (14)

NB

Any BD

4.9 (1.8–13.6)b

Estimates adjusted for gender, age,
area of residence, maternal age, and
maternal level of education.

Rios et al., 2016
[74]

357 (13)

1783 (47)

NB

Any BD

1.6 (0.8–3.0)b

357 (10)

1783 (43)

NB

1 BD

1.3 (0.6–2.6)b

357 (3)

1783 (4)

NB

2 BD

6.3 (1.3–29)b

Estimates adjusted for age and sex,
birth order, maternal age, urban status
of the area of residence and study

188 (9)

544 (9)

NB (<18 months)

Any BD

3.6 (1.3–8.9)b

188 (8)

544 (9)

NB (<18 months)

1 BD

2.9 (1.1–7.9)b

188 (1)

544 (0)

NB (<18 months)

2 BD

-

169 (4)

1239 (38)

NB (18 months)

Any BD

0.8 (0.3–2.3)b

169 (2)

1239 (34)

NB (18 months)

1 BD

0.4 (1.1–1.8)b

169 (2)

1239 (4)

NB (18 months)

2 BD

4.1 (0.7–23.3)b

357 (1)

1783 (13)

NB

Cardiovascular

-

357 (1)

1783 (1)

NB

Digestive

-

357 (6)

1783 (15)

NB

Genitourinary

2.2 (0.8–6.0)b

357 (3)

1783 (14)

NB

Skeleton

-

357 (1)

1783 (0)

NB

CNS

-

357 (1)

1783 (4)

NB

Head and neck

-

Neuroblastoma and other peripheral nervous cell tumors cohort studies
2 (22,856)

NR (NR)

NB

Any BD

1.1 (0.4–3.4)c

NR (NR)

NR (NR)

NB

Any BD (Male)

1.1c

NR (NR)

NR (NR)

NB

Any BD (Female)

1.3c

NR (NR)

NR (NR)

NB (0–4 years)

Any BD (Male)

-

NR (NR)

NR (NR)

NB (0–4 years)

Any BD (Female)

1.3c

NR (NR)

NR (NR)

NB (5–9 years)

Any BD (Male)

6.3c

NR (NR)

NR (NR)

NB (5–9 years)

Any BD (Female)

-

Mili et al., 1993
[28]

4 (19,373)

5 (544,304)

NB

Any BD

20.3 (5.5–52.1)d

Did not exclude any known genetic
syndromes. Estimates adjusted for age.
The authors also note adjusting for sex
and race in some analyses.

Mili et al., 1993
[29]

2 (10,891)

32 (241,473)

NB

Any BD

2.2 (0.3–7.9)d

Did not exclude any known genetic
syndromes. Estimates adjusted for age
and sex.

Agha et al.,
2005 [33]

14 (45,200)

7 (45,200)

SNS

Any BD

2.2 (1.4–3.4)c

NA

NA

SNS

Other anomalies of the
digestive system

5.6 (2.1–14.8)g

Did not exclude any known genetic
syndromes. O/E ratio is age
standardized

Rankin et al.,
2008 [30]

3 (NR)

77a (NR)

NB

Any BD

2.32 (0.76–7.12)f

Bjørge et al.,
2008 [75]

8 (178a)

Windham et
al.,1985 [27]

NR

NB

Any BD

2.3 (1.2–4.8)e

a

NR

Adrenal medulla NB

Any BD

3.2 (1.3–7.8)e

a

3 (95 )

NR

Non-adrenal medulla
NB

Any BD

1.6 (0.5–5.1)e

Carozza et al.,
2012 [31]

31 (115,686)

274 (3,071,225a)

NB

Any BD

1.43 (0.94–2.10)f

Fisher et al.,
2012 [36]

15 (59,258)

NR

NB

Non-chromosomal

2.85 (1.69–4.78)e

1 (6,327)

NR

NB

Chromosomal

2.08 (0.29–14.82)e

11 (44,151)

17 (147,940)

NB spectrum

Structural

2.68 (1.3–5.7)f

8 (44,151)

15 (147,940)

NB

Structural

2.21 (0.9–5.2)f

<5 (44,151)

<5 (147,940)

Other peripheral
nervous system tumor

Structural

6.20 (1–37.1)f

Botto et al.,
2013 [32]

5 (83 )

Did not exclude any known genetic
syndromes. Estimates are age
standardized.

Did not exclude any known genetic
syndromes.

Genetic syndromes were not excluded.
Excluding subjects with chromosomal
anomalies resulted in a lower IRR for
leukemia and total cancers but not for
other cancers.

Children with chromosomal anomalies
were excluded.
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Table 3. (Continued)
Reference

Comparison
group 1¥

Comparison
group 2¥

Cancer type

Birth defect

Risk estimate (95%
CI)

Comments

Dawson et al.,
2015 [34]

5 (32,273)

66a (608,726)

NB/peripheral nervous
system tumors

N BDs

1.41 (0.57–3.49)e

Excluded syndromes known to be
associated with cancer (e.g. DS) (N
category).

Any BD

Too few cases to fit
model

Fisher’s exact test p-value = 0.92.

Neuroblastoma and other peripheral nervous cell tumors case-cohort studies
Johnson et al.,
2008 [76]

2 (145a)

122 (8,217a)

NB

Neuroblastoma and other peripheral nervous cell tumors case series with an external comparison group studies
Narod et al.,
1997 [53]

1,208 (71)

NA

NB

Total

1.4** (NRCT); 0.93
(BC)

1,208 (5)

NA

NB

Ear, head, and neck (ICD9 code 744)

3.3*; 2.2

1,208 (2)

NA

NB

Branchial cleft (7444)

8.3*; 9.5*

1,208 (3)

NA

NB

Septal defects (745)

1.1; 0.57

1,208 (2)

NA

NB

Tetralogy of Fallot (7452)

8.3*; 3.8

1,208 (2)

NA

NB

Pulmonary valve

5.5; 3.9

1,208 (2)

NA

NB

Other aorta

6.7; 118***

1,208 (3)

NA

NB

Cleft lip or palate

2.9; 1.3

1,208 (9)

NA

NB

Gastrointestinal (750–51)

3.1**; 2.4*

1,208 (4)

NA

NB

Pyloric stenosis (7505)

3.1*; 2.0

1,208 (2)

NA

NB

Imperforate anus (7512)

3.7; 4.7

1,208 (15)

NA

NB

Genitourinary (752–53)

1.5; 1.3

1,208 (20)

NA

NB

Musculoskeletal (754–56)

3.0***; 1.4

1,208 (8)

NA

NB

Foot deformity (7545–47)

3.3**; 1.4

1,208 (4)

NA

NB

Spinal (7561)

1.7; 16.7***

1,208 (4)

NA

NB

Cardiac septal

1.5; 0.76

1,208 (5)

NA

NB

Spine and rib

1.7; 14.3***

1,208 (12)

NA

NB

Other

0.48; 0.33

1,208 (16)

NA

NB and other
sympathetic

Genitourinary

1.5; 1.3

Two hundred seventy-five cases with an
established genetic cause were
removed; authors report RRs but do not
define the RR abbreviation.

Retinoblastoma and eye tumor case-control studies
Mann et al.,
1993 [16]

6 (0)

6 (1)

RB

Any BD

-

Not significant (Fisher ‘s test)

Altmann et al.,
1998 [17]

26 (5)

NR (NR)

RB

Any BD

15.0 (5.1–44.2)b

26 (2)

NR (NR)

RB

All chromosomal

54.8 (7.7–391)b

DS cases were not excluded. Any BD
estimates adjusted for 6-month
calendar period, gender, birth weight,
gestational age and maternal age.

Retinoblastoma and eye tumor cohort studies
Windham et al.,
1985 [27]

Mili et al., 1993
[28]

Agha et al.,
2005 [33]

Rankin et al.,
2008 [30]

2 (22,856)

NR (NR)

Eye

Any BD

2.3 (0.6–8.7)c

NR (NR)

NR (NR)

Eye

Any BD (Male)

2.4c

NR (NR)

NR (NR)

Eye

Any BD (Female)

2.2c

NR (NR)

NR (NR)

Eye (0–4 years)

Any BD (Male)

2.5c*

NR (NR)

NR (NR)

Eye (0–4 years)

Any BD (Female)

2.2c

NR (NR)

NR (NR)

Eye (5–9 years)

Any BD (Male)

-

NR (NR)

NR (NR)

Eye (5–9 years)

Any BD (Female)

-

4 (19,373)

22 (544,304)

RB

Any BD

4.7 (1.3–12.1)d

Did not exclude any known genetic
syndromes. Estimates adjusted for age.
The authors also note adjusting for sex
and race in some analyses.
Did not exclude any known genetic
syndromes. O/E ratio is age
standardized.

4 (45,200)

2 (45,200)

RB

Any BD

2.2 (0.9–5.1)c

NA

NA

RB

Chromosomal

10.8 (1.4–71.1)g

NA

NA

RB

Anomalies of the eye

14.3 (2.0–99.1)g

a

RB

Any BD

3.73 (0.99–14.10)f

2 (NR)

32 (NR)

Did not exclude any known genetic
syndromes. Estimates are age
standardized.

Did not exclude any known genetic
syndromes.

(Continued)
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Table 3. (Continued)
Reference

Comparison
group 1¥

Comparison
group 2¥

Cancer type

Birth defect

Risk estimate (95%
CI)

Comments

Carozza et al.,
2012 [31]

13 (115,686)

125 (3,071,255a)

RB

Any BD

2.34 (1.21–4.16)f

Genetic syndromes were not excluded.
The authors note that excluding
subjects with chromosomal anomalies
resulted in a lower IRR for leukemia and
total cancers but not for other cancers.

Botto et al.,
2013 [32]

6 (44,151)

7 (147,940)

RB

Structural

3.54 (1.2–10.5)f

Children with chromosomal anomalies
were excluded.

Dawson et al.,
2015 [34]

0 (32,273)

35 (608,726)

RB

N BDs

0e

Excluded syndromes known to be
associated with cancer (e.g. DS) (N
category).
Two hundred seventy-five cases with an
established genetic cause were
removed; authors report RRs but do not
define the RR abbreviation.

Retinoblastoma and eye tumor case series with an external comparison group studies
Narod et al.,
1997 [53]

549 (36)

NA

RB

Total

1.6 (NRCT); 1.0 (BC)

549 (2)

NA

RB

Cataract (743)

12.5*; 16.6*

549 (5)

NA

RB

Ventricular septal (7454)

6.1*; 4.5*

549 (3)

NA

RB

Other heart (746)

3.5; 2.6

549 (5)

NA

RB

Gastrointestinal (750–
751)

3.8*; 1.8

549 (5)

NA

RB

Genitourinary (752–53)

1.1; 0.88

549 (8)

NA

RB

Musculoskeletal (754)

2.7*; 1.3

549 (5)

NA

RB

Cardiac septal

4.1*; 2.1

549 (5)

NA

RB

Genitourinary

1.1; 0.94

549 (0)

NA

RB

Spine and rib

0; 0

549 (8)

NA

RB

Other

0.67; 0.46

Renal tumors case-control studies
Wilkins et al.,
1984 [77]

105 (NR)

210a (NR)

WT

Any BD

NR

Bunin et al.,
1987 [78]

88 (10)

88 (NR)

WT

Wilms’-associated

1.5 (0.3–8.3)b

88 (13)

88 (NR)

WT

Non-Wilms’-associated

4.3 (1.0–27.6)b

Kajtár et al.,
1990 [79]

34 (13)

148 (41)

WT

Total vertebral

1.62 (0.74–3.52)a,b

34 (5)

148 (5)

WT

Spina bifida occulta
affecting at least two
vertebral arches

4.93 (1.34–18.14)a,b

Schumacher et
al., 1992 [23]

68 (16a)

200 (11)

WT

Rib

5.29 (2.31–12.09)a,b

Mann et al.,
1993 [16]

32 (5)

32 (1)

WT

Any BD

5.74 (0.63–52.24)a,b

Not significant (Fisher’s test)

Altmann et al.,
1998 [17]

42 (4)

NR (NR)

Renal

Any BD

4.6 (1.6–13.8)b

40 (4)

NR (NR)

WT

Any BD

4.9 (1.6–14.5)b

40 (1)

NR (3)

WT

Eye/face/neck

18.9 (1.9–190)b

DS cases were not excluded. Any BD
estimates adjusted for 6-month
calendar period, gender, birth weight,
gestational age, and maternal age.

40 (1)

NR (5)

WT

All chromosomal

15.7 (1.7–153)b

50 (9)

180 (8)

WT

Spina bifida occulta

4.72 (1.72–12.98)a,b

50 (16)

180 (46)

WT

Total vertebral

1.37 (0.69–2.71)a,b

39 (14)

114 (20)

WT

Cutaneous signs of spinal
dysraphism

2.63 (1.17–5.93)a,b

Merks et al.,
2005 [26]

133 (13)

881 (54)

WT

Cervical

1.66 (0.88–3.13)a,b

Zierhut et al.,
2011 [24]

20 (3)

1,133 (51)

Renal

Abnormal ribs

3.73 (1.05–13.22)b

Estimates adjusted for sex and age.

4 (22,856)

NR (NR)

Renal

Any BD

2.2 (0.9–5.7)c

NR (NR)

NR (NR)

Renal

Male

-

NR (NR)

NR (NR)

Renal

Female

4.8c*

Did not exclude any known genetic
syndromes. Estimates are age
standardized.

Méhes et al.,
2003 [80]

The authors noted that the BD
frequency among cases and controls
were similar.

Renal tumors cohort studies
Windham et al.,
1985 [27]

NR (NR)

NR (NR)

Renal (0–4 years)

Male

-

NR (NR)

NR (NR)

Renal (0–4 years)

Female

4.3c*

NR (NR)

NR (NR)

Renal (5–9 years)

Male

-

NR (NR)

NR (NR)

Renal (5–9 years)

Female

6.7c

(Continued)

PLOS ONE | https://doi.org/10.1371/journal.pone.0181246 July 27, 2017

34 / 56

Pediatric cancer risk in association with birth defects: A systematic review

Table 3. (Continued)
Reference

Comparison
group 1¥

Comparison
group 2¥

Cancer type

Birth defect

Risk estimate (95%
CI)

Comments

Mili et al., 1993
[28]

4 (19,373)

38 (544,304)

WT

Any BD

2.8 (0.7–7.1)d

Did not exclude any known genetic
syndromes. Estimates adjusted for age.
The authors also note adjusting for sex
and race in some analyses. Minor
defects were included only if they were
associated with at least one major
defect.

Agha et al.,
2005 [33]

7 (45,200)

3 (45,200)

Renal

Any BD

1.5 (0.8–2.7)c

Did not exclude any known genetic
syndromes.

Rankin et al.,
2008 [30]

1 (NR)

59a (NR)

WT

Any BD

1.01 (0.14–7.29)f

Did not exclude any known genetic
syndromes.

Carozza et al.,
2012 [31]

14 (115,686)

172 (3,071,255a)

Renal

Any BD

1.11 (0.59–1.91)f

Genetic syndromes were not excluded.
Excluding subjects with chromosomal
anomalies resulted in a lower IRR for
leukemia and total cancers but not for
other cancers.

Fisher et al.,
2012 [36]

6 (59,258)

NR

WT

Non-chromosomal

1.45 (0.65–3.26)e

5 (6,327)

NR

WT

Chromosomal

13.43 (5.54–32.55)e

Botto et al.,
2013 [32]

<5 (44,151)

16 (147,940)

Kidney

Structural

1.03 (0.3–3.1)f

<5 (44,151)

15 (147,940)

WT

Structural

1.10 (0.4–3.3)f

0 (44,151)

<5 (147,940)

Other kidney

Structural

0

Dawson et al.,
2015 [34]

6 (32,273)

55 (608,726)

Renal

N BDs

2.02 (0.87–4.69)e

Excluded syndromes known to be
associated with cancer (e.g. DS) (N
category).

124 (8,752a)

WT

Any BD

3.20 (1.37–7.47)e

Estimate adjusted for sex and birth
year.

WT

Any BD

NR

The authors note that reported BD
associations were not confirmed.

CNS

1.12 (CPP); 2.47
(CDC)a,c

The ratio of the rates in NWTS versus
the CPP and Atlanta are represented.

Children with chromosomal anomalies
were excluded.

Renal tumors case-cohort studies
Puumala et al.,
2008 [82]

7 (138a)

Renal tumors nested case-control studies
Lindblad et al.,
1992 [81]

110 (NR)

550 (NR)

Renal tumors case series with an external comparison group studies
Breslow et al.,
1982 [83]

1,905a (NR)

CPP: 53,257a
(NR);
CDC Atlanta:
280,714a (NR)

WT
WT

Aniridia (743.45)

840; 420a,c

WT

Eye, excluding aniridia
cases (743)

0.93–1.48; 4.11a,c

WT

Ear, face, and neck (744)

0.16–4.2, 0.54a,c

WT

Cardiopulmonary system
(745–8)

1.49; 1.48a,c

WT

Cleft palate-lip (749)

0.4; 0.42a,c

WT

Upper alimentary tractdigestive system (750–1)

0.92–1.19; 1.94a,c

WT

Cryptorchidism (752.5)

0.6–2.33; 1.5a,c

WT

Hypospadias (752.6)

2.05; 3.63a,c

WT

Genital (752, excluding
752.5 and 752.6)

0.6–2.33; 1.5a,c

WT

Fused kidney (753.3)

0.6–2.33; 1.5a,c

WT

Double-collecting system
(753.3)

152; NDa,c

WT

Urinary system excluding
fused kidney, doublecollecting system (753)

2.21; 4.29a,c

WT

Clubfoot (754.5–754.7)

0.16–0.56; 0.95a,c

WT

Musculoskeletal system
(754–6, excluding 754.5–
754.7)

0.81–1.34; 2.07a,c

WT

Hair skin and nails (757)

0.48; 7.74a,c

WT

Chromosome defects, DS
(758)

0.45; NDa,c

WT

Accessory spleen (759.0)

31.5; NDa,c

WT

Hemihypertrophy (759.8)

823.33; NDa,c

(Continued)
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Table 3. (Continued)
Reference

Comparison
group 1¥

Comparison
group 2¥

Cancer type

Birth defect

Risk estimate (95%
CI)

Comments

Narod et al.,
1997 [53]

1,148 (106)

NA

WT

Total

2.2***(NRCT);
1.5***(BC)

1,148 (3)

NA

WT

Spina bifida (741)

1.4; 5.0*

1,148 (2)

NA

WT

Microcephaly (7421)

3.2; 5.7

Two hundred seventy-five cases with an
established genetic cause were
removed; authors report RRs but do not
define the RR abbreviation.

1,148 (2)

NA

WT

Transposition of the great
vessels (7451)

11.8*; 4.4

1,148 (7)

NA

WT

Ventricular septal (7454)

4.1**; 3.0*

1,148 (2)

NA

WT

Congenital aortic stenosis
(7463)

4.3; 15.4*

1,148 (3)

NA

WT

Pyloric stenosis (7505)

2.5; 1.6

1,148 (2)

NA

WT

Ovary (7520)

18.2*; 25.0**

1,148 (2)

NA

WT

Uterus (7523)

11.8**; 100***

1,148 (8)

NA

WT

Cryptorchidism (7525)

2.2; 2.7*

1,148 (5)

NA

WT

Hypospadias (7526)

2.9; 1.9

1,148 (14)

NA

WT

Urinary system (753)

3.7***; 58.3***

1,148 (5)

NA

WT

Congenital hip dislocation
(7543)

2.5; 1.4

1,148 (3)

NA

WT

Lower limb (7556)

2.1; 10.3**

1,148 (2)

NA

WT

Skull and facial bones
(7560)

1.9; 2.0

1,148 (3)

NA

WT

Spinal (7561)

1.3; 13.0**

1,148 (2)

NA

WT

Chondrodystrophy (7564)

8.7*; 7.4

1,148 (3)

NA

WT

Spina bifida

2.2; 5.0*

1,148 (10)

NA

WT

Cardiac septal

4.1***; 2.0

1,148 (29)

NA

WT

Genitourinary

2.9***; 2.6***

1,148 (4)

NA

WT

Spine and rib

1.4; 12.1***

1,148 (41)

NA

WT

Other

1.6**; 0.74

NR (2)

NA

Renal carcinoma

Spine and rib

37**; 339***

Hepatic tumors case-control studies
Mann et al.,
1993 [16]

6 (2)

6 (0)

HB

Any BD

-

Not significant (Fisher’s exact test)

Altmann et al.,
1998 [17]

7 (1)

NR (NR)

Hepatic

Any BD

9.3 (0.9–94.2)

DS cases were not excluded. Estimates
adjusted for 6-month calendar period,
gender, birth weight, gestational age,
and maternal age.

Venkatramani et
al., 2014 [84]

COG:387 (1);
UPDB:29 (0)

387 (1); 290 (0)

HB

Cleft lip or palate

COG: 1.05 (0.07–
16.9)b; UPDB: -

387 (4); 29 (0)

387 (2); 290 (0)

HB

Spina bifida or other
spinal

2.12 (0.39–11.7)b; -

387 (37); 29 (0)

387 (30); 290 (1)

HB

Large/multiple birth marks

1.33 (0.81–2.21)b; -

Excluded children with BeckwithWiedemann Syndrome and familial
adenomatous polyposis.
COG estimates adjusted for sex; UPDB
estimates adjusted for birth weight,
maternal age, and maternal education.

387 (1); 29 (0)

387 (0); 290 (0)

HB

Trisomy 18

-; -

387 (2); 29 (0)

387 (1); 290 (0)

HB

Other genetic conditions

2.11 (0.19–23.4)b; -

387 (0); 29 (0)

387 (1); 290 (1)

HB

Down syndrome

-

387 (1); 29 (1)

387 (0); 290 (1)

HB

Rib

-; 4.3 (0.23–80.0)b

387 (3); 29 (0)

387 (0); 290 (0)

HB

Small head/microcephaly

-; -

387 (18); 29 (3)

387 (6); 290 (2)

HB

Kidney, bladder, sex
organ

4.75 (1.74–13.0)b;
12.0 (1.61–89.6)b

387 (4); 29 (0)

387 (2); 290 (1)

HB

Hypospadias

2.1 (0.38–11.4)b;
<0.001 (NA)b

387 (12); 29 (2)

387 (3); 290 (0)

HB

Any kidney/bladder

4.3 (1.2–15.3)b; >99
(NA)b

387 (6); 29 (1)

387 (5); 290 (1)

HB

Sex organ

1.24 (0.37–4.1)b; 25.7
(1.63, >99)b

NR; 29 (2)

NR; 290 (2)

HB

Heart or pulmonary

-; 7.4 (0.87–62.7)b

(Continued)
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Table 3. (Continued)
Reference

Comparison
group 1¥

Comparison
group 2¥

Cancer type

Birth defect

Risk estimate (95%
CI)

Comments

3 (45,200)

0 (45,200)

Hepatic

Any BD

-

NA

NA

Hepatic

Other anomalies of the
digestive system

11.7 (2.9–46.7)g

Did not exclude any known genetic
syndromes. O/E ratios are age
standardized.

NA

NA

Hepatic

Chromosomal

8.0 (1.1–56.8)g

Hepatic tumors cohort studies
Agha et al.,
2005 [33]

a

Carozza et al.,
2012 [31]

16 (115,686)

45 (3,071,255 )

Liver

Any BD

1.00 (0.52–1.83)f

Genetic syndromes were not excluded.
The authors note that excluding
subjects with chromosomal anomalies
resulted in a lower IRR for leukemia and
total cancers but not for other cancers.

Botto et al.,
2013 [32]

8 (44,151)

<5 (147,940)

Liver

Structural

16.54 (3.5–77.9)f

7 (44,151)

<5 (147,940)

HB

Structural

14.47 (3.0–69.7)f

Children with chromosomal anomalies
were excluded.

<5 (44,151)

0 (147,940)

Other liver

Structural

-

Dawson et al.,
2015 [34]

4 (32,273)

10a (608,726)

Hepatic

N BDs

7.54 (2.36–24.03)e

Excluded syndromes known to be
associated with cancer (e.g. DS) (N
category).

Janitz et al.,
2016 [35]

5 (23,368)

<9a (567,867)

Hepatic

Any BD (w/chromosomal)

25.0 (7.2–86.2)e

Hepatic

Non-chromosomal

NR

The exact number of hepatic tumor
cases was suppressed.

HB

Any BD

5.87 (1.88–18.3)e

Adjusted for birth weight, birth year, and
sex.
Two hundred seventy-five cases with an
established genetic cause were
removed; authors report RRs but do not
define the RR abbreviation.

a

5 (22,109 )

a

<9 (567,867)

Hepatic tumors case-cohort studies
Spector et al.,
2008 [85]

5 (36a)

112 (7,788a)

Hepatic tumors case series with an external comparison group studies
Narod et al.,
1997 [53]

NR (2)

NA

HB

Spina bifida

2.0 (NRCT); 4.7 (BC)

165 (3)

NA

Liver

Genitourinary

2.1; 1.9

165 (0)

NA

Liver

Spine and Rib

0; 0

200 (11)

OS

Rib

0.99 (0.27–3.68)a,b

35 (6 )

200 (11)

ES

Rib

3.55 (1.22–10.35)a,b

Mann et al.,
1993 [16]

30 (3)

30 (2)

Bone

Any BD

1.56 (0.24–10.05)a,b

Gelberg et al.,
1997 [12]

130 (NR)

130 (NR)

OS

Any BD

NR

Age range 0–24 years. No significant
associations were reported.

Altmann et al.,
1998 [17]

8 (2)

NR (NR)

Bone

Any BD

23.2 (3.8–143)b

8 (1)

NR (5)

Bone

All chromosomal

28.6 (2.9–280)b

DS cases were not excluded. Any BD
estimates adjusted for 6-month
calendar period, gender, birth weight,
gestational age, and maternal age.

Merks et al.,
2005 [26]

48 (3)

881 (54)

OS

Cervical

1.02 (0.31–3.39)a,b

881 (54)

ES

Cervical

1.28 (0.38–4.28)a,b

a

OS

Any Minor

12.4 (3.6–42.1)a,b

Malignant bone tumors case-control studies
Schumacher et
al., 1992 [23]

Durmaz et al.,
2011[20]
Zierhut et al.,
2011 [24]

55 (3a)
a

39 (3)
a

23 (20 )

200 (70 )

39 (2)

1,133 (51)

Bone

Abnormal ribs

0.95 (0.21–4.31)b

21 (2)

1,133 (51)

OS

Abnormal ribs

1.81 (0.38–8.53)b

15 (0)

1,133 (51)

ES and related
sarcomas of bone

Abnormal ribs

-

3 (0)

1,133 (51)

Other specified and
unspecified malignant
bone

Abnormal ribs

-

Patients with known genetic syndromes
were excluded. Data on 19 specific
minor anomalies was also reported.

Malignant bone tumors cohort studies
Agha et al.,
2005 [33]

6 (45,200)

5 (45,200)

Bone

Any BD

1.3 (0.7–2.4)c

NA

NA

Bone

Other musculoskeletal

4.3 (1.1–17.3)g

Carozza et al.,
2012 [31]

1 (115,686)

19 (3,071,255a)

Bone

Any BD

0.63 (0.02–3.99)f

Did not exclude any known genetic
syndromes. O/E ratio is age
standardized.
Genetic syndromes were not excluded.
The authors note that excluding
subjects with chromosomal anomalies
resulted in a lower IRR for leukemia and
total cancers but not for other cancers.

(Continued)
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Table 3. (Continued)
Reference

Comparison
group 1¥

Comparison
group 2¥

Cancer type

Birth defect

Risk estimate (95%
CI)

Comments

Botto et al.,
2013 [32]

0 (44,151)

<5 (147,940)

OS

Structural

-

<5 (44,151)

<5 (147,940)

ES

Structural

2.07 (0.2–22.8)f

Children with chromosomal anomalies
were excluded.

Dawson et al.,
2015 [34]

2 (32,273)

32a (608,726)

Bone

N BDs

1.19 (0.29–4.96)e

Excluded syndromes known to be
associated with cancer (e.g. DS) (N
category).
Two hundred seventy-five cases with an
established genetic cause were
removed; authors report RRs but do not
define the RR abbreviation.

Malignant bone tumors case series with an external comparison group studies
Narod et al.,
1997 [53]

NR (1)

NA

Bone

Spina bifida

20.0 (NRCT); 50.0*
(BC)

396 (26)

NA

ES

Total

1.58; 1.0

396 (2)

NA

ES

Spina bifida (741)

4.3; 9.5*

396 (2)

NA

ES

Cataracts (7433)

14.3*; 23.0**

396 (2)

NA

ES

Orbit (7436)

8.3; 13.3*

396 (5)

NA

ES

Genitourinary (752–3)

1.5; 1.2

396 (10)

NA

ES

Musculoskeletal (754–6)

2.0; 1.4

396 (2)

NA

ES

Spinal (7561)

2.6; 25.3**

396 (2)

NA

ES

Osteodystrophy (7565)

33.9**; 41.7**

396 (5)

NA

ES

Other

0.70; 0.37

396 (1)

NA

ES

Cardiac septal

1.1; 0.58

396 (5)

NA

ES

Genitourinary

1.5; 1.3

549 (1)

NA

OS

Genitourinary

0.21; 0.19

NR (6)

NA

Bone

Spine and rib

2.4; 22.2***

Soft tissue and other extraosseous sarcomas case-control studies
Schumacher et
al., 1992 [23]

98 (24a)

200 (11)

STS

Rib

5.57 (2.60–11.95)a,b

Mann et al.,
1993 [16]

43 (6)

43 (1)

STS

Any BD

6.81 (0.78–59.22)a,b

Savitz et al.,
1994 [15]

26 (3)

212 (11)

STS

Major

2.4 (0.6–9.4)b

Yang et al.,
1995 [86]

249a (56)

302 (55)

RMS

Any BD

1.3 (0.85–2.02)b

249 (15)

302 (8)

RMS

Major

2.36 (0.92–6.18)b

249a (36)

302 (46)

RMS

Minor

0.94 (0.57–1.55)b

43 (3)

NR (NR)

STS

Any BD

3.5 (1.0–11.8)b

23 (3)

NR (NR)

RMS

Any BD

7.9 (2.2–28.8)b

23 (1)

NR (9)

RMS

Genitourinary

18.2 (2.1–157)b

Merks et al.,
2005 [26]

68 (5)

881 (54)

RMS

Cervical

1.22 (0.47–3.15)a,b

Durmaz et al.,
2011[20]

11 (11a)

200 (70a)

RMS

Any BD

1 (ND-1)a,b

Patients with known genetic syndromes
were excluded. Data on 19 specific
minor anomalies was also reported.

Zierhut et al.,
2011 [24]

30 (1)

1,133 (51)

STS and other
extraosseous sarcomas

Abnormal ribs

0.64 (0.08–4.91)b

Estimates adjusted for sex and age.

Altmann et al.,
1998 [17]

a

15 (1)

1,133 (51)

RMS

Abnormal ribs

1.35 (0.17–10.62)b

15 (0)

1,133 (51)

Other specified or
unspecified STS

Abnormal ribs

-

DS cases were not excluded. Any BD
estimates adjusted for 6-month
calendar period, gender, birth weight,
gestational age and maternal age.

Soft tissue and other extraosseous sarcomas cohort studies
Mili et al., 1993
[29]

2 (10,891)

18 (241,473)

Sarcoma

Any BD

4.1 (0.5–14.8)d

Did not exclude any known genetic
syndromes. Estimates adjusted for age
and sex. Minor defects were included
only if they were associated with at least
one major defect.

Agha et al.,
2005 [33]

7 (45,200)

4 (45,200)

STS

Any BD

1.9 (1.0–3.5)c

Did not exclude any known genetic
syndromes.

Rankin et al.,
2008 [30]

2 (NR)

40a (NR)

RMS

Any BD

2.98 (0.77–11.52)f

Did not exclude any known genetic
syndromes. RMS includes other STS as
noted in a table footnote.

(Continued)
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Table 3. (Continued)
Reference

Comparison
group 1¥

Comparison
group 2¥

Cancer type

Birth defect

Risk estimate (95%
CI)

Comments

Carozza et al.,
2012 [31]

15 (115,686)

102 (3,071,225a)

STS

Any BD

2.12 (1.09–3.79)f

Genetic syndromes were not excluded.
The authors note that excluding
subjects with chromosomal anomalies
resulted in a lower IRR for leukemia and
total cancers but not for other cancers.

Fisher et al.,
2012 [36]

6 (59,258)

NR

RMS

Non-chromosomal

2.26 (1.00–5.11)e

0 (6,327)

NR

RMS

Chromosomal

-

Botto et al.,
2013 [32]

<5 (44,151)

5 (147,940)

RMS

Structural

3.31 (0.9–12.3)f

0 (44,151)

<5 (147,940)

Fibrosarcoma

Structural

-

<5 (44,151)

<5 (147,940)

Other STS

Structural

1.38 (0.1–13.8)f

Sun et al., 2014
[38]

1 (4,484)

33 (1,547,126)

Mesothelial and soft
tissue (<1 year)

Nervous system (cohort
entry on day of birth)

10.47 (1.43–76.58)e

NR (NR)

NR (NR)

Mesothelial and soft
tissue (<1 year)

Nervous system (cohort
entry at BD diagnosis)

24.22 (3.30–177.63)e

5 (4,484)

87 (1,547,126)

Mesothelial and soft
tissue (1–15 years)

Nervous system (cohort
entry on day of birth)

19 (7.72–46.81)e

NR (NR)

NR (NR)

Mesothelial and soft
tissue (1–15 years)

Nervous system (cohort
entry at BD diagnosis)

23.02 (9.34–56.72)e

2 (24,643)

33 (1,547,126)

Mesothelial and soft
tissue (<1 year)

Circulatory system
(cohort entry on day of
birth)

3.81 (0.91–15.86)e

NR (NR)

NR (NR)

Mesothelial and soft
tissue (<1 year)

Circulatory system
(cohort entry at BD
diagnosis)

-

4 (4,484)

874 (1,547,126)

Mesothelial and soft
tissue (1–15 years)

Circulatory system
(cohort entry on day of
birth)

2.99 (1.10–8.14)e

NR (NR)

NR (NR)

Mesothelial and soft
tissue (1–15 years)

Circulatory system
(cohort entry at BD
diagnosis)

0.91 (0.13–6.53)e

Dawson et al.,
2015 [34]

2 (32,273)

53a (608,726)

STS

N BDs

0.71 (0.17–2.90)e

Excluded syndromes known to be
associated with cancer (e.g. DS) (N
category).

Janitz et al.,
2016 [35]

5 (23,368)

<30a (567,867)

STS

Any BD (w/chromosomal)

3.7 (1.3–10.6)e

STS

Non-chromosomal

3.9 (1.4–11.2)e

The exact number of STS cases was
suppressed.

a

5 (22,109 )

a

<30 (567,867)

Children with chromosomal anomalies
were excluded.

Children with chromosomal anomalies
were excluded. Estimates adjusted for
calendar year and sex.

Soft tissue and other extraosseous sarcomas case series studies with an external comparison group studies
Ruymann et al.,
1988 [87]

Narod et al.,
1997 [53]

10 (115)

NWTS: NR
(1,905); CPP: NR
(53,257)

RMS

Genitourinary

NWTS:1.18a,c;
CPP: 3.14a,c

9 (115)

NR (1,905);
NR (53,257)

RMS

CNS

16.64 a,c; 18.62 a,c

13 (115)

NR (1,905);
NR (53,257)

RMS

Upper alimentary tract/
digestive systems

7.68 a,c; 7.05 a,c

4 (115)

NR (1,905);
NR (53,257)

RMS

Cardiopulmonary

2.68 a,c; 4.26 a,c

5 (115)

NR (1,905);
NR (53,257)

RMS

Accessory spleens

6.9 a,c; 217 a,c

NR (115)

NR (1,905);
NR (53,257)

RMS

Musculoskeletal

0.38 a,c; 0.31 a,c

NR (115)

NR (1,905);
NR (53,257)

RMS

Aniridia

ND

NR (115)

NR (1,905);
NR (53,257)

RMS

Hemihypertrophy

0.35 a,c; 43.5 a,c

NR (2)

NA

RMS

Cardiac septal

1.1 (NRCT); 0.56
(BC)

1,248 (18)

NA

STS

Genitourinary

1.7*; 1.5

1,248 (3)

NA

STS

Spine and Rib

1.0; 8.3*

Authors presented rates for two external
comparison groups: 1) the NWTS and
2) the CPP. Rate ratios were calculated
as the ratio of the rate in study
population to the rate in the external
comparison group.

Two hundred seventy-five cases with an
established genetic cause were
removed; authors report RRs but do not
define the RR abbreviation.

(Continued)
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Table 3. (Continued)
Reference

Comparison
group 1¥

Comparison
group 2¥

Cancer type

Birth defect

Risk estimate (95%
CI)

Comments

P-values calculated by Fisher’s exact
test.

Germ cell tumors, trophoblastic tumors, and neoplasms of gonads case-control studies
Swerdlow et al.,
1982 [91]

87 (2)

10,128 (NR)

Testicular

Genitourinary

2.99b (P = 0.15)

87 (2)

10,128 (NR)

Testicular

Inguinal hernias

2.05b (P > 0.05)

Schumacher et
al., 1992 [23]

29 (1a)

200 (11)

Yolk sac carcinoma

Rib

0.61 (0.87–4.94)a,b

Mann et al.,
1993 [16]

41 (7)

41 (1)

GCT

Any BD

8.24 (0.96–70.32)a,b

Shu et al., 1995
[89]

105 (NR)

639 (NR)

GCT

Any BD

1.4 (0.6–3.5)b

Altmann et al.,
1998 [17]

21 (4)

NR (NR)

Gonadal and GCT

Any BD

8.9 (2.6–30.3)b

Merks et al.,
2005 [26]

34 (5)

881 (54)

Germ cell

Cervical

2.64 (0.98–7.09)a,b

Johnson et al.,
2009 [88]

Males: 81a (23);
Females: 192a
(35)

Males: 179a (27);
Females: 240 (40)

GCT

Any BD

Males: 2.5 (1.3–4.9)b;
Females: 1.1 (0.7–
1.8)b

82a (8), NA

180a (2), NA

GCT

Cryptorchidism

10.8 (2.1–55.1)b; NA

a

Hall et al., 2017
[90]

a

a

83 (6), 193 (2)

181 (7), 241 (9)

GCT

Hernia

1.8 (0.6–5.8)b; 0.3
(0.1–1.3)b

83a (5), 195a
(12)

181a (7), 241 (12)

GCT

Congenital heart

1.5 (0.5–5.1)b; 1.2
(0.5–2.8)b

83a (3), 193a
(15)

181a (7), 241 (14)

GCT

Large/multiple birthmarks

1.0 (0.2–4.1)b; 1.4
(0.6–2.9)b

83a (2), 195a (5)

180a (3), 241 (2)

GCT

Skeletal

1.6 (0.2–10.0)b; 3.1
(0.6–16.4)b

82a (5), 193a (8)

181a (5), 241 (8)

GCT

Other

3.0 (0.1–11.1)b; 1.3
(0.5–3.4)b

451 (23)

273,519 (1,527)

GCT

Any BD

9.12 (5.92–14.05)b

451 (7)

273,519 (72)

GCT

Ear/face/neck

47.92 (21.86–
105.04)b

181 (2)

273,519 (1,527)

Yolk sac tumors

Any BD

NR

181 (0)

273,519 (72)

Yolk sac tumors

Ear/face/neck

-

216 (19)

273,519 (1,527)

Teratomas

Any BD

15.43 (9.46–25.18)b

216 (7)

273,519 (72)

Teratomas

Ear/face/neck

93.7 (42.14–208.32)b

Pedigree was shown for one case with a
teratoma.

DS cases were not excluded. Estimate
adjusted for 6-month calendar period,
gender, birth weight, gestational age,
and maternal age.

Estimates adjusted for child’s age.

Estimates adjusted for birth year and
maternal race (White v. non-White).

Germ cell tumors, trophoblastic tumors, and neoplasms of gonads cohort studies
Agha et al.,
2005 [33]

3 (45,200)

4 (45,200)

NA

NA

Any BD

0.8 (0.4–1.7)c

GCT

Other musculoskeletal

12.9 (1.2–19.4)g

Carozza et al.,
2012 [31]

17 (115,686)

60 (3,071,225 )

GCT

Any BD

5.19 (2.67–9.41)f

Fisher et al.,
2012 [36]

8 (59,258)

NR

Non-CNS GCT

Non-chromosomal

2.98 (1.46–6.07)e

Botto et al.,
2013 [32]

a

GCT, trophoblastic and
other gonadal
carcinoma & other

1 (6,327)

NR

Non-CNS GCT

Chromosomal

4.32 (0.60–30.82)e

6 (44,151)

6 (147, 940)

GCT, trophoblastic, and
gonadal

Structural

4.14 (1.3–12.8)f

<5 (44,151)

<5 (147,940)

Teratoma

Structural

5.51 (1.2–24.6)f

<5 (44,151)

<5 (147,940)

Other GCT

Structural

2.76 (0.5–16.5)f

Dawson et al.,
2015 [34]

2 (32,273)

28a (608,726)

Gonadal and GCT

N BDs

1.34 (0.32–5.63)e

Janitz et al.,
2016 [35]

6 (23,368)

11a (567,867)

GCT

Any BD (w/chromosomal)

13.6 (5.0–36.7)e

GCT

Non-chromosomal

14.3 (5.3–38.7)e

a

6 (22,109 )

a

11 (567,867)

Did not exclude any known genetic
syndromes. O/E ratio is age
standardized.
Genetic syndromes were not excluded.
The authors note that excluding
subjects with chromosomal anomalies
resulted in a lower IRR for leukemia and
total cancers but not for other cancers.

Children with chromosomal anomalies
were excluded.

Excluded syndromes known to be
associated with cancer (e.g. DS) (N
category).
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Table 3. (Continued)
Reference

Comparison
group 1¥

Comparison
group 2¥

Cancer type

Birth defect

Risk estimate (95%
CI)

Comments

-

0–4 year olds

Germ cell tumors, trophoblastic tumors, and neoplasms of gonads nested case-control studies
Wanderas et al.,
1998 [92]

32 (0)

3,028 (99)

Testicular cancer

Any BD

Germ cell tumors, trophoblastic tumors, and neoplasms of gonads case series studies with an external comparison group studies
Narod et al.,
1997 [53]

544 (43)

NA

Gonadal and GCT

Total

1.9*** (NRCT);
1.3 (BC)

544 (3)

NA

Gonadal and GCT

Other nervous (742)

3.7*; 3.2

544 (3)

NA

Gonadal and GCT

Septal defects (745)

2.6; 1.3

544 (18)

NA

Gonadal and GCT

Musculoskeletal (754–6)

2.7***; 1.9**

544 (6)

NA

Gonadal and GCT

Spinal (7561)

5.7***; 54.5***

544 (1)

NA

Gonadal and GCT

Spina bifida

1.5; 3.5

544 (6)

NA

Gonadal and GCT

Genitourinary

1.3; 1.1

544 (6)

NA

Gonadal and GCT

Spine and rib

4.3**; 37.5***

544 (19)

NA

Gonadal and GCT

Other

1.4; 0.93

NR (3)

NA

GCT

Cardiac septal

6.4*; 3.3

Two hundred seventy-five cases with an
established genetic cause were
removed; authors report RRs but do not
define the RR abbreviation.

Other and unspecified malignant tumors case-control studies
Méhes et al.,
1985 [19]

55 (35)

Siblings: 44 (26);
Controls: 55 (17)

Solid

Minor

1.21 (0.54–2.74)a,b;
3.91 (1.77–8.65)a,b

Mann et al.,
1993 [16]

22 (1)

28 (0)

Epithelial

Any BD

-

28 (1)

28 (1)

Other

Any BD

1.00 (0.06–16.82)a,b

Altmann et al.,
1998 [17]

7 (0)

NR

Carcinoma, malignant
epithelial

Any BD

-

2 (0)

NR

Other

Any BD

-

Merks et al.,
2005 [26]

124 (8)

881 (54)

Other

Cervical

1.06 (0.49–2.28)a,b

Loder et al.,
2007 [25]

72a (10)

200 (16)

Solid tumor

Abnormal rib number
(normal = 24 ribs)

1.90 (0.80–4.30)b

Solid tumors included WT (n = 17), OS
(n = 14), NB (n = 8), RMS (n = 5), Ewing
sarcoma (n = 3), and other types (n = 9).
Children with a known BD or DS were
excluded.

Durmaz et al.,
2011 [20]

14 (14a)

200 (70a)

WT/GCT

Any minor

1 (NR-1)a,b

12 (10 )

200 (70 )

Others

Any minor

9.3 (2.0–43.6)a,b

Patients with known genetic syndromes
were excluded. Data on 19 specific
minor anomalies was also reported.

Santos et al.,
2016 [109]

281 (55)

176 (29)

Solid tumor

Solitary café-au-lait spots

1.23 (0.75–2.02)a,b

281 (28)

176 (12)

Solid tumor

Multiple café-au-lait spots

1.51 (0.75–3.06)a,b

a

a

DS cases were not excluded. Estimate
adjusted for 6-month calendar period,
gender, birth weight, gestational age,
and maternal age. Cases with other
malignancy types had no
malformations.

A known syndrome diagnosis was
suspected in 4 cases

Other and unspecified malignant tumors cohort studies
Windham et al.,
1985 [27]

Agha et al.,
2005 [33]

Rankin et al.,
2008 [30]

5 (22,856)

NR (NR)

Other

Any BD

1.2 (0.5–3.2)c

NR (NR)

NR (NR)

Other

Any BD (Male)

0.4c

NR (NR)

NR (NR)

Other

Any BD (Female)

2.2c

NR (NR)

NR (NR)

Other (0–4 years)

Any BD (Male)

-

NR (NR)

NR (NR)

Other (0–4 years)

Any BD (Female)

3.1c

NR (NR)

NR (NR)

Other (5–9 years)

Any BD (Male)

2.2 c

NR (NR)

NR (NR)

Other (5–9 years)

Any BD (Female)

-

1 (45,200)

1 (45,200)

Other

Any BD

1.1 (0.3–4.4)c

3 (45,200)

2 (45,200)

Malignant epithelial

Any BD

1.6 (0.6–4.0)c

NA

NA

Carcinomas

Respiratory system

10.9 (1.5–77.2)g

NA

NA

Carcinomas

Urinary system

11.8 (1.7–83.7)g

All other cancers

Any BD

-

0 (NR)

a

73 (NR)

Did not exclude any known genetic
syndromes. Estimates are age
standardized.

Did not exclude any known genetic
syndromes. O/E ratios are age
standardized.

Did not exclude any known genetic
syndromes.
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Table 3. (Continued)
Reference

Comparison
group 1¥

Comparison
group 2¥

Cancer type

Birth defect

Risk estimate (95%
CI)

Comments

Carozza et al.,
2012 [31]

2 (115,686)

19 (3,071,225a)

Other epithelial

Any BD

2.98 (0.34–12.34)c

1 (115,686)

11 (3,071,225a)

Other and unspecified

Any BD

5.05 (0.12–34.75)c

Genetic syndromes were not excluded.
The authors note that excluding
subjects with chromosomal anomalies
resulted in a lower IRR for leukemia and
total cancers but not for other cancers.

Botto et al.,
2013 [32]

0 (44,151)

<5 (147, 940)

Miscellaneous

Structural

ND

Children with chromosomal anomalies
were excluded.

Sun et al., 2014
[38]

3 (4,484)

91 (1,547,126)

Other systems (<1 year)

Nervous system (cohort
entry on day of birth)

11.4 (3.61–36.0)e

NR (NR)

NR (NR)

Other systems (<1 year)

Nervous system (cohort
entry at BD diagnosis)

15.73 (3.87–63.92)e

Children with chromosomal anomalies
were excluded. Estimates adjusted for
calendar year and sex.

7 (4,484)

563 (1,547,126)

Other systems (1–15
years)

Nervous system (cohort
entry on day of birth)

4.1 (1.95–8.65)e

NR (NR)

NR (NR)

Other systems (1–15
years)

Nervous system (cohort
entry at BD diagnosis)

2.84 (1.06–7.59)e

5 (4,484)

75 (1,547,126)

Other systems (<1 year)

Circulatory system
(cohort entry on day of
birth)

4.19 (1.69–10.35)e

NR (NR)

NR (NR)

Other systems (<1 year)

Circulatory system
(cohort entry at BD
diagnosis)

1.57 (0.22–11.30)e

22 (4,484)

464 (1,547,126)

Other systems (1–15
years)

Circulatory system
(cohort entry on day of
birth)

3.1 (2.02–4.76)e

NR (NR)

NR (NR)

Other systems(1–15
years)

Circulatory system
(cohort entry at BD
diagnosis)

0.68 (0.25–1.82)e

2 (32,273)

33a (608,726)

Other epithelial/
melanoma

N BDs

1.17 (0.28–4.88)e

18 (32,273)

235a (608,726)

Embryonal

N BDs

1.43 (0.88–2.30)e

3 (32,273)

72a (608,726)

Other

N BDs

0.80 (0.25–2.53)e

Dawson et al.,
2015 [34]

Excluded syndromes known to be
associated with cancer (e.g. DS) (N
category).

Other and unspecified case series studies with an external comparison group studies
Narod et al.,
1997 [53]

NR (6)

NA

Carcinoma/Other

Genitourinary

1.1; 1.0

NR (1)

NA

Carcinoma

Cardiac septal

0.78; 0.40

Two hundred seventy-five cases with a
known genetic cause were removed;
the RR abbreviation in undefined.

¥

For case-control and nested case-control studies the total number of cancer cases (comparison group 1) and non-cancer cases (comparison group 2) is
shown in columns 2–3 with the number in parentheses indicating the number of individuals with BDs in each comparison group. For cohort studies,

comparison group 1 is noted as above; comparison group 2 shows the number of cancer cases among the number without BDs in parentheses. For casecohort studies, comparison group 1 is the same as for other study designs; comparison group 2 shows the total number of individuals with cancer among the
total number of individuals in the sub-cohort in parentheses.
*p<0.05;
**p<0.01;
***p<0.001;
a

Calculated based on information;

b
c

Odds Ratio;
Rate Ratio

d

Standardized Incidence Ratio;

e
f

Hazard Ratio;
Incidence Rate Ratio;

g

O/E ratio;
Relative Risk

h

https://doi.org/10.1371/journal.pone.0181246.t003
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generally weaker associations for older children and when the follow-up period started at the
time of BD diagnosis [38].

Leukemia (Table 3)
We identified 36 articles reporting findings for associations between leukemia and hematological malignancies and BDs.
Case-control studies (n = 24). Risk estimates ranged from 1.07 to 11.6 [15–17, 39–47] for
associations between any/major BDs and leukemia overall or specific leukemia subtypes. Shu
et al. observed no leukemia cases with BDs other than one case with Down syndrome [48].
Studies excluding DS cases from overall or sub-analyses generally reported weaker associations
[39–41, 44–46, 49]. Several studies reported positive associations between minor BDs and leukemia/hematological malignancies ranging from 1.48 to 67.48 [19, 20, 45, 50–52].
Cleft lip or palate was inconsistently associated with lymphatic and myeloid leukemia [40,
43, 49]. Several studies observed positive associations between hematologic malignancies and
birthmarks [43, 46, 50] and rib anomalies [23–26]. Minor BDs of the hand, foot, eye, nose,
mouth, and ear were all positively associated with hematological malignancies in one study
[20]. Finally, inconsistent results were reported for a number of other specific BDs [41, 43, 45,
46, 53].
Cohort studies (n = 11). In six studies, positive associations were observed between leukemias and any BDs/major BDs ranging from 1.1–21.97 [27–31, 33]. Associations were generally weaker in studies/analyses with DS cases were excluded [27–29, 31, 32, 34–36]. Rankin
et al. noted, however, that “the association between congenital anomalies and childhood leukemia remained after exclusion of Down Syndrome cases” [30]. Notably, Dawson et al. reported
a positive association between other leukemias (types other than ALL or AML) and non-chromosomal BDs [34]. Finally, Sun et al. examined nervous and circulatory system BDs and risk
of lymphatic and haematopoietic tissue malignancies in children without chromosomal anomalies and reported positive associations that were stronger for infants versus children 1–15
years. Associations were generally weaker when follow-up time was counted from the BD diagnosis rather than from birth [38].
Case series with an external comparison group studies (n = 1). Narod et al. examined a
number of specific abnormalities and did not report any consistently increased risks for leukemia [53].

Lymphoma (Table 3)
We identified 17 articles reporting findings for associations between lymphoma and BDs.
Case-control studies (n = 9). Four studies reported inconsistent associations between
lymphoma/lymphoma subtypes and any BDs/major BDs with ORs ranging from 0.7–4.43
[15–17, 54]. Based on 19 lymphoma cases, Mangani et al. reported 0 lymphoma cases with
BDs [47]. Rib anomalies specifically were inconsistently associated with lymphoma subtypes
[23, 24, 26]; however, one study combining lymphoma with leukemia in their analysis reported
a significant OR of 2.0 [25].
Cohort studies (n = 7). Lymphoma was positively associated with any BD in three of four
cohort studies [30, 31, 33, 35]. Fisher et al. and Janitz et al. reported positive associations
between non-chromosomal anomalies and lymphoma [35, 36], while both Botto et al. and
Dawson et al. observed risks for lymphoma/lymphoma subtypes in both directions in children
with non-chromosomal BDs and those not known to be related to cancer [32, 34]. Certain
musculoskeletal anomalies were associated with lymphoma in one study [33].
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Case series with an external comparison group studies (n = 1). Narod et al. reported
findings for cardiac septal defects, genitourinary abnormalities, and spine and rib abnormalities with a significant positive association for spine and rib abnormalities for the British
Columbia registry comparison group only [53].

CNS and miscellaneous intracranial and intraspinal neoplasms (Table 3)
We identified 31 articles reporting findings for associations between CNS tumors and BDs.
Case-control and nested case-control studies (n = 19). Risk estimates for associations
between CNS tumors and any BDs/major BDs ranged from 1.0 to 4.7 [15–17, 55–60]. Two
studies did not report risk estimates; however, one reported no association and the other
reported a decreased frequency of BDs (excluding minor BDs) in cases versus controls [61,
62]. Altmann et al. reported an increased odds of astrocytoma in children with any BD [17].
However, three studies [58, 59, 63] found weak to no evidence that children with any BD/
major BDs have an increased risk for specific CNS subtypes with the exception of other gliomas [58] where a 2–3 fold increased risk was reported. Importantly, these results were
unchanged after excluding seven CNS tumor cases with Neurofibromatosis Type 1 [58]. Partap
et al.’s results contrast with these findings by showing increased odds of a BD history for MBs
and PNETs compared to controls and inverse associations for gliomas [57].
Gold et al. reported a strong positive association only between brain tumors and club foot
[64]. Another study reported universally positive associations for hand, foot, eye, nose, mouth,
and ear minor BDs [20]. Birthmarks/deformities were not associated with brain tumors in one
study [65]. Altmann et al. reported highly significant and strong associations between CNS
tumors and nervous system and eye/face/neck abnormalities [17]. Finally, several investigators
reported that brain tumor cases with varying subtypes had higher odds of rib abnormalities
than controls [23–26].
Cohort studies (n = 11). Six studies reported positive associations for any BD and CNS
tumors ranging from 1.11 to 2.9 [27–31, 33]. Fisher et al. reported increased HRs for CNS
tumors in both children with and without chromosomal BDs of 1.87 and 1.80 [36]. Botto et al.
reported an increased brain tumor incidence in children with structural BDs that was stronger
for other brain tumors [32]. Dawson et al. reported a weak imprecise association of 1.26
between BDs not known to be related to cancer and CNS tumors [34]. Janitz et al. reported
increased risks in children with non-chromosomal BDs that decreased with increasing age
[35].
For specific BD types, nervous system abnormalities were strongly associated with CNS
tumors in three studies [27, 33, 38]. Finally, circulatory system malformations were positively
associated with CNS tumors in one study [38].
Case series with an external comparison group studies (n = 1). Narod et al. reported
inconsistent or inverse associations for total BD and most specific abnormalities with the
exception of hydrocephalus where both RRs were positive and significant [53].

Neuroblastoma and other peripheral nervous cell tumors (Table 3)
We identified 26 articles reporting findings for associations between NB and BDs.
Case-control studies (n = 14). Risk estimates from 11 studies reporting associations
between any BDs/physical anomalies and NB/sympathetic nervous system tumors ranged
from 1.0 to 8.61 [16, 17, 66–74]. Major and minor BDs were positively associated with NB in
four [69–71, 74] and two studies, respectively [69, 71]. Several studies examining specific BDs
generally observed positive associations [69–71], particularly for digestive system/gastrointestinal and genitourinary anomalies [17, 69, 71, 74] and during infancy [69]. Rib anomalies were
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positively associated with NB/other peripheral nerve tumors in three studies to varying degrees
[23, 24, 26].
Cohort and case-cohort studies (n = 11). Children with any BD had a consistently higher
risk of NB across studies with RRs from 1.1–20.3 [27–31, 33, 75]. Fisher et al. and Botto et al.
[32, 36] also reported that non-chromosomal BDs were associated with NB and other peripheral nervous system tumors with individuals in the BD group having a >2-fold higher risk,
while Dawson et al. reported a lower risk estimate of 1.41 for individuals with BDs not known
to be related to cancer [34]. Finally, a case-cohort study reported a similar percentage of cases
and sub-cohort members had BDs recorded in their birth records [76]. For specific anomalies,
Agha et al. reported more observed than expected cases of SNS tumors in those with other
anomalies of the digestive system [33].
Case series with an external comparison group studies (n = 1). Narod et al. reported
results that were imprecise and in opposite directions for total BD. Generally positive associations were observed for specific BDs, particularly for cardiac and gastrointestinal abnormalities
[53].

Retinoblastoma and eye tumors (Table 3)
We identified 10 articles reporting findings for associations between RB/eye tumors and BDs.
Case-control studies (n = 2). Results were mixed with Mann et al. finding no BDs in RB
cases and Altmann et al. reporting a strong positive OR of 15.0 [16, 17]. For specific BDs,
strong associations were reported for chromosomal anomalies in a single study.
Cohort and case-cohort studies (n = 7). Of seven studies, six reported positive associations ranging from 2.2–4.7 between BDs overall or those that excluded individuals with chromosomal anomalies [27, 28, 30–33]. Dawson et al. reported no RB cases [34]. Chromosomal
and eye anomalies were strongly associated with RB in one study [33].
Case series with an external comparison group studies (n = 1). Narod et al. reported
inconsistent results for associations between RB and BDs and strong associations between RB
and cataracts and ventricular septal defects [53].

Renal tumors (Table 3)
We identified 21 articles reporting findings for associations between renal tumors and BDs.
Case-control and nested case-control studies (n = 10). Wilkins et al. reported similar
frequencies of any BD in WT cases and controls [77], while two other groups reported positive
associations [16, 17]. Stronger associations were reported for non-WT associated BDs than
WT-associated BDs in one study [78]. Two studies reported significant positive associations
between WT and spina bifida [79, 80]. WT was also reported as positively associated with eye/
face/neck BDs and chromosomal BDs [17]. WT/renal carcinomas were positively associated
with rib abnormalities in three studies [23, 24, 26]. Finally, Lindblad et al. reported that associations between BDs and WT were not confirmed in a nested case-control study [81].
Cohort and case-cohort studies (n = 9). Risk estimates for cohort and case-cohort studies
examining associations between any BD and WT or renal tumors ranged from 1.0–3.2 [27, 28,
30, 31, 33, 82]. Fisher et al. reported significant risks for WT only in children with chromosomal BDs [36]. In two studies excluding children with chromosomal anomalies and syndromes known to predispose toward cancer, results were mixed [32, 34].
Case series with an external comparison group studies (n = 2). Breslow et al. compared
the rate of different BD types in a case series to two external comparison groups and observed
consistent strongly increased rates of aniridia, double-collecting system, and hemihypertrophy
[83]. Narod et al. reported consistent findings across the two different comparison groups for
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genitourinary and reproductive organ associated BDs. Renal carcinomas were strongly associated with spine and rib malformations in one study [53].

Hepatic tumors (Table 3)
We identified 10 articles reporting associations between hepatic tumors and BDs.
Case-control studies (n = 3). There was no significant association between HB and any
BDs in one study [16], while another reported a non-significant 9.3-fold increased odds of
BDs in hepatic tumor cases versus controls [17]. For specific abnormalities, both spina bifida
and genitourinary conditions were positively associated with HB in one study [84]. Other
abnormalities were examined only in single studies.
Cohort and case-cohort studies (n = 6). One study reported three hepatic tumor cases in
individuals with BDs and none in the comparison group [33]. Carozza et al. reported no association between liver tumors and any BD [31], while Spector et al. reported an almost 6-fold
increased risk of HB in association with any BD [85]. Both Botto et al. and Dawson et al.
reported strongly increased IRRs for liver tumors in individuals with BDs after exclusion of
children with chromosomal BDs and syndromes known to be associated with cancer [32, 34].
In the Janitz et al. study, there were too few hepatic tumor cases to examine statistical associations [35]. Digestive and chromosomal anomalies were positively associated with hepatic
tumors in one study [33].
Case series with an external comparison group studies (n = 1). Narod et al. reported
positive associations between spina bifida and genitourinary abnormalities and HB [53].

Malignant bone tumors (Table 3)
We identified 12 articles reporting associations between BDs and bone tumors.
Case-control studies (n = 7). One study reported no association between OS and any
BDs [12]. Two studies reported positive but imprecise associations (ORs = 1.56 and 23.2)
between bone cancer and any BD [16, 17]. Minor BDs were associated with OS in one study
(OR = 12.4) [20]. One study reported a positive association between bone tumors and chromosomal anomalies [17]. Finally, three studies reported inconsistent associations between rib
anomalies and bone cancer (OS or ES) [23, 24, 26].
Cohort studies (n = 4). Mixed results were reported for any BD/BDs not known to be
related to cancer and bone cancer in three studies [31, 33, 34]. Botto et al. reported a two-fold
non-significant increased incidence of ES in individuals with non-chromosomal structural
BDs [32]. An ~ 4-fold excess of bone tumors was reported in children with other musculoskeletal BDs in one study [33].
Case series with an external comparison group studies (n = 1). Narod et al. reported
consistently strong associations using two different comparison groups between bone tumors
overall and spina bifida; however, the association was based on only one case. Strong positive
associations were also reported between osteodystrophy and cataracts and ES using both comparison groups [53].

Soft tissue and other extraosseous sarcomas (Table 3)
We identified 19 articles reporting associations between BDs and soft tissue and other extraosseous sarcomas.
Case-control studies (n = 8). Four studies reported positive associations between any
BDs/major BDs and STS/RMS ranging from 1.3 to 7.9 [15–17, 86]. Minor BDs were observed
in 100% of RMS cases and only 35% of controls in one study [20]. Further evidence for a positive association between genitourinary malformations and STS was reported for RMS [17].
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Three studies examined associations between rib anomalies and STS/RMS reporting inconsistent associations [23, 24, 26]. Minor BDs were not positively associated with RMS [86].
Cohort studies (n = 9). Five cohort studies examined associations between any BDs and
STS/RMS, with all finding positive associations ranging from 1.9 to 4.1 [29–31, 33, 35]. Three
studies reported positive associations between RMS and non-chromosomal (structural) BDs,
while one study reported a non-significant inverse for STS for BDs not known to be related to
cancer [32, 34–36]. Finally Sun et al., reported strong positive associations between nervous
system BDs and mesothothelial and soft tissue cancers across age groups and weaker associations for circulatory system BDs [38].
Case series with an external comparison group studies (n = 2). One study reported
markedly higher rates of CNS anomalies, upper alimentary tract/digestive systems, cardiopulmonary anomalies, and accessory spleens in the RMS cohort than in the two comparison
groups [87]. Narod et al. reported that genitourinary and spine and rib malformations were
positively associated with STS but this was inconsistent across comparison groups used for RR
calculations. Cardiac septal defects were not significantly associated with RMS [53].

Germ cell tumors (GCT), trophoblastic tumors, and neoplasms of
gonads (Table 3)
We identified 16 articles reporting associations between BDs and GCTs, trophoblastic tumors,
and neoplasms of gonads.
Case-control and nested case-control studies (n = 9). Several studies reported positive
associations between any BDs and gonadal tumors/GCTs ranging from 1.1 to 9.12 [16, 17, 88–
90]. Genitourinary defects and inguinal hernias were positively associated with testicular
tumors [91]. Johnson et al. reported a strong association with cryptorchidism in males [88].
Merks et al. reported an ~3-fold increased odds of cervical anomalies in GCT cases compared
to controls [26]. Hall et al. reported an increased odds of ear/face/neck anomalies in GCT
cases and those with teratomas specifically [90]. In a nested case-control study, no cases had
BDs in the 0–4 year old age group [92].
Cohort studies (n = 6). Among two cohort studies, Agha et al. reported no association
between germ cell, trophoblastic and other gonadal carcinoma and any BD, while Carozza
et al. reported a significant 5-fold increased risk [31, 33]. Fisher et al., Botto et al., and Janitz
et al. reported significant positive associations between GCTs/Gonadal and GCT and nonchromosomal BDs, while Dawson et al. reported a weak positive association for BDs not
known to be related to cancer [32, 34–36]. GCTs were strongly associated with other musculoskeletal anomalies in one study [33].
Case series with an external comparison group studies (n = 1). Narod et al. reported
consistent increased risks between gonadal and GCT tumors and total BDs and weak non-significant associations between these tumors and genitourinary defects. Musculoskeletal, spinal,
and spine and rib malformations were consistently positively associated with [53].

Other tumors (Table 3)
Several studies examined other childhood cancers and various subtype groupings for their
association with BDs. For completeness, we include these results; however, given the heterogeneous nature of the BDs/cancer types and outcomes examined, we do not summarize the
findings.
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Quality assessment (S2 and S3 Tables)
The mean percent total quality point score was higher for cohort (88% ± 13%) than case-control (62% ± 19%) studies. The three case-cohort study reports that were based on the same parent study were of high quality each receiving 89% of the total quality points, while the three
nested case-control studies received a mean of ~85% ± 6% of the total quality points (data not
shown).

Discussion
Associations between BDs and pediatric cancer have been extensively studied. Overall conclusions on pediatric cancer risk in children with BDs are limited by heterogeneity in study
design, subject selection (including inclusion/exclusion criteria), measurement, definitions,
and length of follow-up for ascertaining BDs, as well as covariate adjustment in models. For
example, in studies ascertaining individuals with BDs from BD surveillance systems, standardized definitions using published classification schemes were used to group individuals with
BDs according to BD type (e.g. major, minor, and specific BD types), while for studies ascertaining BDs through parental questionnaire, coding schemes were often elusive. We strongly
emphasize that future studies on this topic should employ and clearly report in their methods
a standardized classification system such as that reported by Rasmussen et al. for the National
Birth Defects Prevention Study [93], which will facilitate pooling and meta-analysis studies
that are needed to more precisely quantify pediatric cancer risk in children with BDs. In spite
of the differences in methodology used by studies on this topic that limit overall conclusions,
several noteworthy findings emerged from this review.
An increased risk for pediatric cancer overall in association with BDs clearly exists with
most case-control and cohort studies reporting positive associations. A seminal Nordic study
of 5.2 million individuals, not included in our review because it did not present pediatric
cancer specific risk estimates, linked medical birth and cancer registries to examine cancer risk
in children with BDs [94]. Cancer risk was significantly increased in individuals with nonchromosomal BDs by ~1.4–1.5 fold, with stronger risks at younger ages, which was also
reported in several studies included in this review [34, 35, 38]. Moreover, a strong association
was observed in both Norway and Sweden (>8 fold) between nervous system abnormalities
and CNS tumors [94]. Collectively, our review and the Nordic data provide strong evidence
for an overall increased cancer risk in children with BDs.
For leukemia, most studies excluding DS cases reported relatively weak or no evidence for
an increased risk of leukemia in children with any BD/major BDs. For example, when considering the results from several cohort studies with overall higher quality than case-controls
studies, generally weak associations were reported between BDs and leukemia when DS cases
were excluded [28, 29, 32, 34–36] with the exception of one study [30]. It is noteworthy that
consistent associations with rib anomalies and minor malformations have been reported in
several studies [19, 20, 23–26, 50, 52]. These data suggest that minor BDs may be linked to leukemia development but most of the observed positive associations between major BDs and leukemia are likely explained by inclusion of DS cases.
For CNS tumors, strong consistent associations with CNS abnormalities were reported in
several studies [17, 27, 33, 38, 53]. When interpreting these results, it is important to consider
the timing of the BD diagnosis. BDs detected only as a result of tests or procedures associated
with the tumor diagnosis may lead to over-ascertainment of BDs in cases compared to controls, a potential issue raised by Altmann et al. [17]. In addition, it is also important to consider
whether the abnormality occurred secondary to the tumor, a concern noted by Narod et al. for
the association between brain/spinal tumors and hydrocephalus [53]. Evidence against these

PLOS ONE | https://doi.org/10.1371/journal.pone.0181246 July 27, 2017

48 / 56

Pediatric cancer risk in association with birth defects: A systematic review

possibilities was provided by Sun et al. who reported a strong positive association between nervous system abnormalities and CNS tumors when follow-up was initiated at the point of the
BD diagnosis (i.e. prior to the cancer diagnosis) [38].
For NB, many studies reported consistent positive associations with BDs overall, although
there was inconsistency for specific BD types [17, 26, 28–34, 36, 53, 66–75] with the possible
exception of gastrointestinal BDs [17, 53, 69, 71]. It is important to note that some of the
observed anomalies were noted as secondary to the tumor [67, 71]. Further research is needed
to clarify specific abnormalities associated with NB and to confirm the timing of the abnormality as congenital.
For RB/eye tumors, most cohort studies reported consistent positive associations with any
BD and structural defects [27, 28, 30–33], some of which may be explained if cases with partial
monosomy 13q were included that is associated with a number of anomalies and an increased
RB risk [95]. Since ~ 40% of RB tumors arise from a germline mutation [96], there is biological
plausibility for developmental abnormalities associated with RB haploinsufficiency. However,
despite mouse studies demonstrating lethality for embryos with Rb1-/- genotypes as well as
neural and hematopoietic abnormalities; heterozygotes did not have any observable defects
[97].
WT was associated with a number of abnormalities, some of which are due to known syndromic causes of WT including Beckwith-Wiedemann and WAGR (Wilms tumor, Aniridia,
Genitourinary anomalies and intellectual disability) syndromes. WAGR syndrome is caused
by a chromosome 11p deletion and is associated with genitourinary abnormalities and aniridia
(absence of the colored part of the iris) [98]. In two recent cohort studies excluding children
with chromosomal anomalies, associations between BDs and WT were weak and imprecise
[32, 36]. It is interesting to note, however, that a greater frequency of non-WT associated BDs
were observed in children with WT versus controls in one study [78], a finding that could suggest an underlying genetic predisposition.
For liver cancer, where most cases are HBs, most studies provided evidence of a positive
association with any BD [17, 32, 34, 85] that may stem from genitourinary abnormalities that
were positively associated with HB in three different study populations [53, 84]. It is unclear if
inclusion of Beckwith-Wiedemann Syndrome or Familial Adenomatous Polyposis cases in
some of studies explains the observed associations.
Although a three studies detected positive associations between BDs (especially for bone
BDs) and bone tumors or bone tumor subtypes [16, 17, 53], cohort study results are mixed
and based on small numbers [31–34]. For STSs, increased risks in children with BDs are evident from most case-control and cohort studies [15–17, 20, 29–33, 35, 36, 86]. However, as
with other cancer types, conclusions about particular abnormalities associated with risk are
limited by the heterogeneous nature of BDs observed/assessed in different studies.
For germ cell and other gonadal tumors, there is a relatively consistent pattern of an
increased risk in association with BDs across studies [16, 17, 31, 32, 34–36, 53, 88, 89] that
could be partially be due to cryptorchidism but only one study provided risk estimates in
males [88].
Although not completely consistent, one of the most intriguing findings is the observed
association between rib anomalies and many different childhood cancer types [23–26].
Although some of these associations could be due to detection bias as a result of diagnostic
tests for malignancy, the Zierhut et al. study was not subject to this type of bias [24].
The biology underlying associations between pediatric cancer and BDs is poorly understood. If the observed statistical associations are causal, a leading theory is that a common
genetic abnormality impairing normal development may subsequently predispose toward
both BDs and malignancy [99–103]. Since family history is absent in most individuals with
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non-syndromic BDs, genetic aberrations could arise through de novo mutations in the parental
germline or through somatic mutations or epimutations arising early in development. For
example, Beckwith-Wiedemann syndrome, can result from genetic and epigenetic mosaicism
accompanied by a variably increased risk of malignancy (typically HB or WT) in the affected
tissues depending on the causative genetic lesion [104]. The striking number of studies showing an association between rib abnormalities and pediatric/adolescent cancer risk may provide
an important clue to underlying genetic commonalities. The finding has frequently been
attributed to possible mutations in homeobox genes [25, 53] but no genetic cause has been
identified so far explaining this statistical observation.
Our study is the first systematic and most comprehensive review on this topic to date. However, there are limitations to consider. At the expense of specificity, we used broad search
terms to capture articles examining associations between BDs and pediatric cancers, identifying >14,000 articles. To be as comprehensive as possible, we identified additional relevant articles through review of article references lists, IARC’s review [11], and PubMed searches.
Despite these efforts, it is still possible that we missed some eligible articles; however, it seems
unlikely that they are systematically missing and therefore their exclusion should not bias our
overall conclusions. In addition, we did not include gray literature [105] (e.g. meeting abstracts
and PhD theses) and therefore publication bias may influence general conclusions.

Conclusions and future directions
Clear positive associations exist between BDs and pediatric cancer with evidence for increased
risks for specific cancer/BD type combinations such as CNS abnormalities and CNS cancer,
rib anomalies and a number of cancer types, and genitourinary abnormalities and HB. With
advances in mutation detection through next generation sequencing technologies it may be
possible to identify genetic causes underlying some of these cases, which will provide insight
into overlaps between genes impacting both development and malignancy and provide a basis
for identification of high risk populations among children with congenital abnormalities.
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